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Abstract 
Aspergillosis, a mycosis caused by fungi from Genus Aspergillus, occurs in many 
different hosts including insects, amphibians, reptiles, birds and mammals. Upper 
respiratory tract aspergillosis (URTA) is an emerging mycosis of domestic cats 
worldwide. The disease encompasses two anatomic forms, sino-nasal aspergillosis 
(SNA) and sino-orbital aspergillosis (SOA). This thesis characterizes the syndrome of 
URTA in cats including clinical disease and treatment outcomes. Phenotypic, 
physiologic and phylogenetic analyses resulted in the discovery of a novel species 
within Aspergillus section Fumigati, A. felis.  Aspects of disease pathogenesis were 
explored through comparison of features from computed tomographic (CT) images of 
soft-tissue and bony structures of the head from affected cats with molecular identity of 
aetiological agents. Evaluation of the specific-Aspergillus antibody response in cats with 
aspergillosis was performed to develop a non-invasive test for rapid diagnosis and shed 
further light on disease pathogenesis. 
 
Clinicopathological findings, aetiology and treatment outcomes in 23 cats with URTA 
recruited retrospectively (1998-2006) and prospectively (2007-2009) were documented. 
Fungal pathogens were identified by PCR and DNA sequencing (ITS1 or ITS1-5.8S-
ITS2 regions, rDNA gene cluster). The median age was 5 y (1.5-13y) and no sex bias 
was identified.  SOA (n=17) was three times more common than SNA (n=6). Pure-bred 
cats with brachycephalic confirmation comprised more than a third of the study 
population (n=9).  Fungal culture was positive in 22/23 cases. Aspergillus fumigatus (n = 
4), Neosartorya fischeri or A. lentulus (n = 1) and a non-speciated Neosartorya spp. (n = 
1) were identified from cats with SNA. In all cases of SOA (n = 17), the fungal pathogen 
was identified as Neosartorya spp. A teleomorphic phase was identified in a subset of 
these isolates, (n=14) indicating a single heterothallic species. ITS sequences from 
these isolates had closest ancestry with several species within the Aspergillus 
viridinutans complex. Cats with SNA were significantly more likely to be infected with A. 
fumigatus and had a better prognosis than cats with SOA. 
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 We describe a novel heterothallic species in Aspergillus section Fumigati, namely A. 
felis (neosartorya-morph) isolated from three host species with invasive aspergillosis 
including a human patient with chronic invasive pulmonary aspergillosis, domestic cats 
with invasive fungal rhinosinusitis and a dog with disseminated invasive aspergillosis. 
Disease in all host species was often refractory to aggressive antifungal therapeutic 
regimens. Four other human isolates previously reported as A. viridinutans were 
identified as A. felis on comparative sequence analysis of the partial β-tubulin and/or 
calmodulin genes. A. felis is a heterothallic mold with a fully functioning reproductive 
cycle, as confirmed by mating-type analysis, induction of teleomorphs within 7 to 10 
days in vitro and ascospore germination. Phenotypic analyses show that A. felis can be 
distinguished from the related species A. viridinutans by its ability to grow at 45 °C and 
from A. fumigatus by its inability to grow at 50 °C. Itraconazole and voriconazole cross-
resistance was common in vitro.  
 
The pathogenesis of URTA, in particular, the relationship between the infecting isolate 
and outcome, is poorly understood. Computed tomography was used to investigate the 
route of fungal infection and extension in 16 cases (SNA n=7, SOA n=9) where the 
infecting isolate had been identified by molecular testing. All cases had nasal cavity 
involvement except one cat with SNA that had unilateral frontal sinus changes. A strong 
association between the infecting species and anatomic form was identified. A. 
fumigatus infections remained within the sino-nasal cavity. Cryptic species infections 
were associated with orbital and paranasal soft-tissue involvement and with orbital lysis. 
These species were further associated with a mass in the nasal cavity, paranasal 
sinuses or nasopharynx. Orbital masses showed heterogeneous contrast enhancement, 
with central coalescing hypoattenuating foci and peripheral rim enhancement.  Severe, 
cavitated turbinate lysis, typical of canine SNA, was present only in cats with SNA.  
These findings support that the nasal cavity is the portal of entry for fungal spores in 
feline URTA and that the route of extension to involve the orbit is via direct naso-orbital 
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communication from bone lysis. Additionally, a pathogenic role for A. wyomingensis and 
a sinolith in a cat with A. udagawae infection are reported for the first time. 
 
Detection of the fungal antigen galactomannan in serum has poor sensitivity for 
diagnosis of URTA in cats. The diagnostic sensitivity of detection of Aspergillus-specific 
antibodies has not been determined. The aims of this study were (i) to determine if a 
commercial aspergillin derived from mycelia of A. fumigatus, A. niger and A. flavus can 
be used to detect serum antibodies against cryptic Aspergillus species and (ii) to assess 
the diagnostic value of detection of Aspergillus-specific antibodies using an agar-gel 
double immunodiffusion (AGID) assay and an indirect IgG ELISA. Sera from 21 cats 
with URTA (Group 1), 25 cats with other upper respiratory tract (URT) diseases (Group 
2) and 84 control cats (Group 3) were tested.  
 
Isolates from cats with URTA comprised A. fumigatus (5), A. flavus (1) and four cryptic 
species; A. felis (12), A. thermomutatus (1), A. lentulus (1) and A. udagawae (1). There 
were significantly more brachycephalic breed cats in Group 1 (52%) compared with 
Group 2 (16%, P=0.0125) or Group 3 (3%, P<0.001). Antibodies of cats infected with 
cryptic fungal species cross-reacted with the aspergillin. The AGID was positive in 43% 
of Group 1 cats and negative in all other cats. The IgG ELISA was positive in 90% of 
Group 1 cats and negative in 96% and 100% of Group 2 and 3 cats respectively, using 
a cut-off value of 9 Elisa Units/mL. Brachycephalic purebred cats are significantly more 
likely to develop URTA than other breeds of cats. Detection of Aspergillus-specific 
antibodies by IgG ELISA has high sensitivity and specificity for diagnosis of feline 
URTA.  
 
Through this program of research understanding of epidemiological, clinical and 
aetiological aspects of feline aspergillosis have been more fully elucidated. Key findings 
include discovery of a novel aetiological agent, A. felis which causes upper respiratory 
(feline), invasive pulmonary (human) and disseminated invasive (canine) aspergillosis in 
both immunocompetent (feline) and immunocompromised (human, canine) host species 
xviii 
 
and is present at least in Australia and Europe. In cats, SOA is the most common 
anatomic form of disease and A. fumigatus infections remain confined to the sinonasal 
cavity, while SOA is associated with A. felis and other cryptic species infections. Cats 
with URTA are systemically immunocompetent and specific anti-Aspergillus IgG 
antibodies are readily detectable in the serum of infected cats. This research represents 
an important step in our understanding of feline aspergillosis.  
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Chapter 1. Introduction 
This research journey began in 2006 when I was referred three unusual cases of upper 
respiratory tract disease in young domestic cats presenting to the Valentine Charlton 
Cat Centre. Subsequent investigations revealed that all three cases had aspergillosis 
affecting the nasal cavity and paranasal sinuses, with additional orbital involvement in 
two cases. At that time very little was known about this disease in cats since only 12 
cases had been described worldwide (Goodall et al., 1984; Hamilton et al., 2000; Peiffer 
et al., 1980; Tomsa et al., 2003; Whitney et al., 2005; Wilkinson et al., 1982). Fungal 
cultures had been performed in only four cases, of which only one had phenotypic 
identification to species level indicating infection with Aspergillus niger (Whitney et al., 
2005). Coincidentally in 2006, colleagues at the Centre for Infectious Diseases at 
Westmead Hospital had requested submission of tissue specimens from humans and 
companion animals with mycoses to evaluate the diagnostic utility of a panfungal PCR 
assay that they had recently developed to amplify the internal transcribed spacer 1 
(ITS1) region of the ribosomal DNA gene cluster (Lau et al., 2007). The molecular 
identification of biopsy tissues from one of my three feline cases was Neosartorya 
pseudofischeri. My interest was immediately piqued, and the ensuing program of 
research stemmed from these three sentinel cases. 
 
The overall objective of my research was to characterise feline upper respiratory tract 
aspergillosis. Specific aims were to describe clinicopathological findings, identify 
aetiological agents, and evaluate diagnostic modalities and treatment outcomes. In 
order to achieve this, case materials including medical histories, computed tomographic 
images, fungal cultures and serological samples were recruited from affected cats 
Australia-wide initially (Chapter three), and subsequently from Europe and the USA 
(Chapters four and five). In Chapter three, the clinicopathological findings and treatment 
outcomes of 23 cats with aspergillosis from around Australia are described. The findings 
from this study set the stage for further research to confirm discovery of a novel 
species, Aspergillus felis (Chapter four). The specific aims of this part of the research 
 
  
program were to identify isolates from clinically confirmed cases of feline aspergillosis 
using phenotypic, physiologic and phylogenetic analyses. Following on from the 
preliminary molecular identification of isolates described in Chapter three using 
comparative multilocus sequencing of the ITS1 region, I sequenced three partial genes 
from six Aspergillus isolates from cats with sino-orbital aspergillosis – betatubulin 
(BenA), calmodulin (CalM) and actin. Preliminary phylogenetic analyses of these results 
revealed the tantalizing possibility that most cases of feline sino-orbital aspergillosis 
were caused by a single novel species of Aspergillus closely related to Aspergillus 
viridinutans, a member of Aspergillus section Fumigati. After reading taxonomical 
studies published by Professor Robert Samson, a world-renowned authority on 
Aspergillus (Samson et al., 2007a), I contacted him and shared my preliminary findings, 
which sparked mutual excitement. I was fortunate to then spend six weeks at the CBS-
KNAW Fungal Biodiversity Centre in Utrecht performing morphological and molecular 
studies of isolates with Professor Robert Samson, Dr Jos Houbraken and Tineke van 
Doorn, funded by an Endeavour Research Fellowship from the Australian Government. 
While in Europe I formed two further fruitful collaborations with Professor Malcolm 
Richardson from the Mycology Reference Centre in Manchester and Dr Maria Dolores 
Pinheiro. Between publication of the manuscript in Chapter three and that in Chapter 
four, a gripping nomenclature debate was playing out around the world concerning 
fungal taxonomy, which is addressed in the literature review in Chapter two. 
Upon my return to Australia I collaborated with Dr Sarah Kidd, Director of the National 
Mycology Reference Centre (Adelaide), who performed antifungal susceptibility testing 
on the isolates described in Chapter four, to complete the phenotypic analyses. 
 
The final part of the research program, outlined in Chapters five and six, turned back to 
the host in which Aspergillus felis was first discovered – the domestic cat. This was 
inspired by the finding that very few cases of sino-orbital aspergillosis have successful 
treatment outcomes and that most cats succumb to neurological involvement (Barrs et 
al., 2012b; McLellan et al., 2006; Smith and Hoffman, 2010). An understanding of 
disease pathogenesis is necessary to develop effective treatments. The specific aims of 
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the research described in Chapter five were to evaluate computed tomographic (CT) 
findings in cats with aspergillosis to determine whether all cats with orbital involvement 
have concurrent involvement of the sino-nasal cavity. A positive finding would support 
the putative route of infection via inhalation of spores and subsequent invasion of the 
orbit. Other aims were to determine if there was any association between CT features 
and the form of aspergillosis and/or infecting species. Around this time I concurrently 
supervised a Master’s project (Whitney et al., 2013a) (Appendix two). Dr Joanna 
Whitney evaluated an immunoenzymatic sandwich ELISA to detect galactomannan 
(GM), a fungal cell wall antigen, in serum (Platelia™ Aspergillus EIA, Bio-Rad, Marnes-
la-Coquette, France), for diagnosis of feline upper respiratory aspergillosis. She found 
that GM quantification by ELISA was not a reliable test for the early, non-invasive 
diagnosis of feline URT aspergillosis (sensitivity 23%, specificity 78%).  Following on 
from this, I embarked on the final stage of my research program to evaluate the 
diagnostic utility of specific anti-Aspergillus antibody detection in serum, using agar gel 
immunodiffusion and Immunoglobulin G ELISA, for diagnosis of aspergillosis. The 
results of this research are outlined in Chapter six. Around this time I was invited to 
write a review on feline aspergillosis, and the discussion of the results of my research 
findings in Chapters three, four are integrated with other published literature in this 
review Chapter seven. Chapter seven also includes further discussion of the research 
findings of Chapters five and six and future directions for aspergillosis research. 
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Chapter 2. Literature Review 
 
2.1 Respiratory Aspergillosis: A One Medicine Approach 
 
Aspergillosis is a mycosis caused by infection with fungi from the Genus Aspergillus that 
affects a diverse range of animal species. It is diagnosed increasingly in humans due to 
an increased prevalence of immunosuppression from cancer, chemotherapy, organ 
transplantation and autoimmune disease (Romani, 2011). Further, global warming is 
predicted to increase the prevalence of fungal infections in mammals by increasing the 
geographic range of pathogenic fungi (Garcia-Solache and Casadevall, 2010). 
Aspergillus spp. are amongst the most common moulds on earth. These ubiquitous, 
filamentous, saprophytic, ascomycetes are distributed primarily in soil and decaying 
vegetation and have an important role in recycling environmental carbon and nitrogen 
(Latge, 1999). The genus is named after “aspergillum”, a brush or implement with a 
perforated head similar to a shower-head used by Roman Catholic priests for sprinkling 
holy water (Figure 1) (Bennett, 2009).  
 
 
 
Figure 1: Line-drawing of an aspergillum, used 
by Catholic priests to sprinkle holy water. 
Aspergillus spp. reproduce asexually by 
producing spores or conidia on a morphological 
structure that resembles an aspergillum. 
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The respiratory tract is the most common site of disease reflecting the primary route of 
infection – inhalation. Infection involves the upper or lower respiratory tracts, is invasive 
or non-invasive as defined by presence or absence of tissue invasion by fungal hyphae 
and occurs in both immunocompetent and immunocompromised hosts. Invasive 
pulmonary aspergillosis (IPA) is the most common form of invasive aspergillosis (IA) in 
humans while upper respiratory tract (URT) aspergillosis, also known as fungal 
rhinosinusitis (FRS), is the most common form in cats and dogs. URT aspergillosis can 
be further subdivided into sinonasal aspergillosis (SNA) and sino-orbital aspergillosis 
(SOA). In addition to feline URT aspergillosis, comparative aspects of respiratory 
aspergillosis in dogs and humans are reviewed.  
 
2.2 Nomenclature and taxonomy 
2.2.1 The Aspergillus fumigatus complex 
 
The genus Aspergillus and the closely related genus Penicillium belong to the family 
Aspergillaceae (order Eurotiales, class Eurotiomycetes, phylum Ascomata). Several 
hundred species have been ascribed to the Genus Aspergillus, which is currently 
subdivided into 4 subgenera (Aspergillus, Circumdati, Fumigati, Nidulantes) and 19 
sections (Houbraken et al., 2014) (Table 1.1).  
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Table 2.1 
Subgenera and Sections in genus Aspergillus (Houbraken et al., 2014) 
 
Subgenus  Section (teleomorph) 
Aspergillus Aspergillus (Eurotium) 
Restricti (Eurotium) 
Circumdati Candidi 
Circumdati (Neopetromyces) 
Flavi (Petromyces) 
Flavipedes (Fennellia) 
Nigri 
Terrei 
Fumigati Cervini 
Clavati (Neocarpenteles, Dichotomomyces) 
Fumigati (Neosartorya) 
Nidulantes Aeni (Emericella) 
Bispori 
Cremei (Chaetosartorya) 
Nidulantes (Emericella) 
Ochracerosei 
Silvati 
Sparsi 
Usti (Emericella) 
 
   
 
The most common isolates to cause respiratory aspergillosis in dogs, cats and humans 
are from the subgenus Fumigati section Fumigati, also known as the Aspergillus 
fumigatus complex (Balajee et al., 2007; Balajee et al., 2006; Barrs et al., 2012a; 
Peeters et al., 2008; Pomrantz and Johnson, 2007, 2010).  
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 The A. fumigatus complex contains asexual members (anamorphs, mitotic phase), 
many of which also have sexual forms (teleomorphs, meiotic phase). The anamorph is 
typically mould-like and bears mitotic spores (conidia) while the teleomorph is 
characterised by the production of meiotic spores (ascospores) that develop within sacs 
(asci) that develop inside enclosed globose fruiting bodies known as cleistothecia 
(Samson et al., 2007a) (Figure 2).  
 
anamorph teleomorphheterothallic fungus with 2 mating types
MAT-1 MAT-2
cleistothecia
100 μm
cleistothecium
2 μm
8-spored asci ascospore  
 
Figure 2. Holomorph of an A. fumigatus complex species, A. felis sp. nov. 
comprising anamorph and teleomorph phases. For heterothallic fungi the 
teleomorph forms at the junction of two colonies of complementary mating type. 
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Heterothallic fungi (e.g. A. fumigatus) require a partner of complementary mating type 
for successful sexual reproduction. The genes that determine mating-type (MAT) are 
located at a single locus, the MAT-1 locus, which contains either a MAT-1-1 “idiomorph” 
or a MAT-1-2 idiomorph (also known as MAT-1 and MAT-2 respectively) (Paoletti et al., 
2005). MAT-1 encodes a MAT protein with an alpha protein and MAT-2 encodes a MAT 
protein with a high-mobility group (HMG) (Rydholm et al., 2007). The MAT proteins act 
as transcription factors to enable sexual reproduction. Homothallic species are self-
fertilising and contain both the alpha and HMG-domain MAT genes within the same 
genome, either fused together or located in close proximity in the MAT-1 locus, or within 
two distinct loci, as is the case for Neosartorya fischeri (Rydholm et al., 2007).   
 
Controversy has surrounded the fungal taxonomy of the Aspergillus fumigatus complex 
because of the system of dual nomenclature used to describe anamorphic and 
teleomorphic phases of the same fungus. Traditionally the anamorphic phase is 
assigned to the genus Aspergillus while the teleomorph of the same organism is 
assigned to the genus Neosartorya. The entire organism, comprising the anamorph and 
teleomorph is referred to as the holomorph. Under classical nomenclature rules the 
teleomorphic name has received taxonomic precedence, such that species with known 
sexual stages were referred to by their teleomorph names (Pitt and Samson, 2007). 
While this system of dual  nomenclature provided a practical solution for distinguishing 
organisms that produce ascospores, confusion arose for organisms such as A. 
fumigatus where the teleomorph (Neosartorya fumigata) was only recently discovered 
and the taxon continued to be referred to by its anamorph name (O'Gorman et al., 
2009). In sweeping reforms to the International Code of Nomenclature for algae, fungi 
and plants (previously known as the International Code of Botanical Nomenclature 
(ICBN) a “one-fungus, one-name” principle was adopted in 2011 (Miller et al., 2011). 
The system of dual nomenclature was deleted, giving anamorph names the same 
priority as teleomorph names, and allowing anamorph names to be used as holomorph 
names. Subsequent to these reforms teleomorph-based genera such as Neosartorya 
are synonymised with Aspergillus (Houbraken et al., 2014) 
8 
 
 
2.2.2 Fungal species identification – a polyphasic approach 
 
It is now well established that members of the Aspergillus fumigatus complex cannot be 
reliably identified solely on the basis of phenotypic features (morphological or 
physiological). Some, termed A. fumigatus-mimetic or “cryptic” species, have very 
similar anamorph colony morphology to A. fumigatus. For species delimitation, that is, 
determination of the boundaries and numbers of species from empirical data, and for 
identification of new species a polyphasic approach incorporating morphological, 
physiological, ecological and phylogenetic methods is considered the gold standard by 
mycologists since it is superior to any of these methods used in isolation (Figure 3) 
(Samson and Varga, 2009; Samson et al., 2007b).  
 
 
DNA
e.g. ITS, β-tubulin
Morphology
Physiology
e.g. extrolites
Ecology
e.g. host, origin
Genetics
e.g. mating tests
Comparative
Genomics
Species
 
Figure 3. The use of combined data sets in polyphasic taxonomic classification of 
an Aspergillus taxon, after Samson and Varga (2009). 
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 The polyphasic taxonomical approach for fungal species delimitation also encompasses 
three species concepts widely used in mycology (Rokas et al., 2007): 
 
(i) Morphological species concept:  species recognition based on morphological 
characters. 
 
(ii) Biological species concept: species recognition based on establishment of 
reproductive isolation (applicable where teleomorphs are identified). 
 
(iii)  Phylogenetic species concept: species recognition based on shared ancestry. 
 
Morphological and physiological methods for characterisation of Aspergillus species 
include macro- and micro-morphology, growth rate at different temperatures and water 
activities, growth on creatine-sucrose agar, conidial colour and secondary metabolite 
profiles. Ecological methods include geographic origin and host species while the most 
widely utilised phylogenetic method is multi-locus sequence typing (MLST) of loci such 
as the internal transcribed spacer (ITS) regions, β-tubulin, calmodulin, actin and other 
intron-rich protein coding genes (Balajee et al., 2007; Samson et al., 2007a; Samson et 
al., 2007b). Recommendations on the best-practice approach for describing new 
Aspergillus species including current requirements of the International Code of 
Nomenclature for algae, fungi and plants are listed in Box 1 (Knapp et al., 2011; 
Samson and Varga, 2009; Samson et al., 2007b). 
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Box 1. Recommendations of an international panel of mycologists on best-
practice approach to describing new Aspergillus species and updated 
requirements from the International Code of Nomenclature for algae, fungi and 
plants, after Samson et al 2007, Knapp et al 2011 and Miller et al 2011 (Knapp et 
al., 2011; Miller et al., 2011; Samson et al., 2007b) 
 
• A polyphasic approach including molecular, morphological, physiological and ecological 
data should be used. 
• New species should be compared to type strains of presumed relatives. 
• Proposed new species should show evidence for evolutionary divergence from other 
taxa, particularly unique DNA characters at multiple independent loci (e.g. ITS, Β-
tubulin, calmodulin, actin, RNA polymerase), in addition to any distinctive extrolites 
and morphological characters. 
• The description required for valid publication of the name of a new taxon may be in 
either English or Latin and should indicate differences from related taxa. 
• Malt Extract Agar and Czapek’s Agar, with referenced formulas, should be used for the 
description. 
• Type cultures of new species should be deposited in at least two international 
recognized culture collections. 
• If type cultures are not made available for the scientific community within 6 months of 
publication of the new species, the species will be considered invalid. 
• A requirement for valid publication of a new species is a unique identifier issued 
through registration with a recognized repository, e.g. Mycobank 
www.mycobank.org/. 
• Sequences must be deposited in recognized genetic databases. 
• From 2012 the one fungus, one name principle will be adopted, where only a single 
name applies to each fungal species. 
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2.2.2.1 Macro- and micro- morphology 
 
Phenotypic features routinely included in species descriptions for identification of A. 
fumigatus complex include colony patterns and the morphology of the conidiogenous 
structures, conidia, asci and ascospores. Colony patterns include colony diameter after 
7-days growth of 3-point inoculations on Czapek agar, Czapek yeast autolysate agar 
(CYA), oatmeal agar (OA) and malt extract agar (MEA) at 25oC and on CYA at 37oC as 
well as colony colour, colony texture and reverse colony colour (Samson et al., 2007a). 
 
Approximately a third of all described Aspergillus species have a known sexual phase 
(teleomorph) and less than 10 of these are heterothallic (Geiser, 2009).  Heterothallic 
fungi within the A. fumigatus complex exist most commonly in their anamorphic form in 
nutritionally rich environments such as in nature and in the host. When conditions are 
unfavourable in nature for vegetative growth, sexual reproduction may be initiated (Pal 
et al., 2007). Cleistothecia of Neosartorya species in the Aspergillus fumigatus complex 
are characterised by walls consisting of flattened hyphae (Figure 2) (Geiser, 2009). 
Asci almost always contain eight ascospores, which are lens-shaped and often have 
two or more equatorial rings (Figure 2). Sclerotia, rounded masses of mycelium with an 
outer melanized rind, resemble cleistothecia grossly, but do not contain ascospores. 
Formation of sclerotia by some fungi is thought to facilitate survival during adverse 
growth conditions (Bennett, 2010).  
 
Differences in ornamentation of conidia can assist in species identification (Balajee et 
al., 2007; Geiser, 2009).   In a study of phylogenetic relationships among A. fumigatus 
and related species using comparative sequence analyses of partial regions of the β-
tubulin, calmodulin and Rodlet A genes, five clades were identified (Yaguchi et al., 
2007). Clades were correlated with conidial morphology using scanning electron 
microscope studies. Differences in conidial ornamentation were identified:  in general 
isolates in clades I and V had lobate-reticulate ornamentation, isolates in clades II -IV 
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had microtuberculate ornamentation while the conidial ornamentation of A. viridinutans 
was intermediate between the other two types (Balajee et al., 2007; Yaguchi et al., 
2007). The ornamentation of ascospores and their equatorial crests, of the teleomorphic 
species within the A. fumigatus complex, is highly but not exclusively species-specific 
since some species have similar ascospores (Samson et al., 2007a). Since the 
widespread implementation of phylogenetics less emphasis is now being placed on 
ascospore ornamentation in systematics (Geiser et al., 2007). Also, induction of 
teleomorphs in vitro is often difficult or impractical – some isolates cannot be induced to 
produce ascospores because of repeated subculturing on rich medium, induction of 
teleomorphs of heterothallic fungi requires possession of isolates of complementary 
mating type, and some species require prolonged incubation times of up to six months 
to induce ascospore formation, e.g. A. fumigatus (Balajee et al., 2005a; O'Gorman et 
al., 2009).  
 
2.2.2.2 Mating tests 
 
For heterothallic fungi the correlation between biological species based on mating tests 
and phylogenetic species based on multilocus sequence typing is very strong (Geiser et 
al., 2007).   
 
2.2.2.3 Fungal growth temperature regimes 
 
Differences in minimum and maximum growth temperatures using standardised media, 
usually MEA and CYA, are a useful phenotypic feature not only for species delimitation, 
but for identification of species in clinical settings. A. fumigatus is particularly 
thermotolerant being able to grow at temperatures over 50oC. Ability to grow at 10oC, 
42oC, 45oC and 50oC for a number of A. fumigatus complex members is depicted in 
Table 2.1 (Balajee et al., 2005b; Hong et al., 2005; Samson et al., 2007a; Sugui et al., 
2010; Yaguchi et al., 2007). 
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Table 2. 1 Growth of A. fumigatus complex members at different temperatures  
 Growth 
Species 10 42 45 >50 
A. fumigatus - + + + 
A. viridinutans + + - - 
A. lentulus  + + + - 
N. udagawae + + - - 
 
2.2.2.4 Metabolomics - Extrolite profiles 
 
The metabolome of a fungus refers to its complete set of small-molecule metabolites. A 
small fraction of these molecules is utilised currently for the classification and 
identification of fungi (chemotaxonomy) based on profiles of outwards-directed 
metabolites (extrolites) as measured by chromatography and mass spectrometry 
(Frisvad et al., 2007; Hong et al., 2008). The secondary metabolites produced by 
Aspergillus species have high species-specificity - each species typically produces a 
unique combination of extrolites or a unique extrolite (Hong et al., 2008). Typical 
secondary metabolites produced by all Aspergillus species include polyketides, non-
ribosomal peptides, terpenoids and compounds of mixed biosynthetic origin (Frisvad et 
al., 2009; Samson and Varga, 2009). One limitation of chemotaxonomy is that while all 
strains of the same species produce the same profile of secondary metabolites, one or 
more secondary metabolites may not be expressed phenotypically in any given strain 
(Frisvad et al., 2009). 
 
Chemotaxonomic analyses require standardised growth conditions including culture 
media, growth temperature and analysis during sporulation. Optimal culture media to 
achieve the highest concentration and number of secondary metabolites in filamentous 
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fungi are those containing high amounts of sucrose and glucose, yeast or malt extract 
and added minerals and trace metals, e.g. dichloran-Rose Bengal-yeast extract-sucrose 
(DRYES), yeast extract-sucrose (YES) agar, malt extract agar (MEA) and potato-
dextrose agar (PDA) (Hong et al., 2008). For comparative chemotaxonomy metabolite 
extraction from isolates should be performed at the same time using isolates grown 
together at the same temperature using the same batch of media (Hong et al., 2008). It 
has been recommended that for species descriptions, a panel of 4 to 8 extrolite be used 
(Samson et al., 2007b). In their revision of the taxonomy of Aspergillus section Fumigati 
Samson et al (Samson et al., 2007a) performed extrolite profiling using the high 
performance liquid chromatography (HPLC)-diode array detection method 
(Smedsgaard, 1997). Extrolites were analysed from cultures grown on YES, oatmeal 
agar (OA) and Czapek yeast autolysate agar (CYA) using agar plugs.  In a recent 
update of the extrolite profile of A. fumigatus 226 extrolites from 24 biosynthetic families 
were detected (Frisvad et al., 2009).  The major extrolites from A. fumigatus are 
depicted in Figure 4.  
 
Figure 4. Extrolite profile of A. fumigatus depicting major and typical extrolites for 
this species, as described by Frisvad et al 2009. Reproduced with permission of 
Informa Healthcare (Frisvad et al., 2009). 
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2.2.2.5 Phylogenetic methods 
 
Molecular characters provide the greatest number of variables for fungal taxonomy and 
can be generated using readily available technology. Phylogenetic methods that have 
been used for speciation of Aspergillus include RFLPs (restriction fragment length 
polymorphisms), AFLP (amplified fragment length polymorphisms), MLEE (multilocus 
enzyme electrophoresis), RAPD-PCR (random amplification of polymorphic DNA), 
ribosomal RNA sequences and protein-coding sequences (Geiser et al., 2007).  
 
Multilocus comparative DNA gene sequence analysis of a combination of genes or 
partial gene regions including internal transcribed space (ITS), calmodulin, β-tubulin, 
actin and Rodlet A is the most common phylogenetic method applied for species 
delimitation and identification within the A. fumigatus complex (Samson et al., 2007a). 
The genome of all fungi contains multiple copies of the ribosomal DNA (rDNA) gene 
complex, consisting of highly variable regions, the ITS regions, which are flanked by 
highly conserved gene sequences that are suitable targets for primers. Sequence 
heterogeneity within the ITS regions is useful for the separation of both genera and 
species, and appropriately exploited as a “panfungal” PCR for identification of fungi in 
clinical specimens (Iwen et al., 2002; Lau et al., 2007). The rDNA gene complex 
includes three genes - the 18s rDNA gene, also known as the small-subunit (SSU) 
rDNA gene, which is about 1800 base pairs (bp) long, the 5.8S gene (159 bp) and the 
28S rDNA, also known as the large-subunit (LSU) rDNA gene (3396 bp) (Figure 5) 
(Chen et al., 2002).  Comparative sequence analyses of the ITS regions, specifically 
ITS1-5.8S-ITS2,  is recommended as an appropriate locus to first identify Aspergillus 
isolates to the level of subgenus/complex (Balajee et al., 2007). However since some 
closely related species show little or no variation in ITS sequences, solid phylogenetic 
species recognition requires concurrent analyses of one or more of the aforementioned 
gene regions (Samson et al., 2007b). Samson et al (Samson et al., 2007a) found that 
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sequencing the calmodulin and β-tubulin genes achieved good species delimitation and 
recognition for A. fumigatus complex members.  
 
 
 
 
Figure 5.  Representation of the ribosomal DNA (rDNA) gene complex in fungi 
denoting gene order of small subunit (SSU) and large subunit (LSU) and position 
of internal transcribed spacer  (ITS) regions, after Chen et al., 2002 (Chen et al., 
2002) 
 
2.3 Aetiological agents of aspergillosis in humans, dogs and cats 
2.3.1 Humans 
 
A. fumigatus, A. flavus, A. terreus and A. niger are the most common causes of IA in 
humans (Klich, 2006; Thompson and Patterson, 2011). Of these A. fumigatus is 
reported most commonly. However, more recently with the application of molecular 
identification techniques, other members of the A. fumigatus complex, known as A. 
fumigatus-mimetic species or ‘cryptic’ species previously mis-identified as A. fumigatus, 
have been increasingly recognised in patients with IA, including A. lentulus, A. 
viridinutans, A. udagawae, N. pseudofischeri, A. fumisynnematus and N. hiratsukae 
(Alcazar-Fuoli et al., 2008; Balajee et al., 2005b; Balajee et al., 2006; Katz et al., 2005; 
Sugui et al., 2010; Vinh et al., 2009a).  Fungal rhinosinusitis (FRS) is most commonly 
caused by A. fumigatus or A. flavus although confirmation of identification of isolates 
using molecular techniques has not yet been reported (Chakrabarti et al., 2009; Hope et 
al., 2005a). 
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Mis-identification of A. fumigatus in human patients with IA has important implications 
for treatment and prognosis. In a review of 86 isolates from human patients with IA 
previously identified as A. fumigatus, 12 isolates were subsequently identified as A. 
udagawae based on beta-tubulin and rodlet A sequences (Sugui et al., 2010).  In this 
subset of patients the median duration of illness was 7 times longer and disease was 
refractory to standard therapy. Similarly, a distinctive form of IA characterised by 
chronicity, propensity to spread across anatomical planes and reduced susceptibility to 
antifungal drugs was initially attributed to infection by A. fumigatus. The molecular 
identity was A. viridinutans (Vinh et al., 2009a).  Also A. fumigatus-mimetic species have 
higher in vitro minimum inhibitory concentrations (MICs) for amphotericin-B and triazole 
antifungal drugs (e.g. voriconazole) than A. fumigatus (Alcazar-Fuoli et al., 2008). 
 
2.3.2 Dogs 
Phenotypic identification of a large number of isolates from dogs with SNA has 
implicated A. fumigatus as the aetiologic agent in most cases (Pomrantz and Johnson, 
2007, 2010).  There are also occasional reports of isolates from the subgenus 
Circumdati (A. flavus and A. niger) (Sharp, 1998) and from the subgenus Nidulantes (A. 
nidulans) (Sharp et al., 1991b) causing SNA in dogs. However, identification of isolates 
was phenotypic in all but one report where molecular identification was performed on a 
small number of isolates only (Peeters et al., 2008). In 14 dogs with clinically confirmed 
SNA, DNA of Penicillium or Aspergillus spp. was detected in nasal mucosal biopsies 
using a genus-specific ITS real-time quantitative PCR (qPCR) assay. Species-specific 
ITS qPCRs to detect DNA of A. fumigatus, A. niger, A. terreus or A. flavus developed by 
Haugland et al (Haugland et al., 2004) were positive for A. fumigatus in 7 dogs and 
negative in the other 7 dogs. It is possible that the negative isolates may have been 
Penicillium spp. or another Aspergillus spp.  Alternatively there may have been 
insufficient A. fumigatus DNA present to be positive with the specific PCR. Fungal 
culture was positive in only 6 of the dogs diagnosed with aspergillosis, of which DNA of 
A. fumigatus was detected in 5. Also on examination of histological Grocott-stained 
sections, fungal hyphae were observed at the surface of the mucosa in biopsies from 
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only 6 of the 14 dogs. A likely reason for the negative culture and histologic results in 
these dogs was that a standardized site for biopsy of sinonasal mucosa was used for 
biopsy collection. Since the distribution of fungal plaques within the sinonasal cavity is 
uneven, fungal plaques were likely missed using this sampling approach. Furthermore, 
seven dogs had also received oral antifungal therapy (ketoconazole or itraconazole) for 
8 to 15 days prior to biopsy collection, which could have contributed to the negative 
culture, histologic and PCR results in affected dogs. Clearly there is a need for 
molecular studies to determine the aetiological agents in canine sinonasal aspergillosis, 
specifically the frequency of involvement of individual species within the Aspergillus 
fumigatus complex and from subgenera other than Fumigati. 
 
2.3.3 Cats 
Little information exists about the aetiological agents of feline upper respiratory tract 
(URT) aspergillosis. Of 22 reported cases fungal culture was not attempted in four 
cases (Peiffer et al., 1980; Smith and Hoffman, 2010; Whitney et al., 2005) and was 
negative in six others (Goodall et al., 1984; Halenda and Reed, 1997; Tomsa et al., 
2003; Whitney et al., 2005). Of the 12 cases in which fungal culture was positive, 
identification was based on phenotypic features alone in 11 cases and on both 
phenotypic features and molecular identification in one case only.  A. fumigatus was 
identified in five cases (Barachetti et al., 2009; Giordano et al., 2010; McLellan et al., 
2006; Quimby et al., 2010; Smith and Hoffman, 2010), an Aspergillus of unknown 
species was identified in three cases (Furrow and Groman, 2009; Hamilton et al., 2000; 
Wilkinson et al., 1982), A. niger  was identified in two others (Furrow and Groman, 
2009; Whitney et al., 2005) and A. flavus in one case (Malik et al., 2004). A. udagawae 
was identified as a cause of feline SOA in a single case report from Japan using 
comparative sequence analysis of the ITS and β-tubulin genes (Kano et al., 2008).  
 
 
2.4. Aspergillosis - parallels between humans, dogs and cats with regard to 
epidemiology, pathogenesis and clinical disease. 
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2.4.1 Humans 
 
In humans aspergillosis is generally classified by body system involvement, pathology 
and pathogenesis. Disease is subcategorized, according to the presence or absence of 
hyphal invasion into tissues, as invasive aspergillosis (IA) or non-invasive aspergillosis. 
IA is further classified according to the presence or absence of angioinvasion, i.e. fungal 
invasion of blood vessels (Hope et al., 2005a).  Invasive aspergillosis (IA) in humans 
occurs predominantly in the sinopulmonary tract of immunocompromised individuals, 
after inhalation of Aspergillus spp. conidia (Segal, 2009). The lung is the most common 
site of disease, with invasive pulmonary aspergillosis (IPA) accounting for over 90% of 
IA cases (Hope et al., 2005a). The classification of sinopulmonary and disseminated 
forms of aspergillosis is summarised in Table 2.2 (Chakrabarti et al., 2009; Hope et al., 
2005a; Panda et al., 2004; Uri et al., 2003). 
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Table 2.2 Classification of disseminated and respiratory aspergillosis in humans. 
Anatomic 
Location 
Invasive/ 
Non-invasive 
Immune status Features of Disease 
Disseminated Invasive Immunocompromised Infection at ≥ 2 non-contiguous sites, 
haematogenous dissemination. 
Lower 
Respiratory 
Tract 
 
Invasive Pulmonary 
Aspergillosis (IPA) 
(Angioinvasive) 
 
Immunocompromised 
- prolonged severe 
neutropenia 
Vascular invasion by fungal elements 
IPA 
(Non-Angioinvasive) 
Immunocompromised 
non-neutropenic: 
- HIV/AIDS 
- corticosteroids 
- hematopoietic stem cell 
transplant recipients 
- heritable immune defect  
No evidence of vascular invasion. 
Pyogranulomatous inflammatory infiltrate. 
Chronic Invasive PA 
(Non-Angioinvasive): 
- chronic necrotizing 
PA 
- chronic cavitary PA 
- chronic fibrosing PA 
Immunocompromised: 
- structural lung disease 
e.g., emphysema 
- corticosteroids 
- HIV/AIDS 
- diabetes, alcohol abuse 
Hyphae mostly contained within cavity with 
only occasional direct tissue invasion 
(chronic necrotizing PA). 
Invasive bronchial 
aspergillosis 
Immunocompromised Hyphal invasion of large airway(s). 
Aspergilloma 
- non-invasive 
Immunocompetent Single cavity with fungal ball. 
No hyphal invasion of parenchyma. 
Upper 
Respiratory 
Tract 
Acute invasive fungal 
rhinosinusitis (FRS) 
(Angioinvasive) 
Immunocompromised: 
- Neutropenia 
- Allogenic stem cell 
transplant recipients 
Hyphal invasion of sinuses and contiguous 
structures e.g. orbit. Coagulative necrosis, 
sparse inflammatory infiltrate, 
angioinvasion. 
 Chronic invasive FRS 
(Angioinvasive) 
Immunocompromised: 
- diabetes 
- corticosteroids 
- HIV/AIDS 
Hyphal invasion of sinuses and contiguous 
structures e.g. orbit. Infiltrative mass, mixed 
inflammatory response, angioinvasion. 
 Granulomatous FRS 
- invasive 
Immunocompetent: 
- Location dependent 
disease Sudan, Middle-
East, Indian subcontinent 
Hyphal invasion of sinuses and contiguous 
structures e.g. orbit. Highly cellular 
granulomatous inflammatory response, no 
angioinvasion 
 Sinus aspergilloma 
(fungal ball) 
- non-invasive 
Immunocompetent: 
- structural sinus disease 
Fungal mass within sinus. Chronic non-
granulomatous inflammatory response to 
fungal mass. 
 Allergic FRS 
- non-invasive 
Immunocompetent Allergic/hypersensitivity response to the 
presence of fungi within the sinus. 
 Chronic erosive non-
invasive  FRS 
Immunocompetent Similar to canine SNA. Marked 
inflammatory response and sinonasal bony 
lysis but no hyphae invasion of mucosa. 
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FRS is defined as invasive when there is hyphal invasion of the mucosal layer. Invasive 
forms of FRS include acute invasive, chronic invasive and granulomatous FRS while 
non-invasive forms  include fungal ball or sinus aspergilloma, allergic FRS and chronic 
erosive non-invasive FRS (Day, 2009; Hope et al., 2005a) (Table 1.2). FRS in humans 
includes infections caused by Aspergillus and other filamentous fungi including Mucor 
spp. (hyalohyphomycoses) and the dematiaceous fungi (phaeohyphomycoses). Further 
discussion of granulomatous FRS and chronic erosive non-invasive FRS is warranted 
here given disease similarities of granulomatous FRS to SOA in cats and of chronic 
erosive non-invasive FRS to SNA aspergillosis in dogs: 
 
 2.4.1.1 Chronic granulomatous fungal rhinosinusitis (FRS) 
Granulomatous FRS occurs in immunocompetent humans subjected to hot, dry 
environmental conditions, poor hygiene and low socioeconomic status (Chakrabarti et 
al., 2009; Siddiqui et al., 2004). This syndrome has mainly been reported in Asia and 
Africa (Pakistan, India, Saudi Arabia, Sudan, other African countries). In contrast to 
other forms of FRS in humans that are mostly caused by A. fumigatus, chronic 
granulomatous FRS is predominantly caused by A. flavus, which has a propensity to 
colonise the nasal and paranasal sinuses in hot, dry climates (Siddiqui et al., 2004).  
Disease is characterised by formation of a necrotic, friable or purulent mass within the 
sinuses followed by invasion of contiguous structures such as the orbit and/or brain, and 
by bony lysis. Clinical presentation includes nasal congestion or discharge, proptosis 
(exophthalmos), restriction of extraocular movements and decreased vision. Disease is 
painful in a third of cases and neurological deficits occur where there is CNS invasion 
(Pushker et al., 2011; Siddiqui et al., 2004). Fungal granulomas in affected patients are 
relatively avascular, consist of a highly cellular inflammatory infiltrate of giant cells, 
histiocytes, plasma cells and fungal hyphae and are necrotic or fibrotic. Angioinvasion 
does not occur, although blood vessels are thickened (Hope et al., 2005a). 
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 2.4.1.2 Chronic erosive non-invasive fungal rhinosinusitis (FRS) 
Chronic erosive non-invasive FRS of humans was first described by Rowe-Jones and 
Moore-Gillon in 1994. Disease is characterised by sinus expansion and bony erosion 
but not tissue invasion, resulting in chronic inflammation intermediate between sinus 
aspergilloma and chronic invasive FRS (Rowe-Jones and Moore-Gillon, 1994). 
However the classification of chronic erosive non-invasive FRS is not without 
controversy, with some investigators suggesting it is really a variant of allergic FRS 
(Chakrabarti et al., 2009). Despite this, chronic erosive non-invasive FRS of humans 
bears many similarities to canine SNA (Panda et al., 2004; Uri et al., 2003) such that 
dogs have been suggested as an appropriate model for study of this disease (Day, 
2009; Peeters et al., 2005). Similarities between human and canine disease include 
chronicity, systemic immunocompetence, the non-invasive nature of the infection with 
fungal hyphae adjacent put not penetrating the sinonasal mucosa, the often extensive 
sinonasal bony lysis and to some degree the histological findings. In both species there 
is an intense mucosal inflammatory reaction to the presence of fungi, which in humans 
consists of neutrophils, lymphocytes and histiocytes, whereas the infiltrate in dogs is 
predominantly lymphoplasmacytic with admixed macrophages and fewer neutrophils 
(Day, 2009).  
 
2.4.2 URT aspergillosis in dogs and cats 
2.4.2.1 Pathogenesis  
In contrast to humans, mycoses with an inhalational route of infection such as 
aspergillosis and cryptococcosis preferentially cause rhinosinusitis over pulmonary 
infection in cats and dogs. This may be associated with anatomical differences in nasal 
cavity and paranasal sinus conformation resulting in initial deposition of inhaled fungal 
spores within the sinonasal cavity in cats and dogs compared to the lower respiratory 
tract in humans. The ability of fungi to cause disease depends on a complex interplay 
between the pathogen (virulence factors) and the host (innate and adaptive immune 
responses). 
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2.4.2.1.1 Innate anti-fungal immunity 
The first line of defense against fungal respiratory infection is the mucosal epithelium of 
the respiratory tract that traps and removes inhaled conidia via the mucociliary escalator 
and acts as an anatomic barrier to invasion (Segal, 2009). Phagocytosis of fungal 
elements, the next line of defense,  by certain host cells (monocytes, macrophages, 
neutrophils and respiratory epithelial cells) results in direct pathogen killing in contrast to 
dendritic cells (DCs) that respond to phagocytosis by promoting the differentiation of 
naïve T cells into effector T helper (Th) cell subtypes (adaptive immunity) (Figure 6) 
(Romani, 2011).  
 
After inhalation, Aspergillus conidia that escape mucociliary clearance are mostly 
phagocytosed by macrophages and DCs. Macrophages ingest and kill conidia 
preventing germination to hyphae, which are invasive. Hyphae resulting from 
germination of conidia that fail to be killed by macrophages, pierce through the cell and 
grow extracellularly. Neutrophils are the dominant host defense against hyphae, which 
are too large to be phagocytosed completely and must be killed by extracellular 
mechanisms. Activation of NAPDH oxidase in macrophages and neutrophils is 
important for conidial and hyphal killing respectively (Shoham and Levitz, 2005). Natural 
killer cells are also important in host-defense and are recruited to the site of infection by 
chemokines (Segal, 2009). Humoral factors involved in the host response to Aspergillus 
include activation of the complement cascade and deposition of complement 
components on the surface of conidia and hyphae. For example complement receptor 3 
(CR3) recognizes C3b or C3d coated β-glucan-containing cell wall components 
(Romani, 2011). 
 
Phagocytic host cells express pattern recognition receptors (PRRs) that recognise 
specific fungal epitopes known as pathogen associated molecular patterns (PAMPs) 
and damaged host cell components known as damage associated molecular 
patterns (DAMPs). The major PAMPs of filamentous fungi are cell-wall components 
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including β-glucans, chitin and mannans while DAMPS include nucleic acids and 
alarmins.  
 
The major PRRs of host cells include: 
(i) C-type lectin receptors (CLRs) – CLRs are a family of transmembrane and soluble 
proteins that have at least one carbohydrate-recognition domains, including dectin-1 
and dectin-2 and the complement-activating mannose-binding lectins, which are 
involved in antifungal immunity. Dectin-1 is the main PRR for β-glucan. Humans with 
genetic deficiencies of dectin-1 are highly susceptible to IFIs.  Ligation of dectin-1 
results in pro- and anti- inflammatory cytokine and chemokine production and can also 
stimulate NADPH oxidase activation (Romani, 2011; Segal, 2009). The NADPH oxidase 
in phagocytes results in the conversion of oxygen to superoxide anion and the 
generation of downstream reactive oxidant metabolites with antimicrobial activity (Segal, 
2009). 
 
(ii) Toll-like receptors (TLRs) – TLRs are a family of transmembrane proteins that 
recognise both PAMPs and DAMPs. TLRs signal the presence of pathogen or tissue 
damage to the host. TLRs are homologous to interleukin-1 receptor 1 and lead to the 
activation of transcriptional factor nuclear factor and mitogen-activated protein kinases. 
In general, activation of TLRs by fungi results in the expression of pro-inflammatory 
cytokines (Segal, 2009). TLR2, TLR4 and TLR9 are the major TLRs involved in 
recognition of fungal PAMPs. A polymorphism in TLR4 in humans is associated with 
increased susceptibility to IPA (Romani, 2011). The morphological phase of the fungus 
encountered by the host-cell has a dramatic effect on differential TLR activation and the 
resultant signaling pathways. When macrophages encounter Aspergillus conidia, TLR4-
dependant pathways are stimulated, resulting in the production of pro-inflammatory 
cytokines such as TNF-α, IL-1α and IL-1β. By contrast when macrophages encounter 
Aspergillus hyphae, TLR2-dependant pathways are activated resulting in IL-10 
production, an anti-inflammatory cytokine (Shoham and Levitz, 2005). 
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 (iii) Nucleotide Oligomerization Domain-like receptors (NOD-like receptors or 
NLRs). NLRs are a family of cytoplasmic proteins that recognise PAMPS and 
endogenous ligands. They have a role in regulation of both inflammatory and apoptotic 
responses. The specific NLRs involved in host recognition of fungi are yet to be 
described. 
 
(iv) Galectin family proteins – e.g. galectin 3 recognises the PAMP of β-mannisidoses 
in the fungal cell wall. 
 
Host factors that predispose individuals to IA include disorders of innate immunity such 
as reduced mucociliary clearance (as occurs with cystic fibrosis), decreased numbers of 
phagocytic cells (i.e. neutropenia) and phagocytic dysfunction (e.g. chronic 
granulomatous disease, in which there is impaired production of oxidative 
intermediates). Long term administration of corticosteroids increases susceptibility to IA 
because of decreased NAPDH activation in phagocytes and also by suppression of 
production of IL-1α, CD14 and MyD88, which are protective against aspergillosis 
(Shoham and Levitz, 2005).  
 
2.4.2.1.2 Adaptive anti-fungal immunity 
Dendritic cells (DCs) modulate the antifungal host response. After exposure to 
Aspergillus conidia and hyphae DCs migrate to the spleen and draining lymph nodes 
inducing specific Th responses which are an essential determinant of host susceptibility 
or resistance to IA (Shoham and Levitz, 2005). In the immune-response to Aspergillus 
Th1 cytokine responses are generally protective while Th2 cytokine responses increase 
susceptibility to IA.  
 
(i) Th1 responses – a dominant Th1 cell response correlates with protective antifungal 
immunity. Activation of Th1 cells is determined by the response of DCs to the 
combination of TLR and CLR signals provided by the fungi. Through production of the 
signature cytokine IFNδ and by aiding production of opsonizing antibodies, Th1 cells 
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enable optimal activation of phagocytes at sites of infection (Romani, 2011). In addition 
to IFNδ other proinflammatory signals characteristic of a Th1 protective response 
include granulocyte-macrophage colony-stimulating factor (GM-CSF), TNF-α, IL-1, IL-6, 
and IL-12, IL-18 as well as the chemokines MIP-1, monocyte chemoattractant protein 
(MCP)-1, and MIP-2 (Shoham and Levitz, 2005). In experimental mouse models of IPA 
augmentation of Th1 responses by administration or depletion of specific cytokines 
enhances antifungal host defense (Cenci et al., 1998).  
 
(ii) Th2 responses – IL-4 and IL-13 are the strongest proximal cytokines to promote 
differentiation of naïve T cells intoTh2 cells (Romani, 2011).  Cytokines produced by 
Th2 cells include IL-4 and IL-5 (Figure 6). Th2 responses favor fungal invasion, fungus-
associated allergic responses (e.g. allergic bronchopulmonary aspergillosis and disease 
relapse (Segal, 2009). 
 
(iii) Th17 responses – The Th17 pathway has a regulatory function in the promotion of 
Th1 responses and suppression of Th2 responses. Th17 cells express mediators to 
recruit neutrophils and produce defensins at sites of infection (Figure 6). Th17 
responses are also implicated in the immunopathogenesis of chronic fungal infections 
possibly by failure to restrain inflammation after IL-17A dependent neutrophil 
recruitment (Romani, 2011). 
 
(iv) T regulatory (Treg) cell responses – The decision of how to respond to infection is 
primarily determined by interactions between pathogens and cells of the innate immune 
system. However, Treg cells feed back into this dynamic equilibrium to regulate 
subsequent immune responses (Romani and Puccetti, 2006). Usually, Treg cells serve 
to restrain exuberant immune reactivity, which benefits the host by limiting tissue 
damage in many chronic infections. However, Treg cell responses can handicap the 
efficacy of protective immunity. Treg cells are a principal source of IL-10 in addition to 
cells infected or exposed to fungal PAMPs (Romani, 2011; Romani and Puccetti, 2006). 
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Thus Treg cell responses are responsible for a spectrum of outcomes ranging from 
protective tolerance to decreased cellular immunity. 
 
Role of IL-10 in fungal infections 
IL-10 is produced by T cells from healthy humans in response to fungal antigen 
preparations, a finding that establishes IL-10 as a signature cytokine of the T-cell 
repertoire in response to fungi (Romani and Puccetti, 2006). In patients with chronic IFIs 
there is an inverse relationship between IFNδ (signature Th1 cytokine) and IL-10. High 
levels of IL-10, present in neutropenic patients with IA negatively impact the production 
of IFNδ and have been linked to susceptibility to IFI (Hebart et al., 2002; Romani, 2011). 
Further, in one study where serial serum IL10 levels were measured, patients that had 
undetected or low levels of IL-10 or that had high levels initially that became 
undetectable had favorable outcomes to therapy in contrast to patients that had 
progressive disease in which IL-10 levels increased  (Roilides et al., 2001).  
 
However, given its prominent effect on resolving inflammation, IL-10 production can be 
a consequence rather than a cause of infection. In chronic fungal infections dominated 
by non-resolving inflammation IL-10 acts as a homeostatic host-driven feedback 
mechanism to limit pathogenic inflammatory responses. The inflammatory process in 
fungal infection is beneficial in containing the infection but an uncontrolled inflammatory 
response is detrimental and may eventually oppose disease eradication (Romani, 
2011). Even in the presence of IL-10, the protective effect of a regulated Th1 response 
is largely preserved, although in some instances, eradication of the pathogen can be 
prevented. 
 
2.4.2.1.3 Fungal virulence factors and evasion of the immune system 
The fungal cell wall changes in structure depending on the morphological phase of the 
fungus. β-1-3-glucans are masked on hyphae and can evade detection by dectin-1, 
while coating of A. fumigatus conidia by melanin and hydrophobins is another 
mechanism that helps evasion of  immune recognition (Romani, 2011). 
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 Figure 6: Model of immune response to inhaled Aspergillus spp., after Segal et al 
2009 and Romani 2011. Ligation of pathogen recognition receptors (PRRs) of host 
macrophages and respiratory epithelial cells by fungal pathogen associated 
molecular patterns (PAMPs) results in induction of chemokines/cytokines that 
recruit neutrophils and other inflammatory cells. Dendritic Cells (DCs) recognise 
PAMPs via PRRs and stimulate antigen-dependent responses in T helper (Th) and 
T regulatory (Treg) cells (Segal, 2009) 
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2.4.2.1.4 Immunology of canine SNA 
 
Several studies have evaluated the immune response to SNA in dogs (Mercier et al., 
2012; Peeters et al., 2006; Peeters et al., 2007; Vanherberghen et al., 2012). In the first 
study the mucosal immune response in SNA was compared to dogs without nasal cavity 
disease through the quantification of messenger RNA (mRNA) encoding cytokines and 
chemokines in nasal mucosal biopsies (Peeters et al., 2006). There was significantly 
more IL8, IL-10, IL-18, TNFα, and monocyte chemoattractant proteins (MCP) 1 – 4 
mRNA expression in the nasal mucosa of dogs with SNA compared to dogs with normal 
nasal mucosa. Given that a dominant Th1 response is associated with production of 
IFNδ by Th1 cells and of the proinflammatory cytokines IL-12, IL-18 and TNFα, the 
upregulation of IL-18 and TNFα in dogs with SNA was considered compatible with this 
type of response (Peeters et al., 2006). A dominant Th1 response is likely important in 
preventing invasive disease. IL-10 is a potent immunosuppressive cytokine that exerts 
both beneficial and detrimental effects on host responses to fungi as discussed 
previously. Upregulation of IL-10 might be important in limiting the extent of local tissue 
destruction (Romani, 2004), but paradoxically could also be the reason why affected 
dogs are unable to clear infection spontaneously. The finding of upregulation of IL-10 in 
dogs with SNA was corroborated by a second study in which the immune response to 
SNA and to lymphoplasmacytic rhinitis (LPR) was compared to determine whether the 
pathogenesis of these diseases was distinctive (Peeters et al., 2007). Quantitative 
reverse transcriptase PCR (qRT-PCR) was carried out on RNA extracted from nasal 
biopsies from dogs with SNA, LPR and control dogs using primers to amplify 
messenger RNA (mRNA) encoding a panel of cytokines and chemokines. SNA was 
associated with significantly increased expression of mRNA encoding IL-6, IL-8, IL-10, 
IL-12p19, IL-12p35, IL-12p40, IL-18, IFN-δ, TNF-α, TGF-β, eotaxin-2 and all four MCPs 
relative to controls. LPR was associated with significantly increased expression of 
mRNA encoding IL-5, IL-8, IL-10, IL-12p19, IL-12p40, IL-18, TNF-α, TGF-β, MCP-2 and 
MCP-3 relative to controls. There was significantly more expression of mRNA encoding 
IL-6, IL-8, IL-10, IL-12p35, IL-12p40, IL-18, IFN-δ, TNF-α, TGF-β and all MCPs, and 
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significantly less expression of IL-5 in dogs with SNA than in dogs with LPR.  A key 
finding of this study was that the immunopathogenesis of SNA and LPR in dogs is 
different, in so far as dogs with LPR mounted a partial Th2 response, while the study 
gave further support that dogs with SNA mounted a Th1 response. This was an 
important finding as it clearly established that cases of LPR do not represent failure of 
diagnosis of SNA, as has been proposed previously (Peeters et al., 2007). Others have 
proposed LPR could represent a hypersensitivity response to colonization of the nasal 
cavity by fungal or bacterial pathogens in others (Windsor et al., 2006). The finding of 
upregulation of IL-5 in dogs with LPR supports this contention. The finding of marked 
upregulation of IFN- δ expression in dogs with SNA was important further evidence that 
this disease is characterised by a Th1 response.  Furthermore, the upregulation of IL-10 
and TGF-β in dogs with SNA was proposed as contributing to failure of clearance of 
infection (Peeters et al., 2007). 
 
In order to explore the hypothesis that a dysfunction in innate immunity could be an 
aetiological factor in the development of SNA a further study quantified the expression 
of messenger RNA (mRNA) encoding two types of PRRs - Toll-like receptors (TLRs) 1–
10 and NOD like receptors (NLRs) 1 and 2 in nasal mucosal biopsies from dogs with 
SNA or no evidence of nasal cavity disease using qRT-PCR normalized against multiple 
housekeeping genes (Mercier et al., 2012). The study demonstrated that TLRs 1-10 and 
both NLRs are expressed in the nasal mucosa of normal dogs. In dogs with SNA there 
was significantly higher expression of all PRRs except for TLR5 and NLR1 compared to 
normal dogs. The significance of these findings is unknown as little is known about the 
function of PRRs in nasal immunity in health and disease. This was the first study to 
demonstrate the expression of mRNA encoding all TLRs in canine tissue. The finding of 
TLR5 interest is of interest since it has also been shown to be down-regulated in 
humans and dogs with inflammatory bowel disease, associated in dogs with three 
different single nucleotide polymorphisms in the TLR5 gene (SNPs) (Kathrani et al., 
2010).  
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In a more recent study, the functional phenotype of peripheral blood mononuclear cells 
(PBMCs) from normal dogs and dogs with SNA after challenge with heat-inactivated A. 
fumigatus conidia was investigated (Vanherberghen et al., 2013). Gene expression for 
specific Th1, Th2, Th17 and Treg cytokines and their related transcription factors was 
quantified. IL-4 and IFN-δ protein in culture supernatant was measured by ELISA. The 
study found that PBMC from dogs with SNA produced adequate mRNA encoding IFN-δ 
and IFN-δ protein. There was significantly greater expression of IL17A mRNA in the 
PBMC from affected v control dogs. In contrast to previous studies where IL-10 
expression in nasal mucosal biopsies was increased, the amount of IL-10 mRNA in 
PBMC from dogs with SNA decreased after conidial challenge. The authors proposed 
that this could have been due to the absence of local inflammatory factors in PBMC 
cultures, or that IL-10 production may only occur in early stages of infection.  It was 
proposed that an uncontrolled inflammatory response driven by IL-17A synthesis could 
counteract the host’s efforts to clear fungal infection through Th-1 directed immunity. 
Another hypothesis was that the Th2 pathway may counteract protective Th-1 immunity. 
 
2.4.2.1.5 Immunology of feline URT aspergillosis 
 
No studies have been performed to determine the immune-response of SNA and SOA 
in cats. 
 
2.4.2.2 Epidemiology 
In both cats and dogs URTA typically occurs in young to middle-aged animals. Of 25 
reported feline cases the mean age at diagnosis was 7.5 years with a range from 1.9 to 
13 years (Barachetti et al., 2009; Furrow and Groman, 2009; Giordano et al., 2010; 
Goodall et al., 1984; Halenda and Reed, 1997; Hamilton et al., 2000; Kano et al., 2008; 
Karnik et al., 2009; Malik et al., 2010; Malik et al., 2004; McLellan et al., 2006; Peiffer et 
al., 1980; Smith and Hoffman, 2010; Tomsa et al., 2003; Whitney et al., 2005). In case-
series of canine SNA, mean age at diagnosis was 5 to 6 years (Billen et al., 2010; Billen 
et al., 2009; Johnson et al., 2006; Pomrantz and Johnson, 2010; Pomrantz et al., 2007; 
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Saunders et al., 2002; Sharman et al., 2010) Males appear to be over-represented in 
canine SNA and possibly in feline URT aspergillosis (16 of 24 cases where gender was 
specified). In combined reports of 377 cases of canine SNA there were 245 males and 
132 females with a male to female ratio of 1.9:1 (Billen et al., 2010; Billen et al., 2009; 
De Lorenzi et al., 2006; Johnson et al., 2006; Mathews et al., 1998; Pomrantz and 
Johnson, 2010; Pomrantz et al., 2007; Saunders et al., 2002; Sharp et al., 1991a; 
Zonderland et al., 2002).  
 
A striking difference between feline and canine URTA is the facial conformation of 
affected animals. As more cases of feline URTA are reported there is an apparent over-
representation of brachycephalic breeds, with 10 of 24 cases being of Persian or 
Himalayan breed (Himalayans are essentially colour-variants of the Persian breed) 
(Barachetti et al., 2009; Hamilton et al., 2000; Karnik et al., 2009; Malik et al., 2004; 
McLellan et al., 2006; Tomsa et al., 2003; Whitney et al., 2005). By contrast 
dolicocephalic and mesaticephalic breeds of dogs are predisposed to SNA and infection 
in brachycephalic breeds is rare. In most case-series comparisons with hospital 
populations to calculate Odd’s ratios were not performed, thus overt breed 
predispositions have not been confirmed. However, breeds repeatedly identified include 
Rottweilers, Labrador Retrievers, Golden Retrievers and German Shepherd dogs (Billen 
et al., 2010; Billen et al., 2009; Mathews et al., 1998; Pomrantz et al., 2007; Saunders et 
al., 2002; Zonderland et al., 2002) 
 
The reasons why brachycephalic cats and dolicocephalic or mesaticephalic dogs are 
predisposed to URTA remain elusive. There is no evidence of an association between 
retrovirus infection and URT aspergillosis, with only one FeLV positive case reported 
(Goodall et al., 1984). Most dogs with canine SNA are systemically healthy. Reduced 
drainage of URT secretions due to brachycephalic conformation alone could be a risk 
factor for aspergillosis in cats. However, since brachycephalic dogs are under-
represented for SNA, it is likely that additional risk factors are present in cats. These 
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could include heritable defects in mucosal immunity, previous viral URT infection and 
previous antibiotic treatment favouring fungal colonisation (Tomsa et al., 2003).  
 
2.4.2.3 Clinical presentation in dogs and cats 
 
In dogs the triad of muzzle pain, profuse mucopurulent to haemorrhagic chronic nasal 
discharge and depigmentation, crusting or ulceration of one or both nares is highly 
suggestive of SNA. Infrequently facial deformity and/or seizures may occur. Presenting 
signs in cats with SNA are more subtle and include a history of sneezing, unilateral or 
bilateral serous to mucopurulent nasal discharge and intermittent epistaxis in 
approximately 40% of cases (Furrow and Groman, 2009; Goodall et al., 1984; Quimby 
et al., 2010; Tomsa et al., 2003; Whitney et al., 2005).  In one case a discharging sinus 
was identified overlying the frontal sinus (Malik et al., 2004).  Nasal depigmentation or 
ulceration has not been documented in cats with SNA. Cats with SOA are usually 
presented for investigation of unilateral exophthalmos. Clinical signs are referable to 
invasive expansion of a fungal granuloma in the ventromedial orbit. In addition to 
exophthalmos, these include dorsolateral deviation of the globe, conjunctival hyperemia, 
third eyelid prolapse and exposure keratitis (Barachetti et al., 2009; Giordano et al., 
2010; Halenda and Reed, 1997; Hamilton et al., 2000; McLellan et al., 2006; Smith and 
Hoffman, 2010; Wilkinson et al., 1982).  In some cases an oral cavity mass in the 
ipsilateral pterygopalatine fossa behind the last molar tooth has been identified, 
reflecting ventral extension of the fungal granuloma from the orbit. Extension of infection 
outside the sinonasal cavity may cause facial distortion, including swelling of the nasal 
bridge, periorbital tissues and soft tissues adjacent the maxilla. At the time of 
presentation, nasal signs may be absent (Smith and Hoffman, 2010). Neurological signs 
occur when there is CNS invasion or involvement of both optic nerves and the optic 
chiasm and include blindness and seizures (Barachetti et al., 2009; Giordano et al., 
2010; Smith and Hoffman, 2010). 
 
2.5 Diagnosis of aspergillosis 
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2.5.1 Serology and antigen detection in tissues and/or body fluids 
    
Serological tests have important applications as early non-invasive diagnostic tests for 
aspergillosis in humans and companion animals. Tests include detection of serum anti-
Aspergillus antibodies and detection of Aspergillus antigens in serum, body-fluids or 
tissue. Structurally, the fungal cell wall consists of structural polysaccharides, primarily 
chitin and glucans, organized into microfibril bundles and an amorphous component, 
primarily glycoproteins and other polysaccharides that cover the inner microfibrillar 
layer. Chitin and glucans provide rigidity for the cell wall and prevent osmotic distension 
of the fungal cell. β-glucans are the most abundant structural polysaccharides and are 
composed of glucose residues in 1-3-β linkages or 1-6-β linkages. Mannan is the most 
abundant of the amorphous polysaccharides (Sentandreu et al., 2004).  
 
 2.5.1.1 Galactomannan detection 
 
Galactomannan (GM) is a water soluble, heat-stable polysaccharide outer cell wall 
component of Aspergillus species that is continuously and actively secreted during 
mycelial growth. It is released into the circulation during hyphal invasion into tissue. GM 
consists of a mannan core and galactofuran side chains (Latge, 2009). Methods for 
measuring GM in serum and body fluids or tissues include a sandwich ELISA 
immunoassay (Platelia™ Aspergillus EIA, BioRad, Marnes-la-Coquette, France) and a 
latex agglutination test (Pastorex Aspergillus latex agglutination (LA) test (Sanofi 
Diagnostics Pasteur, Marnes-La-Coquette, France). The ELISA has largely replaced the 
latex agglutination test due to its lower limit of detection of GM (1 ng/L compared to 15 
ng/L) (Verweij et al., 1995). The Platelia ELISA utilizes a rat monoclonal antibody (EB-
A2) that binds to the galctofuran epitope of the GM antigen, specifically to the (1→5)-β-
D-galactofuranosyl (galf) side chains (Stynen et al., 1995; Swanink et al., 1997).  In 
addition to GM, the culture supernatant of A. fumigatus contains several glycoproteins 
that also react with the EB-A2 antibody (Latge, 2009). 
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 2.5.1.1.1 Galactomannan detection - humans 
 
Serum GM detection is a non-invasive test that yields rapid results in critically ill patients 
not suited for other diagnostic procedures that could give definitive test results, such as 
CT-guided lung biopsy or fine-needle aspirate. Detection of GM in human patients with 
invasive aspergillosis (IA) has the highest sensitivity in immunocompromised patients, 
especially in neutropenic patients (Cordonnier et al., 2009). In non-neutropenic patients 
the sensitivity of the Platelia ELISA is very low. For example, in a meta-analysis of GM 
performance by patient population (including 27 studies and 4284 confirmed cases of 
IA) the sensitivity (22%) and specificity (84%) of the assay was lowest in solid organ 
transplant patients, who are usually not neutropenic (Pfeiffer et al., 2006). Low 
sensitivity of the assay in immunocompetent patients is partly associated with antigen 
clearance by neutrophils, which possess mannose-binding receptors, or by complexing 
via circulating anti-Aspergillus antibodies (Herbrecht et al., 2002; Mennink-Kersten et 
al., 2004).  Other causes of false negative results in patients with IA using the Platelia 
ELISA include low fungal burdens, prior or concomitant antifungal therapy and walled 
off infections (Hsu et al., 2011). 
 
In addition to poor sensitivity in certain patient cohorts, the diagnostic utility of serum 
GM is hampered by poor specificity in other patient cohorts. Risk factors for false-
positive results include patients treated with β-lactam antibiotics such as amoxicillin-
clavulanate or with the sodium-gluconate containing intravenous crystalloid rehydration 
fluid Plasmalyte (Racil et al., 2007; Zandijk et al., 2008). False-positive results are due 
to contamination with small amounts of GM produced by fermentation of Aspergillus 
niger during synthesis of these medical products (Hage et al., 2007). In addition false 
positive results are reported in paediatric patients, reportedly due to absorption of 
dietary GM across an immature or impaired gastrointestinal epithelium (Herbrecht et al., 
2002), and in patients with cryptococcosis due to cross-reactive epitopes on the C. 
neoformans antigen galactoxylomannan that mimic Aspergillus GM (Dalle et al., 2005). 
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Other “false-positive” results can occur with non-Aspergillus filamentous fungal 
infections. GM has been detected in many other filamentous fungi, including Penicillium, 
Paecilomyces, Botrytis, Fusarium, Altenaria, Cladosporium, Trichophyton, Geotrichum  
and Wangiella, albeit at lower levels than for Aspergillus species (Quindos, 2006; 
Swanink et al., 1997). 
 
More recently, the Platelia ELISA has been utilised to detect GM in bronchoalveolar 
lavage fluid (BAL) in patients at risk of IA (Acosta et al., 2011; D'Haese et al., 2012; 
Meersseman et al., 2008; Nguyen et al., 2007). Overall, this method of GM detection 
has is significantly more sensitive than GM detection in serum and has an excellent 
diagnostic accuracy provided results are interpreted in parallel with clinical and 
radiological findings and with consideration of pre-test probabilities. In some studies the 
sensitivity of BAL GM was higher than that for fungal culture and/or microscopy 
(Meersseman et al., 2008), whilst in others the sensitivity of culture and/or microscopy 
and GM in BAL were both high (Nguyen et al., 2007). Regardless, one advantage of 
BAL GM detection is the rapid diagnostic result, with a turnaround time of hours 
compared to several days for positive fungal culture. However, consideration must be 
given to false positive results, with the same risk factors as for serum GM detection, to 
avoid unnecessary treatment of critically ill patients with potentially toxic systemic 
antifungal drugs (Boonsarngsuk et al., 2010; Hage et al., 2007).   
 
2.5.1.1.2 Galactomannan detection - dogs 
 
The Platelia ELISA was evaluated for diagnosis of SNA in dogs in a study of 17 dogs 
with SNA, 18 dogs with nasal cancer, 11 dogs with inflammatory (lymphoplasmacytic) 
rhinitis and 33 control dogs (Billen et al., 2009).  Overall sensitivity was 24% and 
specificity was 82%. Twenty four percent of dogs with SNA tested positive, as did 11% 
of dogs with nasal tumours, 9% of dogs with non-fungal rhinitis and 24% of healthy 
dogs. The low sensitivity of serum GM for diagnosis of canine SNA is perhaps not 
surprising, since in contrast to IA in people, canine SNA in dogs is a non-invasive 
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mycosis in which fungal hyphae colonise the surfaces of the sinonasal epithelium but do 
not penetrate the respiratory mucosa (Peeters et al., 2005).  Likely factors contributing 
to this low sensitivity include the absence of angioinvasion, as well as antigen clearance 
or binding in these systemically immunocompetent dogs.  By contrast, GM is often 
detected in the serum of dogs with systemic mycoses (Garcia et al., 2011). 
 
Interestingly, one study of FRS in humans evaluated the use of GM detection in the 
supernatant of sinonasal pus or fungus ball diluted in saline then centrifuged. The 
sensitivity and specificity of the Platelia ELISA were 87% and 88% respectively 
(Kauffmann-Lacroix et al., 2001). A similar study, utilising nasal lavage fluid for GM 
detection in patients with FRS did not find repeatable results – 7 patients with FRS were 
all negative in the GM ELISA (Kostamo et al., 2007), while 21% of control patients 
tested positive. Despite the disparity in results between these two studies, investigation 
of GM detection in nasal lavage fluid from dogs with SNA warrants further investigation.  
 
2.5.1.1.3 Galactomannan detection - cats 
 
The diagnostic utility of serum GM detection was recently evaluated in cats with URT 
aspergillosis ((Whitney et al., 2013a). The Platelia ELISA was used to detect serum GM 
in 13 cats with confirmed URT aspergillosis including 6 with SNA and 7 with SOA 
(Group 1). Control groups included 15 cats with non-aspergillosis URT disease (Group 
2),  14 cats treated with β-lactam antibiotics for non-respiratory tract disease (Group 3),  
31 healthy young cats  < 2 y of age (Group 4b) and 13 healthy adult cats ≥ 2 y of age. 
One cat with SNA and two cats with SOA caused by an Aspergillus fumigatus-mimetic 
species, tested positive for serum GM.  The overall sensitivity and specificity of the 
assay was 23% and 78% respectively. Similar to human studies, false positive results 
were common in young cats (29%) and in β-lactam antibiotic-treated cats (32%).  The 
specificity of the assay increased to 93% when these known high risk false positive 
groups were excluded from the analysis. In both cats and dogs with URT aspergillosis, 
serum GM testing cannot be recommended as a routine diagnostic test. 
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 2.5.1.2 Serum 1-3-B-D-glucan detection 
 
Unlike GM, which has diagnostic specificity for aspergillosis, 1-3-β-D-glucan (BG) 
present in the fungal wall of most fungal species with the notable exception of the 
zygomycetes (Mucor spp.). Cryptococcal spp. exhibit no, low-level of variable BG 
expression. Detection of BG in serum or BAL fluid is a panfungal diagnostic test for 
detection of invasive fungal infections in people. A limitation of its use is the lack of 
ability to discriminate between fungal general and species which compromises the 
ability to select the most appropriate antifungal agent. Commercial assays developed to 
measure 1-3-β-D-glucan detect its ability to activate a coagulation cascade within 
horseshoe crab haemolymph (Estrella et al., 2011; Thornton, 2010). These assays are 
able to detect BG concentrations approaching 1 pg/ml. Very few studies have evaluated 
the utility of BG detection in serum or body fluids from patients with IA compared to GM 
detection. In a recent study of ICU patients with fungal pneumonia predominantly due to 
IA, using the optimal cut-off for detection based on receiver operating curve analysis of 
> 80 pg/ml, the sensitivity and specificity of BG detection in serum was >80% and the 
negative predictive value was high (93%) (Acosta et al., 2011). It has been suggested 
that BG and GM should be used together as markers for invasive fungal infections (IFI) 
(Hachem et al., 2009). Where both BG and GM were evaluated simultaneously in 
patients with IFI BG had a higher sensitivity than that of GM for detecting IA and other 
mold infections in patients with haematologic malignancy, but had a lower specificity 
(Hachem et al., 2009). Risk factors for false positive BG results include bacteraemia, 
treatment with β-lactam antibiotics, haemodialysis with cellulose products, 
cardiopulmonary bypass, immunoglobulin or albumin infusions and exposure to glucan-
containing gauze during surgery (Hope et al., 2005b; Thornton, 2010). Serum BG 
detection has not been evaluated for the diagnosis of URT aspergillosis in dogs or cats. 
 
2.5.1.3 Serum antibody detection - humans 
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Detection of anti-Aspergillus antibodies in the serum of patients with IA was proven to 
be unreliable for diagnosis, since only a third or less of affected patients mounted a 
detectable antibody response (Herbrecht et al., 2002; Hope et al., 2005b; Kappe et al., 
1996). Aspergillins used in early assays consisted of crude somatic antigen extracts 
from A. fumigatus hyphal biomass, galactomannan or other metabolic antigens and a 
wide range of assay formats were used including immunodiffusion, counter 
immunoelectrophoresis (CIE), complement fixation, haemagglutination assays, indirect-
immunofluorescence, radioimmunoassay and ELISA (Kappe et al., 1996). The majority 
of patients with IA are unable to mount an antibody response to these Aspergillus 
antigens because of immune suppression or malignancy.  The development of other 
non-invasive diagnostic tests for IA was focused on antigen detection subsequently, 
since sensitivity of antigen detection was higher in this cohort of patients. For smaller 
subsets of immunocompetent patients with chronic pulmonary aspergillosis (CPA) 
antibody detection has proved to be a more useful diagnostic tool than GM or BG 
detection. For instance, in a recent study of patients with CPA, the sensitivity and 
specificity of an Aspergillus precipitating antibody (immunodiffusion) test was 74% and 
84% respectively (Ohba et al., 2012). In another study of CPA patients, serum 
Aspergillus precipitating antibody positivity was 89%, compared to 50% for GM 
detection and 15% for BG detection (Kitasato et al., 2009).  
 
More recently the use of purified recombinant antigen preparations containing single 
proteins or polysaccharides has been investigated for serological diagnosis of IA. One 
such protein, recombinant A. fumigatus mitogillin, expressed in E. coli, was found to 
improve the sensitivity of serological diagnosis of IA by detection of specific anti-
mitogillin antibodies. Positive IgG titres were detected in the sera of 64% (27 of 42) 
patients with IPA, but in only 1% of healthy controls (Weig et al., 2001).   
 
2.5.1.4 Serum antibody detection – dogs and cats 
Serum anti-Aspergillus antibodies can be detected by numerous methods including 
counter-immunoelectrophoresis (CIE), agar gel immunodiffusion (AGID) or ELISA.  
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These tests have been applied to individual cases of feline URTA only, thus the 
sensitivity and specificity of antibody detection for diagnosis of feline aspergillosis is 
currently not known. Five of 10 reported cases (9 SNA, 1 SOA) tested seropositive 
(Barrs et al., 2012a; Furrow and Groman, 2009; Goodall et al., 1984; Tomsa et al., 
2003; Whitney et al., 2005). By contrast, two recent studies evaluated serology for 
diagnosis of canine SNA (Billen et al., 2009; Pomrantz et al., 2007). In one study AGID 
was compared with fungal culture of nasal biopsies (Pomrantz et al., 2007), and in the 
other the AGID and ELISA were compared (Billen et al., 2009). For both methods a 
purified aspergillin preparation composed of extracts of A. fumigatus, A. niger and A. 
flavus was used.  In one study fungal culture was more sensitive (81%) than serologic 
testing (67%) while specificity was high for both fungal culture (100%) and serology 
(98%) (Pomrantz et al., 2007). In the second study ELISA had higher sensitivity (88%) 
than AGID (76%) and specificity was high for both methods (ELISA 97%, AGID 100%) 
(Billen et al., 2009). These studies demonstrate that seropositivity for Aspergillus spp. is 
highly suggestive of SNA in dogs but that negative test results do not rule out 
aspergillosis.  
 
2.5.2 Molecular methods for diagnosis of aspergillosis in cats, dogs and humans 
 
For species recognition in the clinical setting comparative sequence based methods 
used in conjunction with traditional phenotype based methods offers a practical 
approach to resolution of species within the genus Aspergillus (Balajee et al., 2007). 
Methods for identification of fungi from clinical specimens include conventional PCR and 
sequencing of DNA extracted from fungal cultures as described in section 1.2.5, or PCR 
of DNA extracted directly from clinical specimens. Depending on the type of clinical 
specimen, conventional PCR or real time quantitative PCR (qPCR) can be performed. A 
major reason for utilization of qPCRs over conventional PCRs in routine diagnostic 
mycology laboratories for diagnosis of aspergillosis in humans is the decreased risk of 
amplification of aerosolized fungal DNA contaminating the environment, since 
amplification and detection take place in the same tube without the need to open it 
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(Bretagne, 2011). In order to take precautions to rule out false negative results in qPCR 
assays standardization of assays is important. This includes the routine incorporation of 
an internal amplification control (IAC) to assess for presence of PCR inhibitors in the 
sample (for example haeme and cells in blood or BAL fluid) and an extraction control to 
confirm successful DNA extraction in the sample. To assess for PCR inhibition each 
sample can be spiked with an exogenous IAC, for example the jellyfish aequorin gene. 
PCR is then performed to detect the aequorin gene in the spiked sample. If amplification 
does not occur then inhibition is present and DNA extraction should be reattempted 
from the original sample (Khot et al., 2008). Examples of DNA extraction controls 
include the GAPDH gene in dogs and cats (Windsor et al., 2006) and the 18s rRNA 
gene in humans (Khot et al., 2008). False positive results can occur due contamination 
with environmental fungi during sample collection, DNA extraction and PCR set-up, or 
from fungal PCR product carry-over. In addition, false positives can occur in the setting 
of suboptimal analytical specificity in the qPCR, resulting from cross-reactivity of the 
target qPCR assay with other (nontarget) fungi or DNA (Khot et al., 2008).  
      
2.5.2.1 Molecular methods using formalin fixed paraffin embedded tissues 
(FFPET) - humans 
 
In situations where fungal elements are seen in histological specimens but fungal 
culture was either negative or not performed, molecular methods are useful to identify 
the infecting fungus. One of the limitations of utilizing FFPET is that they often only yield 
short DNA fragments, thus limiting the gene targets for amplification. To overcome this 
issue probe and primers designed for known pathogens can confirm the identification, 
but only for the predefined species. A conventional panfungal PCR targeting the ITS1 
region and designed to amplify a 361 base-pair product was reported to successfully 
identify the fungal pathogen in 64% of histologically proven invasive fungal infections in 
one study (Lau et al., 2007).   
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Another study compared conventional PCRs amplifying the ITS1 and ITS2 regions, both 
designed to amplify products of > 300 base pairs, with qPCR amplifying Aspergillus spp. 
mitochondrial DNA, designed to amplify a product of < 150 base pairs in patients with 
confirmed sinus fungal balls (a non-invasive form of FRS) (Cabaret et al., 2011). ITS1 or 
ITS2 sequencing identified the aetiologic agent in 10 of 16 cases (A. fumigatus (n=9), 
Lewia spp. (n=1)). The size of the sequences amplified ranged from 120 to 352 base 
pairs. The qPCR amplified Aspergillus spp. DNA in 15 of the 16 cases (sequencing of 
the qPCR products was not performed). The negative sample was the Lewia spp. This 
study illustrates the benefits of qPCR for amplification of short fungal targets for 
predefined species confirmation without the need for sequencing but also illustrates the 
benefits of a panfungal PCR to identify unexpected or unknown fungal pathogens. 
 
Using qPCR and sequencing of the ITS2 and 28S (large subunit) regions of the rDNA 
gene complex (Figure 4), investigators correctly identified fungal pathogens in 80% of 
cases of proven invasive septate mould infections (Rickerts et al., 2011). To minimise 
inadvertent amplification of human rDNA in FFPET biopsies, modified primers were 
used that maximized the number of nucleotide mismatches with the human rDNA gene. 
The primers utilized to amplify the ITS2 region were 5.8S forward and 28S-1 reverse, 
and for the 28S regions were 28-S10 forward and 28S-12 reverse (Khot et al., 2009). 
 
2.5.2.1.1 Molecular methods using FFPET- dogs and cats 
 
Conventional ITS1 PCR was utilized for identification of fungal pathogens in one cat 
with SOA using FFPET from a retrobulbar mass. The fungal pathogen had been 
identified as A. fumigatus on culture while the amplified ITS1 sequences had 100% 
homology with GenBank sequences of Neosartorya pseudofischeri (Lau et al., 2007). 
This was the sentinel case that sparked my interest in feline aspergillosis as I had 
referred the clinical specimen from this cat to these investigators to assist in validation 
of their PCR assay for molecular identification of fungi in FFPET. This was the first case 
to demonstrate molecular identity of SOA in cats and subsequently resulted in 
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collaboration with the same investigators to pursue the aetiology of URT aspergillosis in 
cats (see Chapter three). The application of qPCR for identification of fungal pathogens 
in dogs with SNA using FFPET is discussed in section 2.3 and below. 
 
2.5.2.2 Real time quantitative PCR (qPCR) using clinical specimens 
 
Quantitative PCR is highly sensitive with the potential to detect a few gene copies per 
reaction or less than a single genome for multicopy genes such as the rDNA gene 
complex. Since qPCR can measure the amount of microbial DNA in a clinical sample it 
also has the potential to discriminate between colonization and infection. The nasal 
cavities of cats and dogs can be transiently contaminated or colonized by fungal 
species, as demonstrated by studies evaluating presence of Cryptococcus spp. in cats 
and dogs with negative serum latex agglutination test titres (Duncan et al., 2005a, b). 
Aspergillus spp. colonization of the nasal cavity in dogs and cats has not been 
determined by culture studies. Using a genus specific qPCR to detect ribosomal DNA 
from all Penicillium and Aspergillus  spp. fungal DNA was detected in nasal biopsies of 
dogs with SNA as well as in all the control dogs in that study, demonstrating that fungi 
are likely constituents of the normal flora of the nasal cavity of the dog (Peeters et al., 
2008). Using another rDNA panfungal qPCR to detect fungi in nasal biopsies (FFPET) it 
was demonstrated that dogs with SNA had significantly higher fungal DNA loads than 
dogs with neoplasia and dogs with chronic lymphoplasmacytic rhinitis (LPR). They also 
demonstrated that dogs with LPR had higher fungal DNA loads than dogs with nasal 
neoplasia, suggesting a causal relationship between the inflammation seen in LPR and 
fungal colonization of the nasal cavity (Windsor et al., 2006).  
 
A number of different qPCR assays have been developed to detect fungal DNA in blood 
or BAL fluid of human patients with IA. The assays include a commercial MycAssay 
(Myconostica Ltd) developed for the detection of genomic DNA from 15 different 
species of Aspergillus, including the 4 most common human pathogens (A. fumigatus, 
A. flavus, A. terreus and A. niger). The target is a 114bp segment of the 18S rDNA gene 
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and the assay includes an internal amplification control (IAC) of plant origin to detect 
any inhibitory substances in the sample. A similar pan-Aspergillus qPCR targeting the 
18s rDNA region is specific for over a 100 Aspergillus species (Walsh et al., 2011). 
However, it should be noted that these pan-Aspergillus PCRs will amplify Penicillium 
spp. and occasionally Paecilomyces spp. (Walsh et al., 2011). 
Other pan-Aspergillus or pan-fungal qPCR assays have been developed targeting the 
ITS regions and 28S rDNA regions of the rDNA gene complex (Khot et al., 2009; Khot 
et al., 2008; Rickerts et al., 2011). Species-specific qPCRs targeting the ITS1 regions of 
the major Aspergillus spp. pathogens have also been developed (Walsh et al., 2011). 
Although molecular identification of Aspergillus spp. is most accurate using primers and 
probes targeting two or three gene loci, species-specific qPCRs can be used in clinical 
settings alongside genus-specific qPCRs to provide additional information for targeted 
antifungal therapy. 
 
Quantitative PCR is becoming increasingly utilized as a diagnostic test to detect fungi in 
BAL fluid from patients with IPA and has comparable performance to GM measurement 
(Torelli et al., 2011). In a clinical setting, fungal DNA detection by qPCR can be 
combined with GM and culture results to increase diagnostic accuracy (Walsh et al., 
2011). Also, Aspergillus colonization can be distinguished from invasive infection to 
some extent. In one study where the optimal cut-off threshold cycle value (Ct) of  ≤ 35 
was calculated using receiver operating curve (ROC) analysis, all patients with IPA had 
Ct values of ≤ 35 compared with 50% of patients with Aspergillus colonization of the 
airways (Luong et al., 2011).  
 
2.5.3 Diagnostic imaging  
    
Computed tomography (CT) has virtually replaced conventional radiography for the 
assessment of nasal cavity and orbital disease in dogs and cats. CT was found to be 
more sensitive than plain radiology in the diagnosis of SNA in dogs in two studies, with 
a sensitivity of 88-92% compared with 72-84% for plain radiography (Saunders and Van 
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Bree, 2003; Saunders et al., 2002).  The advantages of CT over radiography include 
increased sensitivity of diagnosis, elimination of superimposition of structures through 
cross-sectional imaging, and multiplanar reconstructions which allow better evaluation 
of skull structures including the cribriform plate and orbit. Imaging studies should be 
performed before rhinoscopy and biopsy since iatrogenic haemorrhage can induce 
imaging abnormalities and obscure subtle lesions (Saunders et al., 2004). Magnetic 
Resonance Imaging (MRI) is also useful for diagnosis of aspergillosis in dogs and cats 
and is generally superior to CT for imaging of soft-tissue changes and inferior for 
detection of changes in cortical bone. In one small prospective study MRI and CT were 
both more sensitive than radiography in detecting changes diagnostic of SNA 
(Saunders et al., 2004)  Generally, MRI is indicated over CT where there is CNS 
involvement (Giordano et al., 2010).  
 
2.5.3.1 Computed tomographic findings in canine SNA 
 
CT findings in dogs with SNA have been well characterised and most commonly 
include: 
 
(i) cavitated-like turbinate lysis  
(ii) a rim of soft-tissue of variable thickness along bones in the frontal sinus, 
maxillary recess and nasal passages. The rim of soft-tissue is due to 
thickening of the mucosa adjacent the inner surfaces of these bones. (Fig 6a) 
(iii) Abnormal presence of soft-tissue accumulation (Fig 6b) 
(iv) Thickened, reactive bony-changes – hyperostosis (Fig 6c) 
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Fig 6a (i) (left) and 6a (ii) (right).  On these transverse CT images of the skull of a 4-
year old male desexed cattle x kelpie dog that presented to the University Veterinary 
Teaching Hospital, Sydney with sinonasal aspergillosis affecting the left side of the 
nasal cavity and frontal sinuses.  There is an accumulation of abnormal soft tissue in the 
left side of the nasal cavity including a thickened rim of soft-tissue in the maxillary 
recess (Fig 6 a (i)) and a rim of thickened tissue adjacent the inner surface of the left 
frontal sinus bone (Fig 6a (ii). Images courtesy University Veterinary Teaching Hospital, 
Sydney. 
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Fig 6b (i) (left) and 6b (ii) (right): Sagittal skull CT images from the dog in Fig 6b (i) – 
On this image, taken to the right of the midline the nasal turbinates are intact and soft 
tissues appear normal. The frontal sinus is also normal. Fig 6 b (ii) On this image, taken 
to the left of the midline there is an accumulation of abnormal soft tissue and some 
turbinate lysis in the rostral nasal cavity. Also, there is a thickened rim of soft-tissue 
around the frontal sinus. Images courtesy University Veterinary Teaching Hospital, 
Sydney. 
 
 
Fig 6c. Transverse CT image of the skull of the same dog in Fig 6a taken at the level of 
the frontal sinuses. The bone of the left frontal sinus is hyperostotic (increased 
radiodensity). Image courtesy University Veterinary Teaching Hospital, Sydney. 
 
2.5.3.2 Computed tomographic findings in feline URT aspergillosis 
 
CT findings have been described in case reports of 11 cats with SNA (Furrow and 
Groman, 2009; Karnik et al., 2009; Tomsa et al., 2003; Whitney et al., 2005) and in 10 
cats with SOA (Barachetti et al., 2009; Giordano et al., 2010; Halenda and Reed, 1997; 
Hamilton et al., 2000; Kano et al., 2008; Karnik et al., 2009; McLellan et al., 2006; Smith 
and Hoffman, 2010). Although CT changes in cats were less specific than those 
documented in dogs with SNA similarities included turbinate lysis and abnormal soft-
tissue accumulation within the nasal passages (Furrow and Groman, 2009; Whitney et 
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al., 2005). Involvement of the nasal cavity was mostly bilateral (Furrow and Groman, 
2009; Karnik et al., 2009) and punctuate lysis of the orbital lamina and palatine bone 
was sometimes observed (Karnik et al., 2009; Whitney et al., 2005). In one report there 
was a calcified discrete density in the middle right nasal cavity presumed to be necrotic 
tissue that had undergone dystrophic calcification (Tomsa et al., 2003). Calcification of 
fungal plaques due to deposition of calcium oxalate or phosphate crystals, thought to be 
fungal metabolites,  occurs in sinonasal Aspergillus sp. infections in humans, in 
approximately 50% of noninvasive Aspergillus sinus fungal balls (mycetomas) with 
maxillary sinus involvement (Lenglinger et al., 1996).  
 
Of the 10 reported cases of feline SOA where CTs were performed, the most common 
findings were a unilateral ventromedial orbital mass resulting in dorsolateral 
displacement and sometimes indentation of the globe, nasal cavity involvement and 
punctuate lysis of the frontal bone (orbital lamina or floor of frontal sinus) (Barachetti et 
al., 2009; Giordano et al., 2010; Halenda and Reed, 1997; Hamilton et al., 2000; Kano 
et al., 2008; Karnik et al., 2009; McLellan et al., 2006; Smith and Hoffman, 2010). Soft-
tissue attenuation and heterogeneous enhancement post-contrast of the orbital mass 
was also reported (Giordano et al., 2010; Karnik et al., 2009; Smith and Hoffman, 2010). 
Features of SOA that overlap those seen in nasal neoplasia included soft tissue mass 
effect and osteolysis. 
 
2.5.4 Histology and Immunohistochemistry 
   
2.5.4.1 Canine SNA 
 
Histologic and immunohistochemical features of canine SNA were characterised in a 
study of 15 affected dogs (Peeters et al., 2005). The most common findings included an 
ulcerated and severely inflamed mucosa, often covered by a plaque of necrotic tissue. 
Fungal infection was non-invasive; fungal hyphae were most commonly present in 
necrotic plaques adjacent the mucosa or within luminal exudates but did not penetrate 
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the mucosal epithelium. Fungal hyphae were directly associated with the mucosal 
surface in two of 15 cases only. The underlying lamina propria was heavily infiltrated by 
mixed mononuclear inflammatory cells in a densely packed sheet disrupting the normal 
mucosal structure. These cells consisted mostly of CD4+ and CD8+ T-lymphocytes and 
IgG+ plasma cells, with fewer MHC II+ activated antigen-presenting cells (macrophages 
and dendritic cells). L1+ macrophages and neutrophils were also present in the lamina 
propria and epithelium, consistent with active recruitment of myelomonocytic lineages 
from the blood. The immunohistological findings in dogs with SNA were consistent with  
a dominant Th1-regulated cell mediated immune response effective in preventing 
systemic dissemination of the fungus but ineffective in clearing the infection from the 
nasal cavity and frontal sinus (Day, 2009; Peeters et al., 2005). 
 
2.5.4.2 Feline URT aspergillosis 
 
Histological findings the sinonasal form of feline URT aspergillosis have not been well 
characterised and immunohistochemical studies have not been described for either 
form. Histologic changes on nasal biopsies reported for feline SNA include severe 
inflammatory rhinitis with lymphoplasmacytic or mixed-cell inflammatory cell infiltrates, 
necrosis, which can be extensive, and mats of fungal hyphae (Furrow and Groman, 
2009; Tomsa et al., 2003; Whitney et al., 2005). 
 
Histopathological changes have been described in seven cases of feline SOA 
(Barachetti et al., 2009; Giordano et al., 2010; Hamilton et al., 2000; McLellan et al., 
2006; Smith and Hoffman, 2010).  Key findings include a propensity to invade 
contiguous anatomic planes including the nasal cavity, orbital tissues external to the 
globe and nictitating membrane. The development of CNS signs in some cases implies 
fungal invasion of CNS tissue, however brain histology was not performed in the two 
cats in which seizures were described (Giordano et al., 2010; Smith and Hoffman, 
2010). In one case with bilateral orbital granulomas and complete loss of vision 
histological changes were present in the optic chiasm which exhibited diffuse, moderate 
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gliosis and spongiosis and a mild lymphocytic–plasmacytic meningitis. However, fungal 
hyphae were not identified within the optic chiasm or other areas of the CNS (Barachetti 
et al., 2009). In cats with SOA orbital granulomas are typically comprised of multifocal to 
coalescing granulomas with abundant areas of coagulative necrosis in which septate 
fungal hyphae are present. Central areas of coagulative necrosis are surrounded by 
zones of eosinophils, macrophages, lymphocytes and fibroplasia. 
 
2.6 Treatment and Prognosis  
  2.6.1 Treatment of canine SNA 
 
In general, the prognosis for treatment of canine SNA is good, but treatment can be 
challenging. Since canine SNA is a noninvasive mycosis, topical therapy is considered 
more effective than systemic therapy because of direct contact with fungal plaques, 
although no large scale studies have evaluated the efficacy of suitable systemic 
antifungal medications such as itraconazole (Peeters and Clercx, 2007).  Topical azole 
antifungals, including 1% clotrimazole, 1% enilconazole or 1% bifonazole are delivered 
intranasally or via sinus trephination. However, multiple applications are often required 
to achieve clinical cure. In a multicentre, retrospective study of 81 dogs with SNA 
treated with topical clotrimazole or enilconazole using catheters placed intranasally 
and/or via sinus trephination, a single treatment was successful in 47% (Sharman et al., 
2010). Similarly, in a smaller prospective study of 23 dogs with SNA treated with a 1% 
clotrimazole intranasal infusion, infection resolved in 48% of cases after one treatment 
(Pomrantz and Johnson, 2010). Techniques reported to improve efficacy of topical 
antifungals include endoscopic/sinuscopic debridement of sinonasal fungal plaques 
prior to therapy (Billen et al., 2010; Zonderland et al., 2002), endoscopic guidance of 
infusion catheters into the caudal frontal sinus (Saunders et al., 2002) and use of depot 
preparations of 1% clotrimazole or 1% bifonazole cream (Billen et al., 2010).   
 
In a canine cadaver study, clotrimazole cream (1% depot preparation) persisted in the 
frontal sinuses 96 h after installation via sinus trephination compared with 1 minute for a 
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clotrimazole substitute solution in propylene glycol, demonstrating a possible advantage 
of increased contact time with fungal plaques using the depot preparation (Hayes and 
Demetriou, 2012). The same study also showed that distribution of a 50 ml infusate of a 
clotrimazole substitute solution instilled via sinus trephination of the lateral frontal sinus 
resulted in inadequate coating of the rostral compartment of the frontal sinus, whereas 
medicating both the lateral and rostral compartments either by double trephination or a 
single oblique trephination resulted in complete coating of all frontal sinus mucosa. In 
cases of canine SNA where there is involvement of the rostral frontal sinus as indicated 
by advanced diagnostic imaging, consideration should be given to medicating both 
rostral and lateral compartments of the frontal sinus. Adverse effects reported in 
association with topical antifungal therapies in the treatment on canine SNA include 
seizures (Billen et al., 2010) and severe pharyngeal oedema (reference). Seizures are 
thought to be the result of direct contact of intranasally instilled antifungal preparations 
with the CNS where fungal infection has resulted in lysis of the cribriform plate (Billen et 
al., 2010). Assessment of the integrity of the cribriform plate by CT examination before 
treatment is recommended. 
 
2.6.2 Treatment of feline URT aspergillosis 
 
Information on treatment of feline SNA is limited to several case reports (Furrow and 
Groman, 2009; Goodall et al., 1984; Tomsa et al., 2003; Whitney et al., 2005).  
Treatment was successful in most cases using treatment regimens including systemic 
antifungal therapy alone, systemic triazole therapy combined with topical intranasal 
clotrimazole or topical therapy alone.  Anatomical landmarks have been defined for 
sinus trephination in cats (Winstanley, 1974). Trephine openings are made slightly to 
the side of the mid-line on a line that joins the anterior borders of the supra-orbital 
processes. 
 
Similar to canine SNA, the importance of debridement of fungal plaques is illustrated by 
resolution of signs in one case after rhinoscopy and sinonasal cavity lavage (Tomsa et 
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al., 2003) and in another after sinusotomy/rhinotomy and instillation of iodoform paste 
(Goodall et al., 1984). Presence or absence of orbital involvement in cats with URTA 
has important prognostic significance. Few cases of SOA have been treated 
successfully despite aggressive therapy including orbital exenteration and use of newer 
generation fungicidal triazoles (posaconazole or voriconazole), liposomal amphotericin-
B and the echinocandin micafungin (Barachetti et al., 2009; Giordano et al., 2010; Kano 
et al., 2008; McLellan et al., 2006; Smith and Hoffman, 2010) .  
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2.7  Aims 
 
The major aim of this thesis was to characterise aspergillosis of the upper respiratory 
tract in cats. Specific aims were to: 
 
(i) Describe the clinical syndrome including clinicopathologic findings. 
(ii) Determine the aetiological agents of disease. 
(iii) Determine the in vitro and in vivo response to antifungal drugs. 
(iv) Evaluate the diagnostic utility of serological assays to detect Aspergillus-
specific antibodies. 
 
The following steps were taken to achieve these goals: 
 
• Cases of aspergillosis were recruited for retrospective and prospective study 
from around Australia for characterisation of clinicopathologic findings and in vivo 
response to antifungal drugs (Chapter 3 and Chapter 5). 
 
• For initial investigation of the aetiological agents of disease comparative 
sequence analyses of the internal transcribed spacer (ITS)1-5.8s-ITS2 and 
fungal mating tests were performed. (Chapter 3). 
 
• For further investigation of the aetiological agents of disease, morphological 
studies, growth temperature studies, genotyping of mating genes, and additional 
comparative sequence analyses of the partial betatubulin and calmodulin genes, 
and phylogenetic analyses were performed on isolates from clinical cases and on 
reference strains of A. fumigatus, A. viridinutans and A. udagawae. To determine 
the in vitro response to antifungal drugs, antifungal drug susceptibility testing was 
performed (Chapter 4). 
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• An agar-gel immunodiffusion assay and an Ig-G ELISA to detect Aspergillus 
specific antibodies were evaluated using sera collected from cats with 
aspergillosis (Chapter 6). 
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Chapter 3. Characterisation of Clinical Disease and 
Treatment Outcomes in Cats with Upper Respiratory 
Tract Aspergillosis. 
3.1 Background 
Give the paucity of information about FURTA at the time this project was initiated, one 
of my objectives was to create a data-base of clinical cases of FURTA and a bank of 
fungal isolates. This was achieved over a three year period from 2006 to 2009. This 
chapter describes clinical features of the disease including anamnesis, physical findings 
and clinicopathological findings on haematology, serum biochemistry, feline retrovirus 
testing results, histopathology and microbiology. The aetiological agents are further 
characterised using PCR and sequencing of the ITS1-5.8S-ITS2 region of the rDNA 
cluster as described in Chapter two, and phenotypic data (mating tests). In addition, I 
explore novel treatment regimens for SOA and establish prognostic differences between 
A. fumigatus and cryptic species infections in cats with URTA. 
3.2 Main article 
Barrs VR, Halliday C, Martin P, Wilson B, Krockenberger M, Gunew M, Bennett S, 
Koehlmeyer E, Thompson A, Fliegner R, Hocking A, Sleiman S, O’Brien C, Beatty JA. 
Sinonasal and sino-orbital aspergillosis in 23 cats: aetiology, clinicopathologic features 
and treatment outcomes. The Veterinary Journal. 2012;19 (1):58-64 
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Aetiology, clinicopathological ﬁndings and treatment outcomes were documented in 23 cats (1.5–
13 years of age) with sinonasal (SNA, n = 6) or sino-orbital (SOA, n = 17) aspergillosis. Cases recruited ret-
rospectively and prospectively were included if fungal hyphae were identiﬁed on cytological or histolog-
ical examination and the fungal pathogen was identiﬁed by PCR and DNA sequencing (ITS1 or ITS1-5.8S-
ITS2 regions, rDNA gene cluster).
Fungal culture was positive in 22/23 cases. In cases of SNA, the fungal pathogen was Aspergillus fumig-
atus (n = 4), Neosartorya ﬁscheri or A. lentulus (n = 1) or a non-speciated Neosartorya spp. (n = 1). In all
cases of SOA (n = 17), the fungal pathogen was identiﬁed as Neosartorya spp. Nine cats had brachycephalic
conformation. Cats with SNA were more likely to be infected with A. fumigatus and had a better prognosis
than cats with SOA.
 2011 Elsevier Ltd. All rights reserved.Introduction
Information about aspergillosis affecting the upper respiratory
tract (URT) of cats is restricted to individual case reports and sev-
eral small case series (Peiffer et al., 1980; Wilkinson et al., 1982;
Goodall et al., 1984; Halenda and Reed, 1997; Hamilton et al.,
2000; Tomsa et al., 2003; Malik et al., 2004; Whitney et al.,
2005; McLellan et al., 2006; Kano et al., 2008; Barachetti et al.,
2009; Furrow and Groman, 2009; Karnik et al., 2009; Giordano
et al., 2010; Quimby et al., 2010; Smith and Hoffman, 2010). Ten
of 25 cats in these reports were Persians or Himalayan Persians,
suggesting a possible brachycephalic breed predisposition. Sinona-
sal aspergillosis (SNA) accounted for approximately half of the re-
ported cases, while the rest had orbital involvement (sino-orbital
aspergillosis, SOA). There is limited information on the aetiopatho-
logical differences between these two disease presentations,
although progression of SNA to SOA has been documented (Hamil-
ton et al., 2000).ll rights reserved.
. Barrs).The identity of fungal pathogens to species level has been re-
ported in nine affected cats: Aspergillus fumigatus (n = 5), A. ﬂavus
(n = 1), A. niger (n = 2) and A. udagawae (n = 1) (Malik et al., 2004;
Whitney et al., 2005; McLellan et al., 2006; Kano et al., 2008;
Barachetti et al., 2009; Furrow and Groman, 2009; Smith and Hoff-
man, 2010; Giordano et al., 2010). However, species identiﬁcation
(A. udagawae) was conﬁrmed by molecular studies in only one
case; this isolate was initially misidentiﬁed as A. fumigatus based
on phenotypic features (Kano et al., 2008). Members of the A.
fumigatus complex cannot be identiﬁed reliably by phenotypic
testing alone (Balajee et al., 2005; Vinh et al., 2009). These ﬁndings
raise the possibility that pathogens other than A. fumigatus could
be an underdiagnosed cause of URT aspergillosis in cats.
Treatment of the orbital form of disease is particularly challeng-
ing and the prognosis for resolution of infection is generally poor
(Hamilton et al., 2000; Kano et al., 2008; Barachetti et al., 2009;
Giordano et al., 2010). Few cases have been treated successfully
(McLellan et al., 2006; Smith and Hoffman, 2010). The objectives
of this study were to document the clinicopathological ﬁndings,
molecular identity of fungal pathogens and treatment outcomes
in cats with URT aspergillosis.57
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Chapter 3 Materials and methods
Cases and samples
Retrospective cases were identiﬁed from the medical records of the University
Veterinary Teaching Hospital, Sydney (UVTHS) and Veterinary Pathology Diagnostic
Services (VPDS), from January 1998 to December 2006. Cases were recruited pro-
spectively from January 2007 to December 2009 following an Australia-wide call
for cases (Barrs et al., 2007). Inclusion criteria were (1) identiﬁcation of fungal hy-
phae on cytological or histological examination of tissue biopsies or sinonasal fun-
gal plaques and (2) molecular identiﬁcation of the isolate from tissue samples (fresh
or formalin-ﬁxed parafﬁn-embedded tissue) and/or culture material. Cats were
classiﬁed as having SNA or SOA on the basis of absence (SNA) or presence (SOA)
of a retrobulbar mass at initial presentation. Clinical data, tissue samples (fresh
and/or formalin-ﬁxed parafﬁn-embedded tissue) and fungal cultures were collected
from each case. Data from postmortem examination were included when available.
Clinical data
Signalment, history, clinical signs, haematology, biochemistry, retrovirus serol-
ogy, latex cryptococcal antigen titres (LCAT), agar gel immunodiffusion (AGID)
serology for Aspergillus spp. antibodies, microbiology, histopathology, treatment
and outcome were recorded. Treatment response was categorised as complete
remission or treatment failure; complete remission was deﬁned as resolution of
all signs P3 months after cessation of therapy; other outcomes were assigned to
the treatment failure group. Cats that could not be assessed for treatment response
were censored.
Morphological identiﬁcation
Samples were cultured at 28 C and 37 C on Sabouraud’s dextrose agar with
added gentamicin and chloramphenicol when bacterial contamination was likely.
Where available, isolates identiﬁed as Neosartorya spp. were retrieved and subcul-
tured on malt extract agar in pairs at 30 C for 30 days in the dark and examined for
cleistothecia (fruiting bodies) at the colony junction. Antifungal susceptibility test-
ing was performed at the Australian Reference Laboratory in Medical Mycology,
Adelaide.
Molecular identiﬁcation
DNA extraction, PCR ampliﬁcation of the ITS1 region (fresh and formalin-ﬁxed
parafﬁn-embedded tissue) and/or ITS1-5.8S-ITS2 region (culture material) of the
rDNA gene cluster was performed from clinical specimens as described previously
using ITS1 (50-TCCGTAGGTGAACCTGCGG-30) and ITS4 (50-TCCTCCGCTTATTGA-
TATGC-30) primers (Chen et al., 2002; Lau et al., 2007). Sequence identity was deter-
mined using BLAST against the GenBank1 and Centraalbureau voor
Schimmelcultures (CBS)2 databases.
Statistical analysis
Statistical analysis was performed using R version 2.6.2. Cats with SNA and SOA
were compared with respect to conformation, clinical signs, fungal isolate and re-
sponse to treatment. Due to the low expected frequencies in some categories, Fish-
er’s Exact Tests were used in preference to v2. The ﬁsher.test() function of R was
used to calculate the P value of conditional independence, the conditional Maxi-
mum Likelihood Estimate of the odds ratio and the 95% conﬁdence interval of the
odds ratio. Signiﬁcance was ascribed to a P value <0.05.Results
Clinical and clinicopathological ﬁndings
Twenty-three cases (4 retrospective, 19 prospective) from New
South Wales (n = 10), Queensland (n = 9), Victoria (n = 3) and Wes-
tern Australia (n = 1) met the inclusion criteria. All cats were neu-
tered (13 female, 10 male). The age range was 1.5–13 years (mean
5.3, median 5 years). There were 12 domestic crossbreds (11
domestic short hair, 1 domestic long hair) and 11 pure breeds com-
prising one Russian Blue, one Cornish Rex and nine cats with
brachycephalic conformation (3 Himalayan Persians, 3 Chinchilla
Persians, 2 Ragdolls, 1 Exotic Shorthair) (Table 1).1 http://www.ncbi.nlm.nih.gov/genbank/.
2 http://www.cbs.knaw.nl/databases/.Six cats had SNA and 17 cats had SOA. Lack of orbital involve-
ment was conﬁrmed by advanced diagnostic imaging (CT; n = 5)
or surgical exploration of the affected frontal sinus and ipsilateral
orbit (n = 1) in all cases of SNA. In cases of SOA, the presence of a
retrobulbar mass was conﬁrmed by advanced imaging (computer-
ised tomography or magnetic resonance imaging; n = 11), at sur-
gery or postmortem examination (n = 4) or by histological
conﬁrmation of a fungal granuloma where the retrobulbar mass
had perforated into the oral cavity ventrally (n = 2). Four of six cats
with SNA and 5/17 cats with SOA were brachycephalic; brachyce-
phalic cats were no more likely to have SNA than non-brachyce-
phalic cats. Five of six SNA and 17/17 SOA cases had a history of
sneezing and nasal discharge within the preceding 6 months,
whereas 8/17 SOA cases had no signs of sinonasal cavity disease
at presentation (Table 2). The only signiﬁcantly different clinical
signs between cats with SNA and SOA were exophthalmos
(P < 0.001) or presence of a mass or ulcer in the pterygopalatine
fossa (P < 0.05) (Table 2; Fig. 1).
Retrovirus serology and LCAT were negative in all cats tested
(FIV: n = 14; FeLV: n = 11; LCAT: n = 9). Aspergillus spp. serology
(AGID) was positive in 2/2 cats tested (Table 1). Haematological
and serum biochemistry ﬁndings for nine cats are presented in Ta-
ble 3. Five cats with SOA and one with SNA were hyperglobulinae-
mic; these six cats all had Neosartorya spp. infections.
Microbiology
Fungal culture was positive in 22/23 cases. In cases of SNA, the
molecular identity of fungal pathogens was A. fumigatus (n = 4),
Neosartorya ﬁscheri or A. lentulus (n = 1) and a non-speciatedNeosar-
torya spp. (n = 1). Fungal isolates from all 17 cases of SOA were
identiﬁed as Neosartorya spp. by DNA sequencing (Table 1). Four-
teen Neosartorya spp. were subcultured in pairs. Cleistothecia and
ascospores were produced by all isolates from at least one pairing
(Fig. 2). No isolates were homothallic. Fourteen of 16 isolates of A.
fumigatus orNeosartorya spp.were resistant to ﬂuconazole (Table 4).
Only isolates of Neosartorya spp. were resistant to itraconazole (3/
13), voriconazole (2/11) and/or posaconazole (1/11). All three iso-
lates of A. fumigatus tested were susceptible to voriconazole and
posaconazole. No isolates were resistant to amphotericin B.
Histopathology
Inﬂammatory inﬁltrates were lymphocytic (n = 2), histiocytic
and eosinophilic (n = 1) or neutrophilic (n = 1) in nasal mucosal
biopsies available from 4/6 SNA cases. Biopsies were available from
13/17 SOA cases. Granulomatous (n = 1) or plasmacytic and eosin-
ophilic (n = 1) rhinitis were evident in nasal biopsies from two
cases. Retrobulbar (n = 11) and nasopharyngeal (n = 2) masses
were characterised by necrosis and well-vascularised granuloma-
tous inﬂammation. Granulomas contained central areas of coagula-
tive and liquefactive necrosis with abundant periodic acid-Schiff-
positive fungal hyphae. Surrounding zones of inﬂammation com-
prised epithelioid macrophages interspersed with variable num-
bers of eosinophils, neutrophils, lymphocytes and plasma cells
extending into a peripheral zone of ﬁbrosis.
Complete postmortem examinations were performed in six cats
with SOA. All had granulomatous mycotic invasion of the nasal
cavities and paranasal sinuses, with variable invasion of the sub-
mucosal tissue, invasion of paranasal soft-tissues ipsilateral to
the affected orbit and lysis of bone (Fig. 3). Inﬂammatory lesions
effaced the adjacent skeletal muscle and bone in some cases.
Two cats that had surgical exenteration of the right orbit subse-
quently became blind in the left eye. In one case, there was mycotic
involvement of the optic chiasm. In the other case, a retrobulbar
mass effaced the left optic nerve. Of nine SOA cases in which ocular58
Table 1
Case details, molecular identity of fungal pathogens and treatment outcomes in 23 cases of feline upper respiratory tract aspergillosis.
Case Sexa Age
(years)
Breeda Diseaseb Fungal
culturec
Aspergillus
serologyc
Fungal species
(% identity)d
Surgeryg Number
of topical
treatmentsh
Systemic antifungalsh Treatment
(months)
Outcomei Disease
free after
cessation
of
therapy
(months)
Clo Enil AMB-
D
AMB-
L
Itra⁄ Pos⁄ Vor⁄ Ter
1 F 2.6 Persian SNA + ND A. fumigatusf
(100%)
R 0 0 +  + +  + 7 CR 28
2 M 13 DLH SNA + ND N. ﬁscheri/N.
aureola/N.
udagawaee (99%)
ST 0 0 + +  +  + 6 CR 24
3 M 5 DSH SNA  ND A. lentulus/N.
ﬁscherif (100%)
ST 0 0 +  +    7 CR 50
4 F 11 Persian SNA + + A. fumigatuse
(100%)
– 0 1 +  + + +  9 TF –
5 F 6.8 Ragdoll SNA + ND A.
fumigatuse(100%)
ST 1 0    +   <1 C –
6 M 7.4 Persian SNA + ND A. fumigatuse
(99%)
ST 2 0    +   7 CR 7
7 F 5 CR SOA + ND N. ﬁscheri/N.
aureola/N.
udagawaee(99%)
– 0 0 +  + + + + 16 CR 19
8 F 8 Exotic SH SOA + ND N.
pseudoﬁscherie,f
(100%)
Ex 0 0 +  +    2 C –
9 F 3.3 Himalayan SOA + ND N. aureola/N.
udagawaee (99%)
Ex 0 0   + +   1.3 TF –
10 M 3.6 DSH SOA + ND N. ﬁscheri/N.
aureola/N.
udagawaee (99%)
Ex 0 0 +   + + + 3 TF –
11 F 2 DSH SOA + ND N. ﬁscheri/N.
aureola/N.
udagawaee (99%)
Ex 0 0 +   +  + 3 TF –
12 F 2.7 DSH SOA + + N. ﬁscheri/N.
aureola/N.
udagawaee (99%)
Ex 0 0   +    3 TF –
13 F 7 DSH SOA + ND N. ﬁscheri/N.
aureola/N.
udagawaee (99%)
Ex 0 0    +   4.5 C –
14 M 4 RB SOA + ND N. ﬁscheri/N.
aureola/N.
udagawaee (99%)
Or 0 0 +  +    2 TF –
15 M 2 Himalayan SOA + ND N. ﬁscheri/N.
aureola/N.
udagawaee (99%)
– 0 0 +   +  + 2 TF –
16 M 2.3 DSH SOA + ND N. ﬁscheri/N.
aureola/N.
udagawaee (99%)
– 0 0       0 NT –
17 F 4 DSH SOA + ND N. ﬁscheri/N.
aureola/N.
udagawaee (99%)
– 0 0    +   4.5 TF –
18 F 5 DSH SOA + ND N. ﬁscheri/N.
aureola/N.
udagawaee (99%)
– 0 0    +  + 10 C –
19 F 8 Himalayan SOA + ND N. aureola/N.
udagawaef (99%)
– 0 0 +   + +  2.5 TF –
20 F 5.9 DSH SOA + ND N. aureolae (99%) – 0 0 +  + +   8 TF –
21 M 1.5 DSH SOA + ND N. aureolae (99%) – 0 0       0 NT –
22 M 8.2 DSH SOA + ND N. aureolae (99%) – 0 0    +   1 TF –
23 M 4.7 Ragdoll SOA + ND N. aureolae (99%) – 0 0    +   6 TF –
a M, male (neutered); F, female (neutered); DLH, domestic longhair; DSH, domestic shorthair; CR, Cornish Rex; Exotic SH, exotic shorthair; RB, Russian blue.
b SNA, sinonasal aspergillosis; SOA, sino-orbital aspergillosis.
c + Positive;  negative; ND, not done.
d % identity with GenBank and Centraalbureau voor Schimmelcultures (CBS) sequences, rounded to nearest whole integer.
e ITS1-5.8S-ITS2 PCR from fungal culture.
f ITS1 PCR from parafﬁn-embedded or fresh tissue.
g R, ventral rhinotomy; ST, sinus trephination; Ex, exenteration (orbital); Or, orbitotomy plus orbital debridement; , not treated surgically.
h Clo, clotrimazole; Enil, enilconazole; AMB-D, amphotericin B deoxycholate; AMB-L, liposomal amphotericin B; Itra, itraconazole; Pos, posaconazole; Vor, voriconazole;
Ter, terbinaﬁne; + treatment prescribed; – treatment not prescribed; * azole drugs were prescribed sequentially not simultaneously;  topical 1% clotrimazole in polyethylene
glycol plus 2% clotrimazole cream (Sissener et al., 2006);  topical 1% clotrimazole in polyethylene glycol.
i CR, complete remission; TF, treatment failure (euthanased); NT, not treated (euthanased at diagnosis); C, censored.
60 V.R. Barrs et al. / The Veterinary Journal 191 (2012) 58–64
Chapter 3histology was performed, none had mycotic invasion of the globe,
but one cat had anterior uveitis.Treatment regimes
Treatment was attempted in all six cases of SNA and 15/17
cases of SOA. Two cats with SOA were euthanased when treatment
was declined. All 21 treated cats received systemic antifungal ther-apy. Treatment regimes included amphotericin B plus itraconazole
or posaconazole (n = 5), amphotericin B plus itraconazole or posa-
conazole plus terbinaﬁne (n = 7) or monotherapy with itraconazole
(n = 2), posaconazole (n = 8) or voriconazole (n = 4) (Tables 1 and
5). Some cats received more than one treatment regime. Debride-
ment of fungal plaques within the SNA was performed in 5/6
SNA cases, of which three were also treated with a topical anti-
fungal azole.     59
Table 2
Clinical ﬁndings at presentation in 23 cats with upper respiratory tract aspergillosis.
Clinical ﬁndings SNAa
(n = 6)
SOAb
(n = 17)
Nasal discharge 4 8
Stertor 4 8
Epistaxis 2 0
TemperatureP 39.2 C 2/4 5/12
Signs of sinonasal cavity disease at presentation 6 9
History of nasal discharge or sneezing within
preceding 6 months
5 17
Discharging sinus 2 0
Unilateral exophthalmos 0 16
Bilateral exophthalmos 0 1
Exophthalmos 0 17
Corneal ulcer 0 6
Pterygopalatine fossa mass 0 13
Pterygopalatine fossa ulcer 0 2
Hard palate ulcer 0 4
Paranasal soft tissue swelling 0 6
Pain on opening mouth 0 2
Mandibular lymph node enlargement 2 8/13
Peripheral vestibular disease 0 1
a SNA, sinonasal aspergillosis.
b SOA, sino-orbital aspergillosis.
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Five cases had complete remission (4 SNA, 1 SOA). In the treat-
ment failure group, there were 12 cats (1 SNA, 11 SOA). Four cats
were censored (1 SNA, 3 SOA). Cats with SNA were signiﬁcantly
more likely to respond to treatment than cats with SOAFig. 1. Exophthalmos (a), mass in the left pterygopalatine fossa (b) and ulceration of t
aspergillosis.
Table 3
Haematology and serum biochemistry values in nine cats with upper respiratory tract asp
Variable Median (range) Number wit
Haematocrit (%) 38 (30–48) 0
Total leucocytes (109/L) 9 (6.5–18.5) 3
Neutrophils (109/L) 5.2 (2.9–13.7) 1
Band neutrophils (109/L) 0 0
Monocytes (109/L) 0.5 (0–1.1) 2
Lymphocytes (109/L) 5.3 (0.9–5.0) 1
Eosinophils (109/L) 0.890 (0.1–2.1) 1
Albumin (g/L) 30 (24–39) 1
Globulin (g/L) 56 (40–106) 0
Urea (mmol/L) 5.5 (4.6–8.1) 0
Creatinine (mmol/L) 119 (100–151) 0
Calcium (mmol/L) 2.5 (2.2–2.8) 0
Alanine amino transferase (IU/L) 33 (3–64) 0
Alkaline phosphatase (IU/L) 20 (13–62) 0(P < 0.05). The four SNA cases with complete remission had resolu-
tion of clinical signs at follow-up 7, 24, 28 and 50 months after ces-
sation of treatment (Table 1). The SNA case with treatment failure
was euthanased 13 months after diagnosis with persistent nasal
signs and chronic kidney disease. Complete remission was
achieved in one SOA case treated with oral itraconazole and
amphotericin B (Table 1, Case 7). However, when treatment was
stopped after 8 months, the cat developed recurrent disease and
was treated with posaconazole (32 weeks) and terbinaﬁne
(16 weeks). The cat remained asymptomatic, with resolution of
disease on CT examination, until 19 months after cessation of ther-
apy, when it developed recurrent SOA. Clinical signs persisted de-
spite treatment with posaconazole and liposomal amphotericin B.
Clinical signs and CT evidence of infection resolved after treatment
with caspofungin, then posaconazole monotherapy, which was
ongoing 12 months later.
All SOA cases with treatment failure were euthanased due to
progressive disease. Five cats treated with systemic antifungal
agents (mean treatment period 2.6 months) and orbital exentera-
tion developed neurological signs, including blindness or reduced
vision (n = 4), circling and pleurothotonus (n = 1), facial muscle fas-
ciculation and stargazing (n = 1) or hyperaesthesia (n = 1). Of six
cats treated with medical therapy alone (mean treatment period
3.9 months), one developed ataxia and paresis.
Of the four cases that were censored, one died during anaes-
thetic recovery and postmortem examination was declined (Ta-
ble 1, Case 5), one had resolution of signs but died 1 month after
treatment stopped (no postmortem examination performed, Case
13), treatment was ongoing in one (case 18) and one was euthan-
ased with heart failure (hypertrophic cardiomyopathy, Case 8).he hard palate (c) due to retrobulbar fungal granulomas in cats with sino-orbital
ergillosis.
h low values Number with high values Reference range
1 30–45
2 8–14
2 3.8–10.8
0 0–0.4
2 0.08–0.6
0 1.6–7
1 0.2–1.4
0 19–38
6 26–51
0 3–10
0 90–180
2 1.75–2.6
1 <60
1 <50
 60
Fig. 2. Cleistothecia (small spherical structures) at the colony junction in paired
cultures of Neosartorya spp. isolates from two cases (inset). Neosartorya spp.
ascospores with roughened side walls and two axial crests. Scanning electron
micrograph (Zeiss EVO LS15). Scale bar = 2 lm.
Fig. 3. Periodic acid-Schiff-stained section of frontal sinus epithelium from a cat
with invasive sino-orbital aspergillosis. Fungal hyphae are present deep within the
sinus epithelium, demonstrating the invasive nature of this mycosis. Scale
bar = 60 lm.
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URT aspergillosis is an emerging infection in cats (Barrs et al.,
2007). In our study, all cats were infected with fungi within the
complex designated Aspergillus section Fumigati subgenus fumigati,
also termed the A. fumigatus complex. This complex contains asex-
ual members (anamorph, Aspergillus spp.), some of which also have
sexual forms (teleomorph, Neosartorya spp.). N. fumigata, the tele-
omorph of A. fumigatus, has only been induced in vitro after an
incubation period of 6 months (O’Gorman et al., 2009). Our ability
to induce teleomorphs with relative ease in vitro within 30 days
provides additional phenotypic evidence that species other than
A. fumigatus cause feline SOA and that these fungal pathogens are
not strict anamorphs. However, induction of teleomorphs is
impractical for routine identiﬁcation, since clinical isolates may
not produce fruiting bodies in the laboratory setting and comple-
mentary mating strains are required for heterothallic species (Bal-
ajee et al., 2007; Kano et al., 2008).
For comparative purposes, we performed ITS1 and/or ITS1-5.8s-
ITS2 PCR and sequencing of archival tissues from the sinonasal cav-
ity of seven dogs with SNA; similar to other reports, the molecular
identity of all seven canine mycoses was A. fumigatus (Peeters et al.,
2005; Windsor et al., 2006). Neosartorya spp. has not been identi-
ﬁed in URT aspergillosis of dogs; however, in canine SNA where
fungal pathogens were identiﬁed by phenotypic features alone, it
is possible that some cases were caused by members of the A.
fumigatus complex and mistakenly identiﬁed as A. fumigatus. There
is growing evidence that infections with Neosartorya spp. are more
common in humans with invasive pulmonary aspergillosis than
earlier thought, having been misidentiﬁed previously as A. fumiga-
tus (Balajee et al., 2005; Vinh et al., 2009; Sugui et al., 2010). A
polyphasic taxonomic approach is the gold standard for species
identiﬁcation within the A. fumigatus complex. This involves a
combination of macro- and micromorphological traits, growthTable 4
Results of in vitro antifungal susceptibility tests.
Fungal species Voriconazole Posaconazole
S I R S I R
Aspergillus fumigatus 3 0 0 3 0 0
Neosartorya spp. 5 4 2 7 3 1
Numbers of isolates susceptible (S), with intermediate/dose-dependent susceptibility (I)temperature regimes, extrolite proﬁles and PCR-based detection
methods (Balajee et al., 2007; Samson et al., 2007).
The pan-mycotic PCR used in this study can be used to identify a
diverse range of fungal genera from clinical specimens, including
both ﬁlamentous fungi and yeasts (Lau et al., 2007). However, as
demonstrated here, the ITS1 and ITS2 regions ﬂanking the
5.8SrDNA may contain insufﬁcient variation to enable identiﬁca-
tion of some individual species within the A. fumigatus complex.
After ITS sequence analysis, comparison of partial b-tubulin gene
sequences, alone or together with partial rodlet A gene sequences,
is recommended for species identiﬁcation (Balajee et al., 2007; Su-
gui et al., 2010).
In our study, SOA (n = 17) was more frequent than SNA (n = 6).
Only cats with SNA were infected with A. fumigatus, while cats with
SOA were infected with other species from the A. fumigatus com-
plex. The reason for such a high proportion of SOA cases in this
study could in part be due to increased recognition of the disease
(Barrs et al., 2007). The ecological niche of species within the A.
fumigatus complex is the soil and A. fumigatus is distributed world-
wide (Latge, 1999; Samson et al., 2007). Some Neosartorya spp.
have a worldwide distribution, whereas others are geographically
restricted.
Cases of SOA have been reported in cats from the USA, Italy and
Japan (Peiffer et al., 1980; Halenda and Reed, 1997; Hamilton et al.,
2000; McLellan et al., 2006; Barachetti et al., 2009; Quimby et al.,
2010; Smith and Hoffman, 2010). The molecular identity of the
causative agent was conﬁrmed in one case as A. udagawae (Kano
et al., 2008).
SOA is an invasive mycosis of apparently immunocompetent
cats. All cats in this study had URT signs, supporting the sinonasal
cavity as the primary site of infection. Furthermore, there was
involvement of the sinonasal cavity in all of the cases submitted
for postmortem examination. Erosions were found in the orbital
lamina, adjacent to the sinonasal cavity, suggesting that extensionItraconazole Fluconazole Amphotericin B
S I R S R S I
1 2 0 0 3 2 1
3 7 3 2 11 10 3
or resistant (R).
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Table 5
Drugs and dosages used in treatment of 21 cats with upper respiratory tract aspergillosis.
Drug Number of
cats treated
Dose Dose commentsa Adverse effects
Amphotericin B deoxycholate 12 0.5 mg/kg in 350 mL 0.45% NaCl
by SC infusion 2–3 times weekly
MCD 9 mg/kg (range 5.5–14 mg/kg)
Liposomal amphotericin B 2 1–1.5 mg/kg IV every 48 h MCD 5 mg/kg
Caspofungin 1 1 mg/kg IV every 24 h MCD 22 mg/kg
Voriconazole 4 5–12 mg/kg PO every 24 h MD 8.3 mg/kg/day. Treatment
duration 4–21 days
Anorexia, dilated pupils,
hind limb ataxia (3/4 cats)
Itraconazole 9 5–20 mg/kg PO every 24 h MD 12 mg/kg PO 24-hourly
Posaconazole 15 2.5–4.5 mg/kg PO every 12 h MD 3 mg/kg PO 12-hourly 1.1–2 elevations in alanine amino
transferase activity (2/10 cats)
Clotrimazole 2 1% topical preparation
in polyethylene glycol
Sinonasal instillation
(via sinus trephination)
Enilconazole 1 1% topical preparation Sinonasal instillation
Terbinaﬁne 7 12.5–20 mg/kg PO every 12–24 h 15 mg/kg PO 12-hourly
a MCD, mean cumulative dose; MD, mean dose.
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Chapter 3of disease occurs via this route. Lysis of the orbital lamina has been
identiﬁed on CT in cats with SOA and progression from SNA to SOA
has been documented (Hamilton et al., 2000; Barachetti et al.,
2009).
More than one-third of cats in our study were pure-bred and
had a brachycephalic conformation, suggesting that brachyce-
phalic cats are predisposed to URT aspergillosis. Since cats were re-
cruited from around Australia, comparison with local demographic
data was not possible. However, data from two Australian states
show that there are 2–3 times more domestic cross-bred cats than
pure-bred cats and that Burmese cats are the most popular pure-
bred cat, comprising up to 25% of the pure-bred population (Leder-
er et al., 2009; Toribio et al., 2009; NSW Cat Fancy Association kit-
ten registration data 2001–2009, unpublished data). In our study,
brachycephalic cats were no more likely to have SNA than non-
brachycephalic cats. Furthermore, we identiﬁed URT aspergillosis
in 13 females and 10 males, which does not support the prepon-
derance of males reported previously (7 females, 14 males).
The basis for an association between brachycephalic conforma-
tion and URT aspergillosis in cats is not clear. In humans, decreased
sinus aeration and drainage of respiratory secretions secondary to
infection, polyps and allergic rhinosinusitis are risk factors for
invasive SNA (Siddiqui et al., 2004). Reduced drainage of URT
secretions due to brachycephalic conformation could be a risk fac-
tor in cats. However, since brachycephalic dogs are under-repre-
sented for SNA, it is likely that additional risk factors are present
in cats. These could include heritable defects in mucosal immunity,
previous viral URT infection and previous antibiotic treatment
favouring fungal colonisation (Tomsa et al., 2003).
There is no evidence in our study or in previous reports of an
association between retrovirus infection and URT aspergillosis,
with only one FeLV positive case reported (Goodall et al., 1984).
Hyperglobulinaemia, the most common biochemical abnormality
in cats in our study, was documented in four previous cases of
SOA (Hamilton et al., 2000; McLellan et al., 2006; Smith and Hoff-
man, 2010). Chronic antigenic stimulation may explain this hyper-
globulinaemia, although electrophoresis was not carried out to
determine whether speciﬁc immunoglobulin peaks were evident.
The majority of isolates in this study were resistant to ﬂuconaz-
ole, which is typical of fungi in the A. fumigatus complex (Alcazar-
Fuoli et al., 2008). A. fumigatus isolates in our study were suscepti-
ble to triazole antifungals and amphotericin B, which is also typical
for this species (Alcazar-Fuoli et al., 2008). Elevated minimum
inhibitory concentrations of voriconazole for Neosartorya spp. have
been described previously (Balajee et al., 2005).
Presence or absence of orbital involvement in cats with URT
aspergillosis has important prognostic signiﬁcance. Completeremission was signiﬁcantly more likely in cats with SNA than
SOA. Further studies are required to investigate whether the infect-
ing fungal species is a major determinant of treatment outcome.
While SOA was only caused by species other than A. fumigatus,
these cases may be more responsive to treatment if diagnosed be-
fore orbital extension. Two out of three SNA cases with complete
remission had infections with Neosartorya spp. or N. ﬁscheri/A.
lentulus.
Due to the potential for SNA to progress to SOA, systemic anti-
fungal treatments were used in all cases. In all SNA cases with
complete remission, gross fungal plaques within the sinonasal cav-
ity were surgically debrided, which could have contributed to
treatment success, as reported for canine SNA (Zonderland et al.,
2002). Favourable outcomes have resulted from the use of single
topical clotrimazole treatment alone (n = 2) or in combination with
systemic antifungal agents (n = 1) in cats with SNA (Tomsa et al.,
2003; Furrow and Groman, 2009). Two cats were disease free 2
and 4 years post-infusion. In our study, one case of SNA resolved
after a second topical clotrimazole treatment. Multiple topical clo-
trimazole treatments can improve outcomes in refractory cases of
canine SNA (Pomrantz and Johnson, 2010). Whether SNA due to A.
fumigatus in cats is more likely to respond to topical antifungal
therapy than infections due Neosartorya spp., which have an in-
creased propensity for invasion, is not yet clear.
Pharmacological data for posaconazole and echinocandins in
cats is lacking. Posaconazole was used in our study because it is
fungicidal against Aspergillus spp. and was reported to cure a feline
SOA case that did not respond to itraconazole and amphotericin B
(McLellan et al., 2006). Posaconazole was well tolerated, with
infrequent mild transient liver enzyme elevations. Use of echino-
candins in humans with invasive aspergillosis is restricted to sal-
vage therapy or combination antifungal therapy in refractory
disease (Patterson, 2006). In our study, caspofungin was well toler-
ated and efﬁcacious in the single cat receiving this agent. Kano
et al. (2008) documented unsuccessful treatment using micafungin
in a cat with SOA.
Adverse effects seen in three cats receiving voriconazole in our
study were similar to those reported in ﬁve other cats (Quimby
et al., 2010; Smith and Hoffman, 2010). The pharmacology of voric-
onazole has not been studied in cats and caution is urged in the
continued use of this drug given the apparent high frequency of
serious neurological adverse effects.
Conclusions
Cats with SNA are signiﬁcantly more likely to be infected with A.
fumigatus and have a better prognosis than cats with SOA. SOA is 62
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Chapter 3an invasive mycosis in cats and is caused by fungal species within
the Aspergillus complex other than A. fumigatus, such as Neosar-
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3.3 Conclusions 
Data from the large cohort described in this publication, combined with previous case 
reports, establishes important aetiological, epidemiological and diagnostic information 
about FURTA.  Our group first published evidence that cryptic species were 
systematically implicated in feline URTA in a meeting abstract (Barrs et al., 2007). The 
publication in this chapter builds on that information, increasing the number of cases 
studied from seven to twenty three. The next corroborating evidence that cryptic species 
were implicated in URTA appeared in a case report from Japan describing a case of A. 
udagawae infection in a cat with SOA (Kano et al., 2008). Here, we provide preliminary 
evidence of an association between anatomic form of FURTA and aetiological agent, 
with the finding that A. fumigatus was only isolated from cases of SNA, and that SOA 
was only caused by cryptic species. An exciting finding was that 14 of the 17 cryptic 
species were identified as heterothallic on mating tests. This opened up the possibility 
that SOA was caused predominantly by a single heterothallic species of Aspergillus, 
and led to the next stage of research described in Chapter four. 
My study corroborates the findings from case-reports of FURTA since 1982, that there 
is no evidence of systemic immune-compromise in the majority of cats with this disease. 
Unlike disseminated invasive aspergillosis in cats, which is frequently associated with 
prolonged corticosteroid therapy or concurrent viral immunosuppression from feline 
leukaemia virus (FeLV), feline immunodeficiency virus (FIV), feline panleukopenia virus 
or feline infectious peritonitis virus (Bolton GR and TT, 1972; Burk RL et al., 1990; Fox 
et al., 1978; Köhler H et al., 1978; Ossent, 1987), with the exception of one cat with 
concurrent FeLV published at a time when FeLV was more prevalent (Goodall et al., 
1984), no such associations have been found in cats with FURTA. 
Through the cohort described here a predilection for pure-bred cats of brachycephalic 
conformation was identified. This risk factor for infection raises further questions for 
research – is disease in these cats due to a conformational abnormality of the skull 
affecting sinus aeration and drainage? Do these closely related cats have an inherited 
disorder of innate immunity?  
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The findings from this study, also establish, that at least in Australia SOA, the more 
invasive anatomic form of disease, is the most common clinical presentation and that 
this form has a poor prognosis. We demonstrate that Aspergillus isolates can be easily 
cultured from tissue biopsies from the sinonasal cavity or orbit of infected cats, an 
important finding that has established culture as the gold standard for diagnosis of 
FURTA. Further, achieving a definitive diagnosis of this condition should be within the 
skill set of most veterinary practitioners since specialized fungal culture media or 
conditions were not required.   
The therapeutic approaches adopted for cats with SOA were similar to those used to 
treat SOA in immunocompetent humans (Panda et al., 2004; Panda et al., 2008; 
Pushker et al., 2011; Sivak-Callcott et al., 2004). Treatment outcomes were poor 
despite lack of evidence of systemic immune compromise and aggressive therapeutic 
protocols combining extensive debridement surgery with the use of modern anti-fungal 
drugs viz posaconazole, voriconazole, caspofungin and liposomal amphotericin B. This 
finding highlights the need for targeted research in this area to investigate the 
pharmacokinetics and pharmacodynamics of each of these drugs in the feline host. The 
adverse effects seen in voriconazole-treated cats in this study have been documented 
elsewhere (Quimby et al., 2010; Smith and Hoffman, 2010). Cats differ to humans and 
other animals due to their reduced ability to metabolise drugs by glucuronidation due to 
substantially reduced hepatic microsomal uridine diphosphate-glucuronosyltransferase 
(UGT) activity (Court and Greenblatt, 2000). In humans posaconazole metabolism has 
been shown to be mediated predominantly through phase-2 biotransformation via UGT 
enzyme pathways (Ghosal et al., 2004). Although posaconazole was clinically well 
tolerated in the cats treated in my study, the optimal dose has not been established.  
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Chapter 4. Identification of the aetiological agents of 
feline aspergillosis and discovery of a novel species – 
Aspergillus felis sp. nov. 
4.1 Background 
Building on the work described in Chapter three, in this publication I perform further 
morphologic, molecular and phylogenetic analyses of isolates from cats with SOA at the 
CBS KNAW Fungal Biodiversity Centre in Utrecht to determine their identity, and in 
doing so, describe a novel heterothallic species in Aspergillus section Fumigati, namely 
A. felis (neosartorya-morph).  
 
4.2 Main article 
Barrs VR, Tineke M. van Doorn TM, Houbraken J, Kidd SE, Martin P, Pinheiro MD, 
Richardson R, Varga J, Samson RA. Aspergillus felis sp. nov., an emerging agent of 
invasive aspergillosis in humans, cats and dogs 2013. PLoS One 8(6): e64871; 
doi:10.1371/journal.pone.0064871 
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Abstract
We describe a novel heterothallic species in Aspergillus section Fumigati, namely A. felis (neosartorya-morph) isolated from
three host species with invasive aspergillosis including a human patient with chronic invasive pulmonary aspergillosis,
domestic cats with invasive fungal rhinosinusitis and a dog with disseminated invasive aspergillosis. Disease in all host
species was often refractory to aggressive antifungal therapeutic regimens. Four other human isolates previously reported
as A. viridinutans were identified as A. felis on comparative sequence analysis of the partial b-tubulin and/or calmodulin
genes. A. felis is a heterothallic mold with a fully functioning reproductive cycle, as confirmed by mating-type analysis,
induction of teleomorphs within 7 to 10 days in vitro and ascospore germination. Phenotypic analyses show that A. felis can
be distinguished from the related species A. viridinutans by its ability to grow at 45uC and from A. fumigatus by its inability
to grow at 50uC. Itraconazole and voriconazole cross-resistance was common in vitro.
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Introduction
Aspergillosis, a mycosis caused by infection with fungi belonging
to the genus Aspergillus, occurs in a diverse range of human and
animal hosts. In humans, aspergillosis is diagnosed increasingly
due to the introduction of novel immunosuppressive regimens
among patients undergoing bone-marrow or solid organs trans-
plants, or treatment for malignancies [1]. Further, the prevalence
of fungal infections in mammals is predicted to increase due to
global warming leading to expansion of the geographic range of
pathogenic fungi [2]. Invasive aspergillosis (IA) in humans occurs
predominantly in the sinopulmonary tract of immunocompro-
mised individuals after inhalation of Aspergillus spp. conidia.
Although Aspergillus fumigatus is the most common cause of IA, A.
fumigatus-like species including A. lentulus, A. udagawae (Neosartorya
udagawae), A. novofumigatus, N. pseudofischeri and A. viridinutans are
being increasingly identified using molecular techniques [3–9].
These cryptic species have reduced or variable susceptibility to
antifungal drugs used for standard therapy of IA including
amphotericin B and azoles, which is of concern [5,10].
In domestic cats and dogs, in contrast to humans, fungal
rhinosinusitis (FRS) is more commonly reported than invasive
pulmonary aspergillosis (IPA) [11–12]. We recently described an
emerging clinical syndrome of chronic invasive FRS, also known
as sino-orbital aspergillosis (SOA), in apparently immunocompe-
tent cats [13]. Disease is characterized by extension of a sinonasal
mycosis into the orbit to form an expansive retrobulbar fungal
granuloma with progressive invasion of contiguous anatomic
structures including the oral cavity, subcutaneous paranasal tissues
and central nervous system. Preliminary investigations suggested
that the majority of infections were caused by a heterothallic A.
fumigatus-like species. Here we identify these isolates using
phenotypic, physiologic and phylogenetic analyses as A. felis sp.
nov. and demonstrate that this species is a cause of IA in cats, dogs
and humans.
Materials and Methods
Fungal Strains
Twenty isolates of A. felis were available for study including 19
from clinical specimens and 1 isolate from an indoor air sample in
Germany (Table 1). Seventeen isolates were from domestic cats (15
with FRS and retrobulbar masses (SOA), 1 with sinonasal cavity
infection only (sinonasal aspergillosis, SNA), 1 with a thoracic
mass), one isolate was from a dog with disseminated IA and one
isolate was from a human with chronic IPA. Three A. felis isolates,
including the human isolate, had been identified and reported
previously as A. viridinutans [14,15]. Five additional isolates from
cats with FRS or IPA were examined including two isolates of A.
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fumigatus, A. udagawae (1), A. lentulus (1) and N. pseudofischeri (1)
(Table 1).
Except for isolates MK246, MK284 and MK285, which were
obtained from the Commonwealth Scientific and Industrial
Research Organisation FRR Culture Collection, North Ryde,
NSW, Australia [14], all cases of invasive FRS (SOA), IA and IPA
were proven invasive fungal infections based on histopathologic
and/or cytopathologic detection of hyphae in needle aspiration or
biopsy specimens with evidence of associated damage (Figure 1)
[16]. For phylogenetic analyses, a PubMed search for A. viridinutans
isolates from human clinical specimens deposited in GenBank with
accession numbers for the internal transcribe spacer (ITS) regions,
partial b-tubulin (benA) and/or calmodulin (calM) sequences was
carried out. The sequences of four isolates previously identified as
A. viridinutans (GM 02/39, CM 4518, IFM 54303, CM 3147) were
identical to A. felis sp. nov. (Table 1). Reference strains included in
the study are listed in Table S1.
Clinical data
Cats with invasive FRS were presented by their owners for
veterinary investigation of unilateral exophthalmos caused by a
retrobulbar fungal granuloma. All had nasal discharge at
Table 1. Isolates from clinical specimens and an indoor air sample included in this study.*
Strain no./Other
designation Species MAT1{ Source GenBank accession number
ITS benA CalM MAT1
DTO 131E3 A. felis 1 Cat, RBM, Australia JX021671 - - KC797634
DTO 131E4 A. felis 2 Cat, RBM, Australia JX021673 JX021692 - KC797622
DTO 131E5 A. felis 1 Cat, RBM, Australia JX021674 JX021693 JX021719 KC797627
CBS 130244 A. felis 1 Cat, RBM, Australia JX021675 JX021694 JX021717 KC797630
DTO 131E9 A. felis 1 Cat, RBM, Australia JX021676 JX021696 - KC797628
DTO 131F1 A. felis 1 Cat, RBM, Australia JX021677 JX021697 - KC797629
DTO 131F2 A. felis 2 Cat, RBM, Australia JX021678 JX021698 - KC797623
DTO 131F3 A. felis 2 Cat, RBM, Australia JX021679 JX021699 - -
CBS 130245 (T) ` A. felis 2 Cat, RBM, Australia JX021685 JX021700 JX021715 KC797620
DTO 131F6 A. felis 2 Cat, RBM, Australia JX021680 JX021702 JX021721 KC797624
CBS 130246` A. felis 1 Cat, SNC, Australia JX021681 JX021704 JX021724 KC797631
DTO 131G1 A. felis 2 Cat, RBM, Australia JX021682 JX021705 JX021725 KC797625
CBS 130247` A. felis 1 Cat, RBM, Australia JX021683 JX021706 JX021726 KC797632
CBS 130248` A. felis 2 Cat, RBM, Australia JX021684 JX021707 JX021727 KC797621
CBS 130249 A. felis 2 Dog, VH, Australia JX021686 JX021711 JX021713 -
CBS 130250 A. felis 11 Cat, RBM, UK JX021689 JX021712 JX021714 KC797633
MK 246, FRR 5679 A. felis 2 Cat, TM, Australia" - AY590129 - KC797626
MK 284, FRR 5680 A. felis 2 Cat, RBM, Australia" - AY590130 - -
MK 285, FRR 5681 A. udagawae 1 Cat, RT, Australia" - AY590133 - -
DTO 131F5 A. lentulus 1 Cat, SNC, Australia - - JX021720 -
DTO 131F7 A. fumigatus - Cat, SNC, Australia - - JX021722 -
DTO 131E7 A. fumigatus - Cat, SNC, Australia - - - -
DTO 131G4 N. pseudofischeri 1–2 Cat, SNC, Australia - - JX021716 -
CM 5623 A.felis 11 Human, lung, Portugal** - - KC305167 -
GM 02/39{{ A.felis - Human, sputum/BAL,
Spain**
- HQ127257 - -
CM 4518{{ A.felis - Human, nail, Spain - EU310871 - -
IFM 54303{{ A.felis - Human, Japan - AB248299 AB259973 -
CM 3147{{ A.felis - Human, oropharyngeal
exudate, Spain
- EU310843 - -
DTO 176F1 A. felis 2 Indoor air Stuttgart,
Germany
- - KC305168 -
*DTO, internal culture collection of CBS-KNAW Fungal Biodiversity Centre, Utrecht, Netherlands; RBM, retrobulbar mass; VH, vitreous humor; TM, thoracic mass; RT,
respiratory tract; SNC, sino-nasal cavity; T, type strain; BAL, bronchoalveolar lavage.
{Mating type genotype and phenotype; 1, MAT1-1; 2, MAT1-2.
`Isolate included in temperature growth studies.
1Mating genotype only, negative mating test result.
"Previously reported as A. viridinutans-like [14].
**Previously reported as A. viridinutans in patients with IA [8,15].
{{Sequence data only, sequences sourced from GenBank search for A. viridinutans.
doi:10.1371/journal.pone.0064871.t001
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presentation or historical evidence of sneezing or nasal discharge
within the previous 6 months. The cats had no significant
intercurrent diseases and were considered to be systemically
immunocompetent [13]. The dog with disseminated IA presented
with panuveitis, spinal pain, cardiac murmur and fever subsequent
to immunosuppressive therapy with cyclosporine and prednisolone
for immune-mediated hemolytic anaemia. The human patient
with chronic IPA was a 56 year old man with type II diabetes
mellitus receiving immunosuppressive therapy (prednisolone,
etarnecept and methotrexate) for rheumatoid arthritis. Infection
was protracted over 18 months and extended from a solitary lung
nodule across anatomic planes to involve cervical lymph nodes
and pleural space [15].
Morphological characterization
Isolates were grown for 7 days as 3-point inoculations on
Czapek agar, Czapek yeast autolysate agar (CYA), malt extract
agar (MEA) and oatmeal agar (OA) at 25uC and 37uC. Media
were prepared as described by Samson et al [17]. To determine
MAT1-1 and MAT1-2 phenotypes, mating tests for teleomorph
induction were performed by crossing a selection of isolates on
MEA and OA in all possible combinations of opposite mating type
and incubating at 30uC in the dark. Additional mating tests were
performed using one isolate with confirmed phenotype and
genotype of MAT1-1 (CBS 130246) and of MAT1-2 (CBS
130245) (Table 1). Cleistothecia produced from each positive
mating were crushed and examined microscopically for the
presence of ascospores. To determine ascospore viability and heat
resistance 4-week old cleistothecia from two paired matings (CBS
1302456 DTO 131E9, DTO 131E96 DTO131F3) were
ruptured, suspended in 0.05% Tween 80 and heated to 70uC
for 60 min as described previously [18]. Aliquots of ascospore
suspension (200 mL) were cultured on 5% MEA, incubated at
28uC and examined by light microscopy after 18 h incubation for
spore germination (Olympus BH2). Isolates were also mated with
type strains of A. viridinutans (CBS 127.56), A. fumigatus (CBS
133.61) and A. udagawae (CBS 114217, CBS 114218).
For radial growth determination, MEA was inoculated with
3 mL of conidial suspension (36107 conidia/mL) in the centre of
the plate and colony diameters were measured after 7 days
incubation at temperatures ranging from 6uC in increasing
increments of 3uC to 33uC, and at 36uC, 40uC, 45uC and 50uC.
Morphologic features were studied by light microscopy (Olympus
BH2 and Zeiss Asioskop 2 Plus) and by scanning electron
microscopy (Zeiss EVO LS15). Temperature growth studies were
performed using two replicates each of type strains of A.
viridinutans, A. fumigatus and clinical isolates CBS 130245, CBS
130246, CBS 130247 and CBS 130248 (Table 1 & Table S1).
Phylogeny and Molecular Identification
Isolates were grown on MEA for 7 days at 37uC and genomic
DNA was extracted using the Ultraclean microbial DNA isolation
kit (MoBio, Solana Beach, CA) according to the manufacturer’s
instructions. Amplification of the ITS regions, including ITS-1,
ITS-2 and the 5.8S rDNA gene (primers ITS1 and ITS4), and
parts of the b-tubulin (benA) (primers Bt2a and Bt2b) and
calmodulin (calM) gene (primers cmd5 and cmd6) was performed
as described previously [19–21]. Sequencing reactions were
performed with the Big Dye Terminator Cycle Sequencing Ready
Reaction kit and carried out for both strands. Sequencing
reactions were purified by gel filtration through Sephadex G-50
(Amersham Pharmacia Biotech, Piscataway, NH), equilibrated in
double-distilled water and analyzed on the ABI PRISM 310
Genetic Analyzer (Applied Biosystems).
Sequence alignments were performed using ClustalW software
incorporated in MEGA version 5 [22]. Alignment positions with
gaps or missing data were excluded, and all characters were
unordered and of equal weight. The maximum parsimony (MP)
tree was obtained using the Close-Neighbour-Interchange algo-
rithm with search level 3 in which the initial trees were obtained
with the random addition of sequences (10 replicates). The tree
was drawn to scale with branch lengths calculated using the
average pathway method. To assess the robustness of the topology,
500 bootstrap replicates were run by MP and tree length, and
consistency index (CI) and retention index (RI) were calculated.
Aspergillus clavatus (CBS 513.65) was the out-group in the trees
based on benA and calM and N. pseudofischeri (CBS 208.92) was the
out-group in the tree based on ITS sequence data. Unique ITS,
benA and calM sequences were deposited in the GenBank
nucleotide sequence database under accession numbers:
JX021671- JX021727 and KC305167-KC305168 (Table 1).
Degenerate primers were constructed to amplify the alpha
domain-encoding sequence from the MAT1-1 gene family and the
high mobility group (HMG) domain-encoding sequence from
Figure 1. Tissue invasion by fungal hyphae in a cat with SOA. Hematoxin & Eosin- (A) and Grocott- (B) stained section of nasal mucosa and
turbinates demonstrating granulomatous rhinitis (A) and submucosal invasion by septate branching fungal hyphae (B).
doi:10.1371/journal.pone.0064871.g001
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MAT1-2. MAT1-1 primers (AFM1_F65655 (59- CCT YGA CGM
GAT GGG ITG G –39) and MAT1_R6215 (59- TG TCA AAG
ART CCA AAA GGA GG –39) were designed by identifying
regions of conserved sequences in A. clavatus, Neosartorya fischeri and
A. fumigatus. MAT1-2 primers (MAT2_F6086 (59- TCG ACA AGA
TCA AAW CYC GTC –3) and MAT2_R6580 (59- CTT YTT
GAR CTC TTC YGC TAG G –39) were designed by identifying
regions of conserved sequence in A. nidulans, N. fischeri and A.
fumigatus. PCR reactions were set up as described previously [23].
PCR cycle parameters were denaturation at 95uC for 5 min, then
30 cycles of denaturation at 95uC for 30 s, annealing at 48uC for
30 s, extension at 72uC for 1 min, and a final extension at 72uC
for 5 min. MAT1-1 and MAT1-2 sequences were deposited in the
GenBank nucleotide sequence database under accession numbers
KC797620-KC797634 (Table 1).
Nomenclature
The electronic version of this article in Portable Document
Format (PDF) in a work with an ISSN or ISBN will represent a
published work according to the International Code of Nomen-
clature for algae, fungi, and plants, and hence the new names
contained in the electronic publication of a PLOS ONE article are
effectively published under that Code from the electronic edition
alone, so there is no longer any need to provide printed copies. In
addition, new names contained in this work have been submitted
to MycoBank from where they will be made available to the
Global Names Index. The unique MycoBank number can be
resolved and the associated information viewed through any
standard web browser by appending the MycoBank number
contained in this publication to the prefix http://www.mycobank.
org/MycoTaxo.aspx?Link = T&Rec = . The online version of this
work is archived and available from the following digital
repositories: PubMed Central, LOCKSS.
Antifungal Susceptibility Testing
Susceptibilities of 13 A. felis isolates to amphotericin B,
itraconazole, posaconazole, voriconazole, fluconazole, 5-flucyto-
sine, caspofungin, anidulafungin and micafungin were assessed
using the Sensititre YeastOne YO10 microdilution trays (Trek
Diagnostic Systems, Thermo Fisher Scientific, Australia), which
have been demonstrated to yield comparable results to the CLSI
M38-A standards for molds [24]. Susceptibility to terbinafine
(Novartis Pharmaceuticals Corporation, Sydney, Australia) was
assessed according to the CLSI M38-A2 standard [25]. Endpoints
for all drugs were determined after 48 h incubation at 35uC. For
amphotericin B, itraconazole, posaconazole, voriconazole, flucon-
azole and 5-flucytosine, endpoints were read as the lowest
concentration with a complete color change, indicating total
inhibition of fungal growth (minimum inhibitory concentration,
MIC).The echinocandin endpoints were read as the lowest
concentration revealing a partial color change, which also
corresponded to the lowest concentration of drug leading to the
growth of small compact hyphal forms as compared to the hyphal
growth observed in the drug free control (minimum effective
concentration, MEC). The terbinafine endpoint was read as the
first dilution with 100% growth inhibition (MIC). Aspergillus flavus
(ATCC 204304) and Candida parapsilosis (ATCC 22019) isolates
were used as quality control strains.
Results
Sequence-based analyses
The calM data set consisted of 487 characters, including 171
parsimony informative sites. MP analysis resulted in 792 equally
parsimonious trees (tree length 350 steps, CI 0.547297, RI
0.778512) (Figure 2). Of the aligned benA sequences, a region
with 394 positions, including 63 parsimony informative characters,
was selected for analysis. MP analysis resulted in 241 equally
parsimonious trees (length 447, CI 0.583113, RI 0.802253)
(Figure 3). The ITS data set consisted of 499 characters, including
34 parsimony informative sites. MP analysis resulted in 377
equally parsimonious trees (length 34, CI 0.800000, RI 0.947917)
(Figure S1).
The tree topology inferred from calM grouped 17 feline isolates,
the canine isolate (CBS 130249), 2 human isolates (CM 5623, IFM
54303), and the air sample (DTO 176) in a clade with 84%
bootstrap support that had a most recent ancestor in common with
N. aureola and A. udagawae (86% bootstrap support). A. viridinutans
was positioned basal to these three species. Five other isolates from
cats with FRS were identified as A. fumigatus (DTO 131-E7, DTO
131-F7), A. udagawae (MK 285), A. lentulus (DTO 131-F5) and N.
pseudofischeri (DTO 131-G4) (Table 1, Figure 2). Analysis of benA
showed a similar grouping as observed in the MP analysis of calM.
In addition, three other sequences deposited in GenBank and
originating from human clinical specimens (GM 02/39, CM 4518,
CM 3147) belonged to the major clade comprising most clinical
specimens, with high bootstrap support (95%). A. viridinutans was
basal to this clade, but this relationship was lacking statistical
support (Figure 3). On MP analysis based on ITS sequences 17
feline isolates, the canine isolate and the human isolate CM 5623
clustered together in a monophyletic group (Figure S1). All isolates
belonging to this group shared identical ITS sequences. Based on
the molecular data, and the phenotypic and physiological data
presented below, we decided to name the strains in this clade
Aspergillus felis sp. nov.
Mating-type analysis
Crosses with opposite mating partners on MEA and OA
resulted in cleistothecia and ascospores within 7 to 10 days for all
A. felis (neosartorya-morph) isolates except for CBS 130250 and
CM 5623 (Table 1, Figure 4). Cleistothecia formed in small
clusters mainly in the barrage zone and to a lesser extent within
adjacent mycelium (Figure 4). Ascospores germinated on MEA
after exposure to heat and gave rise to characteristic A. felis
colonies. The PCR-based mating-type assay successfully amplified
the fragments of the alpha- or HMG-domain genes in all A. felis
isolates. The MAT genotype successfully matched the MAT
phenotype for all isolates with positive mating tests. In addition,
the PCR amplicons were sequenced (GenBank KC797620-
KC797634) and a homology search on GenBank confirmed their
designation to MAT1-1 or MAT1-2. Mating tests with A. udagawae,
A. viridinutans and A. fumigatus were negative. Immature cleistothe-
Figure 2. Partial calmodulin gene (calM)maximum parsimony (MP) tree. Phylogenetic analysis for A. felis sp. nov isolates and closely related
species as conducted in MEGA5 [22] showing best scoring MP tree constructed using the close-neighbor-interchange algorithm [40]. Bootstrap
percentages of the MP analysis are presented at the nodes for values .70%. Trees are drawn to scale, with branch lengths calculated using the
average pathway method, expressed in units of the number of changes over the whole sequence. Isolates from clinical specimens used in this study
are in bold. Isolate DTO 176-F1 was from an indoor air sample in Germany.
doi:10.1371/journal.pone.0064871.g002
Aspergillus felis sp. nov., A New Fungal Pathogen
PLOS ONE | www.plosone.org 5 June 2013 | Volume 8 | Issue 6 | e64871
Chapter 4
71
Aspergillus felis sp. nov., A New Fungal Pathogen
PLOS ONE | www.plosone.org 6 June 2013 | Volume 8 | Issue 6 | e64871
Chapter 4
72
cia containing no ascospores were observed along colony junctions
for matings of A. felis isolates with A. viridinutans and A. fumigatus.
Morphological and physiological characterization
Phylogenetic analysis showed that A. felis is closely related to N.
aureola and A. udagawae. The ascospore morphology supports this
Figure 3. Partial b-tubulin gene (benA) maximum parsimony (MP) tree. Phylogenetic analysis for A. felis sp. nov isolates and closely related
species as conducted in MEGA5 [22] showing best scoring MP tree constructed using the close-neighbor-interchange algorithm [40]. Bootstrap
percentages of the MP analysis are presented at the nodes for values .70%. Trees are drawn to scale, with branch lengths calculated using the
average pathway method, expressed in units of the number of changes over the whole sequence. Isolates from clinical specimens used in this study
are in bold.
doi:10.1371/journal.pone.0064871.g003
Figure 4. Aspergillus felis. Colonies growing 7 days at 25uC on CYA (A) and MEA (B); Crossing of CBS 130245 and 130246 at 30uC (C); Conidiophores
and conidia (D, E and G); Cleistothecium (F); Ascospores (H-I).
doi:10.1371/journal.pone.0064871.g004
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phylogenetic relationship since A. felis, N. aureola and A. udagawae all
produce lenticular ascospores with two prominent equatorial crests
and an echinulate convex surface (Figure 4) [26]. However, A. felis
can be distinguished from N. aureola by its heterothallic reproduc-
tion mode and from A. udagawae by its ability to grow at 45uC
(Figure 5), since the maximal growth temperature for A. udagawae is
42uC [5]. Also A. felis has ascospores which are 5.0–7.063.5–
5.0 mm compared to 5–5.564–5 mm in A. udagawae [26] (Figure 4).
A. viridinutans is phylogenetically and phenotypically related to A.
felis and both species share the production of ‘‘nodding’’ conidial
heads and weakly sporulating colonies (Figure 4), but can be
differentiated by maximum growth temperatures. A. felis is able to
grow at 45uC, while in our study A. viridinutans exhibited no growth
at 45uC (Figure 5). A. fumigatus is phenotypically similar but is able
to grow at 50uC, while none of the tested A. felis grew at this
temperature (Figure 5).
Species description of A. felis
Aspergillus felis Barrs, van Doorn, Varga & Samson, sp.
nov. [urn:lsid:indexfungorum.org:names: Mycobank MB 560382]
(Figure 4).
Etymology. named after the first host in which clinical
disease was described. Felis is a genus of cats in the family Felidae.
Diagnosis. Aspergillus felis (neosartorya-morph) is phenotypi-
cally similar to A. viridinutans, but differs by its ability to grow at
45uC. This species is phylogenetically related to N. aureola and A.
udagawae and differs to N. aureola in having a heterothallic
reproduction mode [26–27].
Typus: ex. retrobulbar mass in domestic short-haired cat,
Australia (CBS H-21125-holotypus, culture ex-type: CBS 130245).
Description. Colonies grow rapidly on CYA agar attaining a
diameter of 5.0 to 5.5 cm in 7 days at 25uC and on MEA reach
5.5 cm in diameter in 7 days at 25uC (Figure 4, panels A and B).
On CYA the colony texture is mostly floccose; colonies are usually
Figure 5. Radial growth determination at temperatures ranging from 96C to 506C. Type strains of A. viridinutans (CBS 127.56) and A.
fumigatus (CBS 133.61) and 4 isolates of A. felis (CBS 130245, CBS 130246, CBS 130247, CBS 130248).
doi:10.1371/journal.pone.0064871.g005
Table 2. Antifungal susceptibility results for 13 A. felis isolates from clinical specimens from cats.*
Drug MIC/MEC (mg/mL) Distribution Among Tested Isolates GM
0.008 0.015 0.03 0.06 0.125 0.25 0.5 1 2 4
AMB{ 1 11 1 0.50
ITZ{ 1 2 2 4 1 3 0.22
VCZ{ 1 3 1 5 3 1.38
POS{ 4 3 2 1 2 1 0.10
TB{ 13 0.25
CSP` 1 7 4 1 0.05
ANF` 13 0.015
MCF` 11 2 0.009
*MIC, minimum inhibitory concentration ({); MEC, minimum effective concentration (`), GM, geometric mean mg/mL; AMB, amphotericin-B; ITZ, itraconazole; VCZ,
voriconazole; POS, posaconazole; TB, terbinafine; CSP, caspofungin; ANF, anidulafungin; MCF, micafungin.
doi:10.1371/journal.pone.0064871.t002
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white and often sporulate poorly. On MEA colonies are more or
less velvety with abundant greenish sporulation occurring after 5
to 7 days. In reverse, colonies are cream to light green.
Conidiophores are uniseriate with greenish stipes and subclavate,
‘‘nodding’’ heads (Figure 4, panels D and E). Vesicles are
subclavate with a diameter of 15–16.5 mm. Conidia are green,
globose to subglobose, finely roughened and 1.5–2.5 mm in
dimensions. Cleistothecia are white to creamish, 100–230 mm.
Asci are globose, 8-spored, 12–16 mm in diameter (Figure 4, panel
H). Ascospores are lenticular with two prominent equatorial crests
and with short echinulate convex surfaces 5.0–7.063.5–5.0 mm
(Figure 4, panel I).
Occurrence. This species had been found in cats with
chronic invasive FRS and retrobulbar masses (SOA), IPA or with
sinonasal cavity infection only (sinonasal aspergillosis, SNA), in a
dog with disseminated IA, in a human with chronic IPA and in an
indoor air sample in Germany.
Barcode. GenBank JX021685 (ITS). This species can be
identified with ITS, b-tubulin and/or calmodulin sequences.
Taxonomy. In July 2011, the dual nomenclature system was
abandoned and replaced with single name nomenclature [28]. We
followed the recommendations of the International Commission
on Penicillium and Aspergillus here and describe this species in
Aspergillus, even though it produces a teleomorphic state. Using the
old nomenclature rules, this species would have been included in
the genus Neosartorya. In accordance with the Amsterdam
declaration on fungal nomenclature we refer to the newly
discovered teleomorph by an informal cross reference name in
lower case Roman type Aspergillus felis (neosartorya-morph) [29].
Antifungal susceptibilities
There was no observed activity of fluconazole or 5-flucytosine
against A. felis. The distribution of MIC/MECs of other
antifungals among those isolates that could be tested is shown in
Table 2. A bimodal MIC distribution was observed for the
triazoles against A. felis, with high MICs to at least one of the
triazoles observed in four isolates including two isolates that
exhibited cross-resistance to ITZ/VCZ and ITZ/VCZ/POS,
respectively. Another A. felis isolate had a high MEC of
caspofungin (2 mg/mL) but MECs of the other echinocandins
were comparable to the other isolates tested within this species.
Discussion
Considering the morphological, biological and phylogenetic
species concepts, we present evidence for a novel species within
Aspergillus section Fumigati, A. felis sp. nov [30]. The BenA and CalM
phylogenies indicate genetic isolation of A. felis. We also established
reproductive isolation; A. felis is a heterothallic fungus with a fully
functioning reproductive cycle as determined by teleomorph
induction and detection of MAT1-1 and MAT1-2 genes by PCR
in isolates of corresponding phenotype. Ascospores were demon-
strated to be both viable and heat resistant. The heterothallic
mode of reproduction for A. felis should be confirmed further by
the establishment of meiotic recombination in ascospore progeny
as was described by O’Gorman and Dyer in their parallel
discovery of a functional heterothallic sexual cycle in A. fumigatus
[18]. No teleomorph has as yet been isolated in vitro for A.
viridinutans although results of mating-type genotype determination
in our study indicate it is a heterothallic fungus. Cryptic sexual
states are being increasingly identified in mitosporic fungi [31].
For heterothallic fungi a strong correlation has been established
between biological species based on mating tests and phylogenetic
species based on multilocus sequence typing [32]. Differences in
maximum growth temperature were also identified between A. felis
and the type strain of A. viridinutans. A. felis is a thermotolerant
fungus, as defined by a maximum growth temperature of $45uC
and a minimum growth temperature of ,20uC. The maximal
growth temperature of both A. viridinutans and A. udagawae has been
reported as 42uC [5,33].
Species within Aspergillus section Fumigati cannot be reliably
identified on the basis of morphologic criteria alone [4]. In
contrast to other Aspergillus species, A. felis can be reliably identified
with ITS sequences only. Molecular identification of A. fumigatus-
like molds in human patients with IA has important clinical
relevance since clinical disease characteristics vary with infecting
species and MICs of antifungal drugs, especially triazoles, are often
high [5–7,10,34]. This is exemplified in a study of 86 isolates from
patients with IA identified as A. fumigatus on phenotypic features.
When the same isolates were later identified by sequencing the
partial benA and rodlet A genes, 12 (14%) were identified as A.
udagawae [5]. In patients with A. udagawae infection, the median
duration of illness was 7 times longer than in patients with
confirmed A. fumigatus infection, disease was refractory to standard
therapy and MICs of various antifungals of A. udagawae isolates
were higher than those for A. fumigatus [35]. Similarly, a distinctive
form of IA characterized by chronicity, propensity to spread across
Figure 6. Cat with sino-orbital aspergillosis (invasive fungal rhinosinusitis) caused by A. felis with exophthalmia and prolapse of the nictitating
membrane (third eyelid) associated with a retrobulbar fungal granuloma (A). Coronal CT scan soft-tissue post-contrast view showing retrobulbar
fungal granuloma occupying the inferior aspect of the orbit with involvement of the adjacent paranasal subcutaneous tissues (B).
doi:10.1371/journal.pone.0064871.g006
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anatomical planes and reduced antifungal susceptibility was
attributed to infection with A. viridinutans based on comparative
partial benA and rodlet A gene sequence analyses [15]. We re-
examined this isolate (CM 5623) and our molecular data show that
it belongs to A. felis. On our phylogenetic analyses, the partial BenA
and/or CalM sequences of four other human isolates from clinical
specimens identified previously as A. viridinutans signified identity
with A. felis [33–34]. One of these (GM 02/39) was from a patient
with IA and co-infection with A. novofumigatus, another A. fumigatus
sibling species [8]. These findings are strongly supportive of a
pathogenic role for A. felis in IA in humans. It is likely that analysis
of other clinical isolates identified worldwide as A. viridinutans
would reveal more strains of A. felis; determining the geographical
distribution and prevalence of this species as an emerging fungal
pathogen would be of interest. Our finding that A. felis was present
in an air sample in Germany indicates that this species can be
distributed by airborne propagules. This strain readily produced
cleistothecia within 7 days after mating with CBS 130246 (MAT1-
1).
Similar to chronic atypical IPA of humans, A. felis infection in
feline invasive FRS has a protracted clinical course and spreads
across anatomical planes to involve contiguous tissues (Figure 6).
Domestic cats, the most common host described with A. felis
infection, represent a suitable model for translational research of
naturally occurring IA caused by A. fumigatus-like molds in
immunocompetent hosts. In contrast to disease in humans,
mycoses such as aspergillosis and cryptococcosis typically cause
rhinosinusitis rather than pulmonary infection in cats. This may be
associated anatomical differences in the nasal cavity and paranasal
sinuses resulting in preferential deposition of inhaled fungal spores
within the sinonasal cavity in cats compared to the lower
respiratory tract in humans. Most isolates in the current study
were obtained from cats with sino-orbital aspergillosis that failed to
respond to aggressive multimodality therapy including posacona-
zole, amphotericin-B and, in some cases, radical orbital debride-
ment surgery (exenteration) [13]. The majority were euthanased
due to disease progression with severe signs including blindness
and generalised seizures. IPA in the two human patients from
which A. felis was isolated, was similarly refractory to treatment
with posaconazole, voriconazole and caspofungin or liposomal
amphotericin-B and caspofungin respectively [8,15]. Infections
were fatal in both cases. In addition to A. felis, we have
demonstrated that other species in the Aspergillus section Fumigati
cause FRS in domestic cats including A. fumigatus, A. udagawae, A.
lentulus and N. pseudofischeri.
Epidemiological cut off values (ECV) of amphotericin B for
several Aspergillus species have recently been determined using the
CLSI broth microdilution method [36]. The modal MIC of
amphotericin B for 3, 988 A. fumigatus isolates was 0.5 mg/mL and
the ECV that captured 95% of the modelled wild-type population
was #2 mg/mL. MICs of amphotericin B were #1 mg/mL for all
13 A. felis isolates tested in our study and were #0.5 mg/mL for 12
of these. By contrast, three other cryptic species A. lentulus, A.
udagawae and A. fumigatiaffinis have comparatively high MICs of
amphotericin B [4,34]. Elevated MICs of amphotericin B have
been associated with poor clinical outcomes for infections caused
by A. terreus and A. udagawae [35,37]. Including antifungal
susceptibility data published previously for human A. felis isolates
CM 5623, CM3147, CM4158 and GM 02/39, high MICs of
voriconazole (4 mg/mL) and/or itraconazole ($1 mg/mL) oc-
curred in 41% (7/17) of A. felis isolates [8,15,34]. Similar
susceptibility trends have been observed in N. pseudofischeri [34].
However, where azole cross resistance was identified in A. fumigatus
isolates it was usually between itraconazole and posaconazole
(54%) and was uncommon between itraconazole and voriconazole
(7%) [38]. High MICs of itraconazole (.16 mg/mL) and
voriconazole (4 mg/mL) correlated with clinical outcome in one
case of A. felis IA in a human (isolate CM5623) where sequential
administration of these failed to control disease progression [15].
Additionally, one feline isolate with a caspofungin MEC of 2 mg/
mL in this study, along with two human isolates with MEC of
1 mg/mL reported previously [8,34] suggests variable susceptibility
of A. felis to caspofungin in vitro. Caspofungin ECVs accounting for
95% and 99% of the modelled A. fumigatus population were set at
0.5 mg/mL and 1 mg/mL, respectively [39]. The antifungal
susceptibility profile of A. felis indicates that it is another A.
fumigatus--like mold with in vitro resistance to antifungal agents used
routinely for prophylactic therapy and treatment of IA.
Conclusion
A. felis is an important new species in Aspergillus section Fumigati
applying a polyphasic taxonomical approach including molecular,
morphological, physiological and ecological data. A. felis is an
emerging agent of invasive aspergillosis in cats, dogs and humans.
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4.3 Further discussion and conclusions 
In describing this new species we apply the revised taxonomic approach, that is, the 
one-fungus one-name principal outlined in Chapter 2. In doing so, we are amongst the 
first mycologists to apply this controversial revision (Houbraken et al., 2014). The 
growth temperature studies that I performed show that A. felis can be distinguished from 
the related species A. viridinutans by its ability to grow at 45 °C and from A. fumigatus 
by its inability to grow at 50 °C. This information has application for mycologists with 
regard to discerning cryptic and non-cryptic species isolated from clinical samples and 
sparked the following comment from Prof. Maiken Cavling Arendrup, MD, PhD, 
Chairman of The EUCAST Antifungal Susceptibility Testing Subcommittee and 
President of the Nordic Society for Medical Mycology, after our manuscript was posted 
on the ProMED-mail list-serve of the international society of infectious diseases: 
 
 “Whilst reliable species identification of these cryptic species requires molecular 
techniques, separation of A. fumigatus from the other species is possible simply by 
taking advantage of the unique thermo-tolerance of A. fumigatus ; that is, A. fumigatus 
but not the others, is able to grow at high temperatures in the range of 48-50 deg C or 
higher. At SSI [Statens Serum Institut] this is systematically done for all A. fumigatus 
complex isolates and if not confirmed as A. fumigatus sensu stricto by this procedure, 
molecular identification is adopted. Following this procedure no A. felis has been 
detected so far suggesting it is currently a rare pathogen. If this procedure may 
misidentify some isolates when 48 deg C rather than 50 deg C is used (and which is the 
current standard at many reference laboratories in Europe) is however not evident from 
the current PLoS ONE publication.” 
Further information has since come to light in a recent publication in which another 
novel species was discovered in Aspergillus Section Fumigati, specifically in the 
Aspergillus viridinutans complex (Novakova et al., 2013). The A. viridinutans complex 
now includes five species, A. viridinutans, A. udagawae, A. wyomingensis, A. felis and, 
A. aureolus. Novakova and others found that all A. viridinutans complex isolates tested 
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had maximum growth temperatures between 42°C and 45°C and no isolates grew at 
47°C. Therefore, for those laboratories using failure of growth at 48°C to discern cryptic 
from non-cryptic isolates, this technique should reliably distinguish A. viridinutans 
complex members from A. fumigatus sensu stricto. Like all morphological methods for 
fungal identification, results of growth temperature studies should be interpreted with 
caution. The authors of a guest editorial on our publication in Chapter three identified an 
A. fumigatus strain, confirmed by molecular methods, that was unable to grow at 50°C 
(Garcia et al., 2012a). 
 
With the application of molecular tools for fungal identification, cryptic species are being 
increasingly detected as pathogens, e.g. A. udagawae as outlined in Chapter 2. 
(Gyotoku et al., 2012; Sugui et al., 2010; Vinh et al., 2009b). The frequency of A. felis as 
a pathogen amongst human hosts is yet to be elucidated. Cryptic species are thought to 
account for approximately 5% of cases of IA in humans. In this research study we 
identified A. felis from morphological and molecular analyses as a cause of IA in one 
human host. We also determined that several sequences of human isolates from 
patients with aspergillosis that had been deposited on GenBank as A. viridinutans were 
actually A. felis. More recently new isolates have been identified on similar analyses of 
sequences deposited in GenBank (Novakova et al., 2013). Retrospective molecular 
studies of archived fungal cultures and clinical specimens from patients with 
aspergillosis to determine the frequency of cryptic species as pathogens including A. 
viridinutans complex members as pathogens, is warranted in Australia. 
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Chapter 5. Computed Tomographic Features of Feline 
Sino-nasal and Sino-orbital Aspergillosis. 
 
5.1 Background 
In Chapter two I described the clinicopathological features of FURTA. At the end of case 
recruitment for that study in 2009 computed tomographic (CT) findings were available 
for only a small cohort of cases due to the limited availability of on-site veterinary CT. In 
2008 the Valentine Charlton Cat Centre (VCCC) installed an on-site CT which increased 
the ability to recruit cases for study. Between 2007 and 2012 16 cases were recruited 
prospectively through a multi-centre study, including eight cases with on-site CTs 
performed at the VCCC.  At the time this study was submitted for publication, 
descriptions of CT features of FURTA were limited to several case reports and one case 
series of cats with URTA that did not recognise the two anatomical forms of disease 
(SNA and SOA) (Karnik et al., 2009). The objectives of this study were to describe the 
CT features of URTA, to determine whether cats with SOA have concurrent involvement 
of the sinonasal cavity, and to determine if there was any association between CT 
features and the anatomic form of aspergillosis and/or infecting species.  
 
5.2 Main article 
Barrs VR, Beatty JA, Dhand NK, Talbot JJ, Bell E, Abraham LA, Chapman P, Bennett 
S, van Doorn T, Makara M. Computed tomographic features of feline sino-nasal and 
sino-orbital aspergillosis. The Veterinary Journal 2014 Feb 28. doi: 
10.1016/j.tvjl.2014.02.020. [Epub ahead of print]. 
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A B S T R A C T
Feline upper respiratory tract aspergillosis (URTA) occurs as two distinct anatomical forms, namely,
sino-nasal aspergillosis (SNA) and sino-orbital aspergillosis (SOA). An emerging pathogen, Aspergillus
felis, is frequently involved. The pathogenesis of URTA, in particular the relationship between the infect-
ing isolate and outcome, is poorly understood. In this study, computed tomography was used to inves-
tigate the route of fungal infection and extension in 16 cases (SNA n = 7, SOA n = 9) where the infecting
isolate had been identiﬁed by molecular testing.
All cases had nasal cavity involvement except for one cat with SNA that had unilateral frontal sinus
changes. There was a strong association between the infecting species and anatomic form (P = 0.005).
A. fumigatus infections remained within the sino-nasal cavity, while cryptic species infections were
associatedwith orbital and paranasal soft-tissue involvement andwith orbital lysis. Cryptic species were
further associated with a mass in the nasal cavity, paranasal sinuses or nasopharynx. Orbital masses
showed heterogeneous contrast enhancement, with central coalescing hypoattenuating foci and periph-
eral rim enhancement. Severe, cavitated turbinate lysis, typical of canine SNA, was present only in cats
with SNA. These ﬁndings support the hypothesis that the nasal cavity is the portal of entry for fungal
spores in feline URTA and that the route of extension to involve the orbit is via direct naso-orbital
communication from bone lysis. Additionally, a pathogenic role for A. wyomingensis and a sinolith in a cat
with A. udagawae infection are reported for the ﬁrst time.
Crown Copyright © 2014 Published by Elsevier Ltd. All rights reserved.
Introduction
Feline upper respiratory tract aspergillosis (URTA) was ﬁrst
described in 1982 (Wilkinson et al., 1982) and is now being
increasingly reported (Kano et al., 2008, 2013; Barachetti et al.,
2009; Furrow and Groman, 2009; Karnik et al., 2009; Giordano
et al., 2010; Smith and Hoffman, 2010; Barrs et al., 2012; Declercq
et al., 2012). Disease occurs over a wide geographic range, includ-
ing Australia, the USA, the UK, mainland Europe, and Japan
(Goodall et al., 1984; Tomsa et al., 2003; Smith and Hoffman, 2010;
Barrs et al., 2012, 2013; Declercq et al., 2012; Kano et al., 2013). Two
anatomic forms have been reported, namely, sino-nasal aspergil-
losis (SNA) and sino-orbital aspergillosis (SOA; Barrs et al., 2012).
The environmental saprophytic fungi that cause these infections
are most commonly from the Aspergillus fumigatus complex,
including A. fumigatus and A. felis, a closely related, recently dis-
covered cryptic (A. fumigatus-mimetic) species (Kano et al., 2008,
2013; Barrs et al., 2012, 2013; Whitney et al., 2013).
SNA and SOA have dramatically different prognoses (Barrs and
Talbot, 2014), but the determinants of these alternate outcomes are
poorly understood. It is suspected that the nasal cavity (NC) is the
route of infection in all cases and that SOA is an extension of NC
infection, but systematic imaging studies to support this have not
been conducted (Barrs et al., 2012). In humans with aspergillosis,
invasion is generally associated with impaired host immunity
rather than the virulence of the infecting fungal species (Romani,
2011). Data from feline cases suggest an inﬂuence of fungal species
on pathogenesis; A. fumigatus infections are frequently associated
with non-invasive sino-nasal cavity (SNC) infections, while a
cryptic species, A. felis, causes invasive sino-orbital disease (Barrs
et al., 2012, 2013).
* Corresponding author. Tel.: +61 2 9351 3437.
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Descriptions of computed tomography (CT) ﬁndings in cats
with URTA are limited to case reports (Halenda and Reed, 1997;
Hamilton et al., 2000; Whitney et al., 2005; McLellan et al., 2006;
Kano et al., 2008; Barachetti et al., 2009; Furrow and Groman,
2009; Giordano et al., 2010; Smith and Hoffman, 2010), and one
case series of mycotic rhinitis that included ﬁve cats with URTA,
but did not distinguish between SNA and SOA or identify the
aetiologic agents (Karnik et al., 2009).
The objectives of the present study were to describe the CT
features of URTA, to determine whether cats with SOA have con-
current involvement of the SNC, and to determine if there was any
association between CT features and the form of aspergillosis
and/or infecting species.
Materials and methods
CT examinations of the heads of cats with conﬁrmed URTA from February 2007
to October 2012 were identiﬁed retrospectively. Criteria for the diagnosis of URTA
were identiﬁcation of fungal hyphae on cytology or histology of tissue biopsies,
or sino-nasal fungal plaques and molecular identiﬁcation of the isolate using
comparative sequence analyses of the internal transcribed spacer (ITS) regions
(ITS1–5.8S-ITS2), partial β-tubulin and/or partial calmodulin genes (Barrs et al.,
2013). Signalment data were collected for review.
CT examinations were included if thin bone and soft-tissue transverse images
of the skull obtained perpendicular to the soft palate were available for review. The
examinations were performed at one of ﬁve centres (Table 1; Phillips Brilliance, 16
Slice, Phillips Medical Systems; Toshiba Aquilion, 16-slice, Toshiba Medical Systems
Corporation; Toshiba X vision, 1-slice helical, Toshiba Medical Systems; Siemens
Somatom Duo, 2-slice helical scanner; Siemens Esprit plus, 1-slice helical scanner,
Siemens, Medical Solutions). The ﬁeld of view was adjusted to the individual skull
dimensions and a 512 × 512 matrix was used.
CT scans were reviewed by a Board certiﬁed radiologist (MM), blinded to isolate
identity and clinical ﬁndings. Where more than one examination had been per-
formed, only the ﬁrst was reviewed. Non-ionic iodinated contrast was administered
at 660 mg/kg iodine IV (Omnipaque, GE Healthcare). Standard bone and soft-tissue
window algorithms were used (Table 1). Images were reviewed using standardised
bone (window width, 4500 HU; window level, 1100 HU) and soft-tissue (window
width, 400 HU; window level, 40 HU) display settings.
Cases were assigned to one of two groups, SOA or SNA, based on the presence or
absence of a retrobulbar mass, respectively. Criteria for CT evaluation, adapted from
a previous study (Karnik et al., 2009), included the amount and laterality of soft-
tissue attenuation within the SNC, extension of lesions within the nasal cavity, lysis
and/or sclerosis of the bones forming the NC (turbinates, septum, nasal bone and
adjacent maxilla) and paranasal bones (frontal bone, orbital bone [orbital lamina],
palatine bone, zygomatic bone, tympanic bullae and cribriform plate), nasopharyn-
geal (NP) involvement, paranasal soft-tissue involvement, and lymph-node
involvement.
The severity of NC lesions was graded as none, minimal (affecting less than
one-third), moderate (affecting two-thirds), or severe (affecting more than two-
thirds). The NC was divided into rostral (rostral to teeth 104 and 204), middle
(extending from teeth 104 and 204 to 108 and 208), and caudal (caudal to teeth 108
and 208) regions. Lysis, soft-tissue attenuation and sclerosis of the paranasal bones
were graded as none, minimal, moderate, or severe. The pattern of contrast
enhancement was described as none, normal mucosal enhancement, homoge-
neous, heterogeneous, or peripheral.
Statistical analyses
Frequency tables were prepared for all variables. Associations between the
two anatomic forms of URTA and the respective aetiologic agent identiﬁed
(A. fumigatus or cryptic species), and between anatomic form and variables
indicative of soft-tissue attenuation, lysis and reactive bone lesions in nasal and
paranasal regions, were evaluated using contingency tables and Fisher’s exact tests.
Variables representing severity were collapsed into two categories, (1) severe and
(2) non-severe, for statistical analyses, because of the limited number of observa-
tions in each class. A 5% level of signiﬁcance was used and all P values were two
sided. Analyses were conducted using commercially available software (SAS 2002–
2003).
Results
Sixteen cats met the inclusion criteria, including seven cats
with SNA and nine with SOA. Post-contrast images were available
in 13 cases (six SNA, seven SOA). One cat with SOA that had orbital
exenteration before CT was excluded from statistical analyses of
orbital CT features. Signalment data and molecular identity of
fungal pathogens are presented in Table 2.
Isolates not reported previously were A. fumigatus (two SNA;
Cases 2 and 5), A. felis (two SOA; Cases 11 and 13), A. udagawae
(two SOA; Cases 14 and 15) and A. wyomingensis (one SOA; Case
16). One cat with A. fumigatus infection was co-infected with
Scedosporium aurantiacum (Case 5). Anatomic form was highly
associated with infecting species; of cats with SNA, ﬁve were
infected with A. fumigatus and two with cryptic species, while all
nine cats with SOA were infected with cryptic species (P = 0.005;
Table 3). CT ﬁndings signiﬁcantly associated with cryptic species
infections included the presence of a mass in the NC, frontal
sinus (FS), sphenoid sinus (SS) or NP; paranasal soft-tissue atten-
uation; orbital soft-tissue attenuation; and orbital bone lysis
(Table 3).
CT ﬁndings, including frequency and severity of soft-tissue
attenuation and bone lysis in the NC, nasopharynx, paranasal
sinuses and tympanic bullae, are presented in Table 4. All cats had
NC involvement, including increased soft-tissue attenuation and
turbinate lysis, except one cat with SNA that had unilateral FS
changes only. Of three cases with cryptic infections and focal soft-
tissue NC masses, there was homogeneous enhancement in the
two cases in which contrast medium was administered. Severe
turbinate lysis occurred only in cats with SNA (three A. fumigatus,
one A. felis; P = 0.005; Fig. 1). FS involvement was unilateral in
12/13 cases andwas ipsilateral to the affected orbit in ﬁve cats with
SOA. FS changes were characterised by soft tissue opaciﬁcation
without enhancement, consistent with ﬂuid or poorly vascularised
tissue in 11 cases.
FS attenuation was more severe in cats with SOA (P = 0.040;
Table 4). One case of SNA and A. fumigatus infection had moderate
thickening of the FS mucosa with homogenous contrast enhance-
ment, while another with SOA had a soft-tissue attenuating mass
within the FS (Fig. 2). No contrast study was available for the latter.
SS soft-tissue attenuationwas accompanied by ipsilateral (n = 8) or
bilateral (n = 1) FS involvement. SS changes were consistent with
ﬂuid in seven cases and with a mass in two cats with SOA. One
mass showed central heterogeneous contrast enhancement and
Table 1
Factors used for acquisition of computed tomographic images.
Centrea Number of cases Reconstructed slice
thickness bone
tissue algorithm
(mm)
Reconstructed slice
thickness
soft tissue
algorithm (mm)
Beam collimation
(number of data
channels)
Detector row
width (mm)
Tube potential (kV) Tube current (mA) Pitch factor
VCCC 8 1 3 16 0.75 120 200 0.4
RPAH 2 0.75 3 16 0.75 120 200 0.4
UMVCH 3 2 2 1 0.75 120 100 1
MUVH 2 2 2 2 0.75 130 120 1
VSEC 1 1 1 1 1 130 60 1
a VCCC, Valentine Charlton Cat Centre, Sydney, Australia; RPAH, Royal Prince Alfred Hospital, Sydney, Australia; UMVCH, University of Melbourne Veterinary Clinic and
Hospital, Melbourne, Australia; MUVH, Murdoch Veterinary Hospital, Perth, Australia; VSEC, Veterinary Specialist and Emergency Centre, Levittown, Philadelphia, USA.
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homogeneous peripheral enhancement. The other mass was a cal-
ciﬁed density of 1835 HU, consistent with a sinolith, identiﬁed in a
cat with A. udagawae infection (Fig. 3).
Of the 10 cats with increased soft-tissue attenuation of the
nasopharynx (Table 4), ﬁve had homogeneous contrast enhance-
ment of NPmucosa only, most consistent with ﬂuid. Five other cats
with cryptic infections (four SOA; one SNA, A. lentulus) had an NP
mass, with heterogeneous and homogeneous enhancement,
respectively, in the two cats with SOA in which contrast was
administered.
Tympanic bullae changes were seen in two cases of SNA
without NP involvement (Table 4). One showed minimal bullous
effusion on the left side in the case with right FS involvement only.
The other had bilateral NC involvement and a minimal
Table 2
Signalment, aetiologic agent and anatomic form of aspergillosis.
Case Age (years) Sexa Breeda Forma Species GenBank accession numbers
ITSa benAa CalMa
1b 6.8 F Ragdoll SNA A. fumigatus – – –
2 8 F SSH SNA A. fumigatus – – –
3b 11 F Persian SNA A. fumigatus – – JX021722
4b 7.4 M Persian SNA A. fumigatus – – –
5 2.8 F DSH SNA A. fumigatus/Scedosporium
aurantiacum
– – –
6b 14.8 F DLH SNA A. lentulus – – JX021720
7b 13 M DLH SNA A. felis JX021681 JX021704 JX021724
8b 5 F CR SOA A. felis JX021675 JX021694 JX021717
9b 2 M HIM SOA A. felis JX021682 JX021705 JX021725
10b 2 F DSH SOA A. felis JX021683 JX021706 JX021726
11 2.3 F DSH SOA A. felis – – –
12b 3.6 M DSH SOA A. felis KF558318 JX021700 JX021715
13 2.8 M BSH SOA A. felis KF703495 KF703496 –
14 4.1 M Persian SOA A. udagawae – KF703497 KF703498
15 4.7 M DSH SOA A. udagawae – – KF703499
16 1.5 M BSH SOA A. wyomingensis JX021685 JX021709 –
a F, female (neutered); M, male (neutered); SSH, Scottish Shorthair; DSH, Domestic Shorthair; DLH, Domestic Longhair; CR, Cornish Rex; HIM, Himalayan; BSH, British
Shorthair; SNA, sino-nasal aspergillosis; SOA, sino-orbital aspergillosis; ITS, internal transcribed spacer; benA, betatubulin; CalM, calmodulin.
b Signalment and molecular identiﬁcation reported previously (Barrs et al., 2012, 2013).
Table 3
Associations between aetiologic agent and anatomic form or computed tomographic features in cats with URTA.
Categories A. fumigatus frequency (%) Cryptic species frequency (%) P
Anatomic form SNAa 5 (71) 2 (29) 0.005
SOAa 0 (0) 9 (100)
NC, FS, SS or NP mass Yes 0 (0) 8 (100) 0.026
No 5 (63) 3 (37)
Paranasal soft-tissue involvement Yes 0 (0) 10 (100) 0.001
No 5 (83) 1 (17)
Orbital soft-tissue involvement Yes 0 (0) 9 (100) 0.002
No 5 (83) 1 (17)
Orbital bone lysis Yes 2 (17) 10 (83) 0.022
No 3 (100) 0 (0)
NC, nasal cavity; FS, frontal sinus; SS, sphenoid sinus; NP, nasopharyngeal.
a SNA, sino-nasal aspergillosis; SOA, sino-orbital aspergillosis.
Fig. 1. Transverse skull CT images (bone algorithm) of two cats with SNA due to A. fumigatus infection showing severe ‘cavitated’ turbinate lysis (a) bilaterally (arrows) and
(b) in the left nasal cavity.
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soft-tissue attenuating mass in the bulla with homogenous con-
trast enhancement.
Reactive bony changes of the nasal and paranasal bones are
presented in Table 5. Nasal bone sclerosis was always accompanied
by sclerosis of the frontal or zygomatic bone.
Paranasal bone lysis and soft-tissue abnormalities are described
in Table 6. Cryptic species infections (n = 11) were associated with
orbital (P = 0.002) or paranasal soft-tissue involvement (P = 0.001;
Table 3). Orbital masses were characterised by heterogeneous con-
trast enhancement, with central coalescing hypoattenuating foci
and peripheral rim enhancement (Fig. 4). Masses were located in
the rostral and ventromedial aspect of the orbit, causing dorsolat-
eral displacement of the globe. The largest mass displaced the
zygomatic arch laterally. Orbital masses typically extended ros-
trally to the rostral aspect of the zygomatic arch and caudally to the
rostral aspect of the ramus of the mandible, immediately rostral to
the temporomandibular joint. In all cases of SOA, lateral extension
into the paranasal maxillary soft tissues was identiﬁed, resulting in
Table 4
Soft-tissue attenuation and bone lysis in the nasal cavity, nasopharynx, paranasal sinuses and tympanic bullae on computed tomography in 16 cats with upper respiratory
tract aspergillosis.
Categories SNA frequency (%) SOA frequency (%) Total Pa
Type of sino-nasal disease Bilateral 5 (38) 8 (62) 13 0.55
Unilateral 2 (67) 1 (33) 3
Type of bilateral involvement Asymmetric 4 (36) 7 (64) 11 1.0
Symmetrical 1 (50) 1 (50) 2
Nasal region involved Rostral to caudal 4 (44) 5 (56) 9 1
Middle 1 (33) 2 (67) 3
Middle to caudal 1 (33) 2 (67) 3
Caudal 1 (100) 0 (0) 1
Nasal cavity soft-tissue attenuation None 1 (100) 0 (0) 1 0.162
Minimal 1 (33) 2 (67) 3
Moderate 3 (60) 2 (40) 5
Severe 2 (29) 5 (71) 7
Turbinate lysis None 1 (100) 0 (0) 1 0.005
Minimal 2 (33) 4 (67) 6
Moderate 0 (0) 5 (100) 5
Severe 4 (100) 0 (0) 4
Nasal septum lysis Minimal 1 (50) 1 (50) 2 0.55
Moderate 1 (100) 0 (0) 1
Cribriform plate lysis Minimal 1 (33) 2 (67) 3 0.213
Moderate 1 (100) 0 (0) 1
Nasal bone or adjacent maxilla lysis None 3 (33) 6 (67) 9 0.615
Minimal 2 (40) 3 (60) 5
Moderate 2 (100) 0 (0) 2
Frontal sinus soft-tissue attenuation None 1 (33) 2 (67) 3 0.040
Minimal 1 (100) 0 (0) 1
Moderate 4 (80) 1 (20) 5
Severe 1 (14) 6 (86) 7
Sphenoid sinus soft-tissue attenuation None 4 (57) 3 (43) 7 0.789
Minimal 0 (0) 1 (100) 1
Moderate 1 (100) 0 (0) 1
Severe 2 (29) 5 (71) 7
Nasopharyngeal soft-tissue attenuation None 5 (83) 1 (17) 6 0.153
Minimal 0 (0) 3 (100) 3
Severe 2 (29) 5 (71) 7
Nasopharyngeal mass No 6 (55) 5 (45) 11 0.585
Yes 1 (20) 4 (80) 5
Tympanic bulla involvement No 5 (36) 9 (64) 14 0.175
Yes 2 (100) 0 (0) 2
a Variables representing severitywere collapsed into two categories (severe and non-severe) for statistical analyses because of limited number of observations in each class.
Fig. 2. Transverse skull CT images (bone algorithm) showing (a) right frontal sinus mucosal thickening in a cat with SNA and A. fumigatus infection (arrow) and (b) a
soft-tissue attenuating mass in the left frontal sinus of a cat with SOA (right orbital mass) due to A. felis infection (arrow).
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a distinct mass effect in eight cases. Orbital masses extended ven-
trally into pterygopalatine fossa of the oral cavity in six cases
(Fig. 4). Soft-tissue attenuation adjacent to an area of complete
lysis of the nasal bone was present in one cat with SNA due to
A. felis infection.
Orbital bone lysis was detected in both anatomic forms andwas
signiﬁcantly associated with aetiologic agent (A. fumigatus v
cryptic species) (Tables 3 and 4). Orbital lysis was complete in four
cases (SNA and SOA, n = 2 each) and punctate in eight cases (SNA
and SOA, n = 2 each; Fig. 5). Of the four cats with frontal bone lysis,
Fig. 3. (a) Dorsal and (b) transverse skull CT images (bone algorithm) showing a calciﬁed density (1835 HU) in the sphenoid sinus of a cat with SOA and A. udagawae infection
(white arrows). Note the soft-tissue attenuating material bilaterally (asterisks) in (a) the nasal cavity and (b) frontal sinuses; and (a) left orbital lysis (black arrow).
Table 5
Reactive bone lesions of the nasal and paranasal bones on computed tomography in 16 cats with upper respiratory tract aspergillosis.
Categories SNA frequency (row %) SOA frequency (row %) Total Pa
Nasal bone sclerosis None 2 (22) 7 (77) 9 0.126
Minimal 3 (60) 2 (40) 5
Moderate 2 (100) 0 (0) 2
Frontal bone sclerosis None 2 (29) 5 (71) 7 0.541
Minimal 0 (0) 1 (100) 1
Moderate 3 (60) 2 (40) 5
Severe 2 (67) 1 (33) 3
Zygomatic bone sclerosis None 7 (50) 7 (50) 14 0.475
Moderate 0 (0) 2 (100) 2
Cribriform plate sclerosis None 6 (40) 9 (60) 15 0.438
Moderate 1 (100) 0 (0) 1
a Variables representing severitywere collapsed into two categories (severe and non-severe) for statistical analyses because of limited number of observations in each class.
Fig. 4. Transverse post-contrast soft-tissue images of the head reconstructed using a soft-tissue algorithm showing left orbital masses in two cats with SOA and A. felis
infection. There is heterogeneous contrast enhancement, with central coalescing hypoattenuating foci and peripheral rim enhancement. There is (a and b black arrow)
compression and dorsal displacement of the globe, and (a, white arrow) extension into the oral cavity; (b, white arrow) nasopharynx, and (a and b, black asterisk) adjacent
paranasal maxillary soft tissues.
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two with SNA also had palatine bone lysis (Table 5). Frontal, pala-
tine and zygomatic bone lysis was punctate in all cases, except for
one cat that had SOA and a focal area of severe complete palatine
lysis. Severe mandibular lymph node enlargement was docu-
mented only in cases of SOA (P = 0.011). All enlarged lymph nodes
enhanced homogeneously.
Discussion
This study of CT ﬁndings in feline sino-nasal and sino-orbital
aspergillosis documented involvement of the SNC in all cases,
regardless of the anatomic form. This supports the hypothesis that
orbital involvement in feline SOA occurs subsequent to NC infec-
Table 6
Paranasal bone lysis and paranasal soft-tissue abnormalities in 16 cats with upper respiratory tract aspergillosis.
Categories SNA frequency (%) SOA frequency (%) Total Pa
Unilateral orbital soft-tissue attenuation None 7 (100) 0 (0) 7 0.0002
Severe 0 (0) 8 (100) 8
Paranasal soft-tissue attenuation (facial) None 6 (100) 0 (0) 6 0.003
Mild 0 (0) 1 (100) 1
Moderate 1 (100) 0 (0) 1
Severe 0 (0) 8 (100) 8
Paranasal soft-tissue (facial) mass No 7 (88) 1 (12) 8 0.001
Yes 0 (0) 8 (100) 8
Pterygopalatine fossa mass No 7 (70) 3 (30) 10 0.011
Yes 0 (0) 6 (100) 6
Orbital bone lysis No 3 (100) 0 (0) 3 0.077
Yes 4 (33) 8 (67) 12
Orbital bone lysis None 3 (100) 0 (0) 3 0.231
Minimal 0 (0) 1 (100) 1
Moderate 3 (43) 4 (57) 7
Severe 1 (25) 3 (75) 4
Type of orbital bone lysis Unilateral 0 (0) 6 (100) 6 0.061
Bilateral 4 (67) 2 (33) 6
Frontal bone lysis None 4 (33) 8 (67) 12 1
Minimal 2 (100) 0 (0) 2
Moderate 1 (50) 1 (50) 2
Palatine bone lysis None 4 (33) 8 (67) 12 0.262
Minimal 2 (100) 0 (0) 2
Moderate 0 (0) 1 (100) 1
Severe 1 (100) 0 (0) 1
Zygomatic bone lysis None 7 (54) 6 (46) 13 0.213
Minimal 0 (0) 2 (100) 2
Moderate 0 (0) 1 (100) 1
Mandibular lymph node enlargement Not scanned 0 (0) 1 (100) 1 0.011
Minimal 4 (100) 0 (0) 4
Moderate 3 (50) 3 (50) 6
Severe 0 (0) 5 (100) 5
Retropharyngeal lymph node enlargement Not scanned 1 (33) 2 (67) 3 0.135
None 3 (100) 0 (0) 3
Minimal 2 (50) 2 (50) 4
Moderate 0 (0) 3 (100) 3
Severe 1 (33) 2 (67) 3
a Variables representing severitywere collapsed into two categories (severe and non-severe) for statistical analyses because of limited number of observations in each class.
Fig. 5. (a) Reconstructed dorsal and (b) transverse skull CTs showing regions of severe complete bilateral orbital lysis (arrows) in a cat with SNA due to A. felis (a) and
bilateral moderate punctate lysis (arrows) in a cat with SNA due to A. entulus (b).
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tion following inhalation of Aspergillus conidia, but evaluation of
serial CTs over time would be required to deﬁnitively demonstrate
extension of disease from the NC to the orbit. Upper respiratory
tract signs can be absent at the time of diagnosis when exophthal-
mos is present (Smith and Hoffman, 2010; Barrs et al., 2012), but
the extent of SNC involvement should be evaluated, as this might
inform therapeutic decisions. All cats with SOA had evidence of
naso-orbital communication due to lysis of the orbital lamina,
identifying direct extension as the most likely route of orbital
involvement. This is supported by ﬁndings on CT, surgery or at post
mortem in other cases, and by the fact that haematogenous spread
has not been reported (Wilkinson et al., 1982; Hamilton et al.,
2000; Barachetti et al., 2009; Giordano et al., 2010; Barrs et al.,
2012). Orbital extension directly from the frontal sinus has been
documented in one case (Halenda and Reed, 1997).
Interestingly, orbital bone lysis was common, regardless of ana-
tomic form. In dogs with SNA due to A. fumigatus, orbital lysis is
common, but SOA is rare (Saunders et al., 2002). Thus, additional
factors are clearly necessary for the establishment of mycotic
orbital disease in cats. Previous studies have found that
A. fumigatus infections were conﬁned to the SNC, while cases of
SOAwere caused by cryptic species, particularly A. felis (Kano et al.,
2008, 2013; Declercq et al., 2012; Barrs et al., 2013; Barrs
and Talbot, 2014). Imaging ﬁndings presented here are consistent
with this putative role for fungal species in disease outcome.
Species-speciﬁc fungal virulence factors could be involved in the
establishment of invasive orbital disease. SOA in cats is similar to
chronic granulomatous fungal rhinosinusitis in immunocompe-
tent humans. This is an uncommon disease reported in Africa and
Asia and caused by A. ﬂavus, which has a propensity to colonise the
nasal and paranasal sinuses in hot, dry climates (Thompson and
Patterson, 2012). Similar to humans and dogs with SNA, nasal and
paranasal bone lysis in feline URTA is probably due to a pro-
inﬂammatory response by the host and fungal virulence factors,
such as dermonecrolytic toxins (Peeters and Clercx, 2007;
Thompson and Patterson, 2012). Fungal osteomyelitis has not been
reported in feline URTA.
In addition to SNC involvement, CT features common to both
anatomic forms included unilateral involvement of paranasal
sinuses, and paranasal bone lysis and/or sclerosis. Cribriform plate
lysis, a relative contraindication for topical antifungal treatment in
canine SNA (Day, 2009), was detected in 25% of cases, highlighting
the importance of CT evaluation in treatment planning. Some CT
features were associated with infecting species and/or anatomic
form. Orbital masses, abnormal paranasal soft-tissue attenuation
and a mass effect in the NC, FS, SS or NP were only associated with
cryptic species, while severe ‘cavitated’ lysis was only present in
cats with SNA, including three cats with A. fumigatus infection. In
dogs, A. fumigatus is the aetiologic agent of SNA in 98% of cases
(Talbot et al., 2014). Characteristic CT features in canine cases
include cavitated turbinate lysis, a rim of soft tissue of variable
thickness along bones in the FS, maxillary recess and nasal pas-
sages, abnormal presence of soft-tissue accumulation and reactive
bony change (Saunders et al., 2002, 2004; Saunders and Van Bree,
2003). Isolated FS involvement, documented in one cat in this
study, has also been reported in canine SNA (Johnson et al., 2006).
Post-contrast features of orbital masses are similar to those
reported in SOA in humans and in mycotic rhinosinusitis due to
non-Aspergillus spp., including cryptococcosis, in cats, (Sivak-
Callcott et al., 2004; Karnik et al., 2009; Pushker et al., 2011).
Central hypoattenuating foci have been interpreted as areas of
necrosis and peripheral enhancement as inﬂammatory response
(DeLone et al., 1999; Almutairi et al., 2009). A similar pattern of
enhancement can be seen with neoplasia in humans, where
peripheral enhancement has been interpreted as well-perfused,
viable tumour tissue (Nino-Murcia et al., 2000). Whether post-
contrast features will aid in differentiating SOA from neoplasia in
feline cases requires further characterisation of neoplastic changes
in cats.
Previous retrospective analyses of CT ﬁndings in feline sino-
nasal disease included few cases of mycotic rhinosinusitis (0–5%;
Schoenborn et al., 2003; Tromblee et al., 2006). CT features asso-
ciated with sino-nasal neoplasia included lysis of the paranasal
bones, especially bilateral orbital bone lysis, moderate to severe
turbinate destruction, lysis of the nasal septum, a homogeneous
mass within the sino-nasal cavity, unilateral abnormal soft tissue
or ﬂuid within the frontal or sphenoid sinuses, and extension of
the disease process into the orbit or paranasal facial soft tissues
(Schoenborn et al., 2003; Tromblee et al., 2006). Interestingly,
these were all features of aspergillosis in our study.
Changes in the tympanic bulla were rare and likely incidental in
the present study. In contrast, one study reported that 28% of cats
with sino-nasal neoplasia or inﬂammatory disease had bulla effu-
sion secondary to auditory tube obstruction or ascending infection.
However, only 1/46 cats in that study had sino-nasal disease of
fungal aetiology (Detweiler et al., 2006).
Here we report sinolithiasis for the ﬁrst time in feline URTA.
Rhinolithiasis has been reported in one cat with SNA (Tomsa et al.,
2003). Sinoliths, described in 50–75% of humans with maxillary
sinus fungal mycetomas, are deposits of calcium-containing fungal
metabolites in necrotic areas of mycelial plaques. Predisposing
factors include chronic inﬂammation, impaired sinus drainage and
the presence of a nidus of material of endogenous or exogenous
origin, e.g. endodontic ﬁlling materials, around which calciﬁcation
occurs (Lenglinger et al., 1996).
Molecular identiﬁcation revealed two new isolates of
A. udagawae from Australia and the USA. These, in addition to
two previous isolates reported in Japan, establish A. udagawae as
the second most common cause of feline SOA (Kano et al., 2008,
2013). A. udagawae is the most common cryptic species to cause
invasive pulmonary aspergillosis in humans (Vinh et al., 2009).
A. wyomingensis, reported here for the ﬁrst time as a cause of feline
SOA and as a pathogen, is a recently described soil saprophyte
related to A. felis and to A. udagawae (Novakova et al., 2014). Accu-
rate species identiﬁcation is important, since cryptic species are
more resistant to antifungal drugs than A. fumigatus (Barrs et al.,
2013). Previous studies of feline URTA have demonstrated that
breeds of cats with brachycephalic conformation are over-
represented (Tomsa et al., 2003; Whitney et al., 2005; Barrs et al.,
2012). These have included Himalayans, Persians, Exotic short-
hairs, American shorthairs and Ragdoll cats. In this study, we
additionally report disease in British and Scottish shorthair cats.
Prospective studies are required to determine whether the
increased risk of URTA in these breeds is genetic due to common
ancestry, or if it is associated with SNC conformation combined
with other factors such as viral upper respiratory tract infection
(Barrs and Talbot, 2014).
The limitations of this study included the small sample size and
its retrospective design, which precluded standardisation of CT
conditions for each examination.
Conclusions
Common computed tomographic features of both anatomic
forms of feline upper respiratory tract aspergillosis include asym-
metric, bilateral sino-nasal cavity involvement, moderate to severe
soft-tissue attenuation of the nasal cavity, sphenoid sinus and
frontal sinus, moderate to severe turbinate lysis, and orbital bone
lysis. A strong association was identiﬁed between the infecting
fungal species and the anatomic form of the disease. Cryptic
species were signiﬁcantly associated with sino-orbital aspergillo-
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sis, the presence of a mass in the nasal cavity, sinuses or nasophar-
ynx, with paranasal soft-tissue attenuation, and orbital bone lysis.
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5.3 Conclusions 
The findings from this study increase our understanding of the pathogenesis of URTA in 
cats. Extrapolating from other host species (e.g. humans) and considering the virulence 
factors of the infecting agent (i.e. air-borne infectious propagules) it is intuitive that 
orbital infections in cats are an extension of a sinonasal cavity infection subsequent to 
inhalation and colonization. Despite this, some authors have continued to discuss the 
possibility of retrobulbar infection via the conjunctiva with secondary “descending” nasal 
cavity infection (Giordano et al., 2010; Smith and Hoffman, 2010). Our systematic study 
shows that all cats with URTA have involvement of the sinuses and/or nasal cavity. To 
prove definitively that sinonasal colonisation occurs first in cats with SOA would require 
serial CTs over time in an experimental model of infection. However, as I established 
previously, in many cats with SOA clinical signs indicative of sinonasal cavity infection 
appear before up to six months before signs of orbital involvement. (Barrs et al., 2012a).  
The CT findings that I have reported in this study are of clinical relevance to veterinary 
practitioners and also to diagnostic imaging specialists. The CT features of FURTA 
overlap those reported previously in cats with malignant neoplasia arising from the 
sinonasal cavity, including lymphoma and adenocarcinoma. This highlights the point 
that mycotic rhinosinusitis should be considered as a differential diagnosis in cats with 
CT findings consistent with neoplasia and where there is extension of the disease 
process from the nasal cavity to involve paranasal tissues including the orbit. An 
increased awareness of mycotic disease may make further investigations necessary to 
achieve definitive diagnosis more likely to be performed, including biopsy, serology and 
fungal cultures. Further information likely to be of use to those interpreting feline CTs is 
the finding that cats with SNA due to A. fumigatus infection, have similar CT features to 
those described in canine SNA including severe cavitated turbinate lysis.  
Together with those cases described in Chapter 3, this work brings the number of cases 
of FURTA that I have published to 30. When analysed together with all other reported 
cases where molecular identification has been described, some interesting new 
epidemiological data emerge.  With the two additional isolates of A. udagawae 
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described here we can now establish that the two most common causes of SOA in cats 
are A. felis and A. udagawae, both members of the A. viridinutans complex (Barrs et al., 
2013b; Kano et al., 2008; Kano et al., 2013). Further, A. udagawae has a wide 
geographic distribution and has been documented to cause disease in human and feline 
hosts in Australia, the U.S.A and Japan (Gyotoku et al., 2012; Sugui et al., 2010; Vinh et 
al., 2009b). I also established a pathogenic role for first time, for the recently described 
A. wyomingensis (Novakova et al., 2013), the newest member of the A. viridinutans 
complex. 
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Chapter 6. Detection of Aspergillus-specific 
Antibodies by Agar Gel Double Immunodiffusion and 
IgG-ELISA in Feline Upper Respiratory Tract 
Aspergillosis. 
6.1 Background 
The sensitivity of serological tests to detect fungal antigen or Aspergillus-specific 
antibody in aspergillosis depends on the systemic immunocompetence of the host. 
Tests to detect fungal antigen, namely the cell wall antigen galactomannan, have a 
sensitivity of up to 90% in immunocompromised patients, including neutropenic human 
patients with pulmonary aspergillosis and dogs with disseminated invasive aspergillosis 
(DIA) (Garcia et al., 2012b; Maertens et al., 1999). However, these tests have a very 
low sensitivity (30% or less) in non-neutropenic humans with aspergillosis, in 
immunocompetent dogs with SNA, and in cats with URTA (Billen et al., 2009; Kitasato 
et al., 2009; Whitney et al., 2013b). Conversely, detection of Aspergillus-specific 
antibodies has a high test sensitivity of up to 90% in immunocompetent patients 
including dogs with SNA and humans with chronic pulmonary aspergillosis (Billen et al., 
2009; Guitard et al., 2012; Ohba et al., 2012) while a detectable antibody response is 
mounted in less than 30% of immunocompromised patients including neutropenic 
humans with aspergillosis and dogs with DIA (Day et al., 1985; Hope et al., 2005b; 
Schultz et al., 2008).  
 
The diagnostic value of serological tests to detect Aspergillus-antibodies in cats with 
URTA has not been evaluated.  The objectives of this study were to determine if the 
sera of cats infected with cryptic species in Aspergillus section Fumigati cross react with 
antigens in a commercially available aspergillin derived from mycelia of A. fumigatus, A. 
niger and A. flavus and to assess the diagnostic value of detection of Aspergillus-
specific antibodies using an agar-gel immunodiffusion (AGID) and IgG ELISA tests. 
 
91 
 
6.2 Main article 
 
Barrs VR, Ujvari B, Dhand NK, Peters IR, Talbot J, Johnson LR , Billen F, Martin P, 
Beatty JA, Belov K., 2014. Detection of Aspergillus-specific antibodies by agar gel 
double immunodiffusion and IgG ELISA in feline upper respiratory tract aspergillosis. 
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A B S T R A C T
Feline upper respiratory tract aspergillosis (URTA) is an emerging infectious disease. The aims of this
study were: (1) to assess the diagnostic value of detection of Aspergillus-speciﬁc antibodies using an agar
gel double immunodiffusion (AGID) assay and an indirect immunoglobulin G (IgG) ELISA; and (2) to de-
termine if an aspergillin derived from mycelia of Aspergillus fumigatus, Aspergillus niger and Aspergillus
ﬂavus can be used to detect serum antibodies against cryptic Aspergillus spp. in Aspergillus section Fumigati.
Sera from cats with URTA (group 1: n = 21) and two control groups (group 2: cats with other upper re-
spiratory tract diseases, n = 25; group 3: healthy cats and cats with non-respiratory, non-fungal illness,
n = 84) were tested. Isolates from cats with URTA comprised A. fumigatus (n = 5), A. ﬂavus (n = 1) and
four cryptic species: Aspergillus felis (n = 12), Aspergillus thermomutatus (Neosartorya pseudoﬁscheri, n = 1),
Aspergillus lentulus (n = 1) and Aspergillus udagawae (n = 1).
Brachycephalic purebred catswere signiﬁcantlymore likely todevelopURTA thanotherbreeds (P = 0.013).
The sensitivity (Se) of the AGID was 43% and the speciﬁcity (Sp) was 100%. At a cut-off value of 6 ELISA
units/mL, the Se of the IgG ELISA was 95.2% and the Sp was 92% and 92.9% for groups 2 and 3 cats, re-
spectively. Aspergillus-speciﬁc antibodies against all four cryptic species were detected in one or both
assays. Assay Se was not associated with species identity. Detection of Aspergillus-speciﬁc antibodies by
IgG ELISA has high Se and Sp for diagnosis of feline URTA.
© 2014 Elsevier Ltd. All rights reserved.
Introduction
Feline upper respiratory tract aspergillosis (URTA) is increasingly
being recognised (Barrs and Talbot, 2014). There are two anatomical
forms of disease, sino-nasal aspergillosis (SNA) and sino-orbital as-
pergillosis (SOA) (Barrs et al., 2012, 2014). A strong association has
been identiﬁed between the infecting fungal species and the ana-
tomical form of disease; SNA ismost commonly caused by Aspergillus
fumigatus,while Aspergillus felis, a recently discovered ‘cryptic’ species
in Aspergillus section Fumigati (Aspergillus viridinutans complex), is
the most common cause of SOA (Barrs et al., 2013, 2014; Barrs and
Talbot, 2014). So-called cryptic species are indistinguishable onmor-
phological features from A. fumigatus sensu stricto.
Similar to SNA in dogs, feline SNA is usually non-invasive, such
that fungal hyphae do not penetrate the respiratorymucosa (Whitney
et al., 2005); in contrast, in SOA fungal hyphae invade sino-nasal
and paranasal tissues. Invasive mycoses typically occur in
immunocompromised hosts. However, systemic immunodeﬁ-
ciency has not been detected in most cats with URTA (Barrs et al.,
2012), one exception being a cat with feline leukaemia virus (FeLV)
infection (Goodall et al., 1984).
The sensitivity (Se) of serological tests for detection of fungal
antigens or Aspergillus-speciﬁc antibodies in aspergillosis depends
on the systemic immunocompetence of the host as reﬂected by
the ability to clear fungal antigen from the circulation and to mount
an antibody response. An ELISA to detect a fungal cell wall antigen,
galactomannan (GM), in serum (Platelia Aspergillus EIA, Bio-Rad)
has a Se of up to 90% in immunocompromised patients, including
neutropenic human patients with pulmonary aspergillosis and dogs
with disseminated invasive aspergillosis (DIA) (Maertens et al., 1999;
Garcia et al., 2012). However, the Se of this test is <30% in non-
neutropenic human patients with aspergillosis, in immunocompetent
dogs with SNA and in cats with URTA (Billen et al., 2009; Kitasato
et al., 2009; Whitney et al., 2013).
* Corresponding author. Tel.: +61 2 93513437.
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Conversely, detection of serum Aspergillus-speciﬁc antibodies by
agar gel double immunodiffusion (AGID) or by immunoglobulin G
(IgG) ELISA has a high test Se in immunocompetent patients, in-
cluding dogs with SNA (67–88%) and humans with chronic
pulmonary aspergillosis (74–94%) (Pomrantz et al., 2007; Billen et al.,
2009; Guitard et al., 2012; Ohba et al., 2012). A detectable anti-
body response is mounted in <30% of neutropenic humans with
aspergillosis and dogs with DIA (Day et al., 1985; Hope et al., 2005;
Schultz et al., 2008).
We hypothesised that Aspergillus-speciﬁc antibodies would be
detectable in the majority of cats with URTA, since most cats with
URTA are not, as far as it is possible to currently evaluate, systemi-
cally immunocompromised. The aims of this study were: (1) to
assess the diagnostic value of detection of Aspergillus-speciﬁc an-
tibodies using an AGID assay and an indirect IgG ELISA; and (2) to
determine if a commercial aspergillin derived from mycelia of
A. fumigatus, Aspergillus niger and Aspergillus ﬂavus can be used to
detect serum antibodies against cryptic Aspergillus spp. in Aspergillus
section Fumigati.
Materials and methods
Signalment data and serum (1–2 mL per cat) were collected prospectively from
cats diagnosed with URTA (group 1), cats with upper respiratory tract (URT) signs
not attributable to aspergillosis (group 2), and from cats without respiratory or fungal
disease (group 3). Samples were collected with informed consent according to the
guidelines of the Animal Ethics Committee of the University of Sydney (approval
number N00/9–2012/5774, date of approval 22 June 2012). Serum samples were col-
lected at the time of diagnosis and were stored at –80 °C for batch testing.
Animals
Group 1: Cats with upper respiratory tract aspergillosis (n = 21)
Inclusion criteria for cats with URTA were a complete medical history, consis-
tent clinical signs, identiﬁcation of fungal hyphae on cytology and/or histopathology
of tissue from the sino-nasal cavity or orbit, and a positive fungal culture (Barrs
et al., 2012). Cases with mixed fungal infections were excluded. Isolates were
identiﬁed using phenotypic features and comparative sequence analyses of the
internal transcribed spacer (ITS) regions (ITS1-5.8S-ITS2), partial β-tubulin and/or
partial calmodulin genes (Barrs et al., 2013), except for A. fumigatus identiﬁcation,
where consistent phenotypic features and demonstration of growth at 50 °C were
acceptable alternatives to molecular identiﬁcation (Barrs and Talbot, 2014). Isolates
comprised A. fumigatus (n = 5), A. ﬂavus (n = 1) and four cryptic species in Aspergillus
section Fumigati, i.e. A. felis (n = 12), Aspergillus thermomutatus (syn. Neosartorya
pseudoﬁscheri, n = 1), Aspergillus lentulus (n = 1) and Aspergillus udagawae (n = 1)
(Table 1).
Cats were classiﬁed as having SOA (n = 12) or SNA (n = 9) based on the presence
(SOA) or absence (SNA) of a retrobulbar mass on computed tomography (CT) or
magnetic resonance imaging (MRI) at diagnosis. Sera were tested for antibodies
against feline immunodeﬁciency virus (FIV) and FeLV antigen (IDEXX SNAP Combo,
IDEXX Laboratories). Medical histories were analysed for the presence of co-
morbidities. All cats were neutered, comprising 11 male neutered (MN) and 10
female neutered (FN) cats, and the median age was 5 years (range 2–14 years).
Breeds comprised domestic crossbred (n = 8), Persian (n = 4), Ragdoll (n = 3), Hima-
layan (n = 2), British shorthair (n = 1), Scottish shorthair (n = 1), Cornish Rex (n = 1)
and Abyssinian (n = 1).
Group 2: Control cats with other URT disease (n = 25)
Inclusion criteria were: (1) consistent clinical signs, e.g. sneezing, nasal dis-
charge; (2) absence of fungal hyphae on cytology or histology of tissue collected
from the sino-nasal cavity; and/or (3) serological, histopathological or endoscopic
diagnosis of another URT disease. Standard diagnostic investigations included latex
antigen cryptococcal serology (CALAS, Meridian Bioscience), upper airway endos-
copy, CT examination of the sino-nasal cavity, fungal culture and biopsy. This
group included cats with chronic rhinosinusitis (n = 9), nasal neoplasia (n = 10)
(lymphoma, n = 4; adenocarcinoma, n = 3; squamous cell carcinoma, n = 2; osteo-
sarcoma, n = 1), upper respiratory cryptococcosis (n = 5) and nasopharyngeal stenosis
(n = 1). All cats were neutered (13 MN, 12 FN). The median age was 11 years
(range 4–16 years). Breeds comprised domestic crossbred (n = 14), Persian (n = 2),
Siamese/Oriental (n = 2), Russian blue (n = 2), Cornish Rex (n = 2), British shorthair
(n = 1), Burmilla (n = 1) and Tonkinese (n = 1).
Group 3 (i and ii): Control cats without respiratory or fungal disease (n = 84)
Inclusion criteria for group 3 were (i) healthy cats presenting to the Valentine
Charlton Cat Centre (VCCC) for neutering, vaccination or wellness examination, and
for group 3 were (ii) sick cats presenting to the VCCC for non-fungal, non-respiratory
illness. Exclusion criteria for groups 3 (i) and 3 (ii) were any clinical signs within
the last 4 weeks or ﬁndings at physical examination suggestive of respiratory disease.
This group comprised (i) 36 healthy cats, including ﬁve male entire (M), 11 MN, six
female entire (F) and 14 FN, and (ii) 48 cats presented for non-fungal, non-
respiratory illness (one M, 23 MN, 24 FN). Diagnoses in cats with non-respiratory
disease included hyperthyroidism or post radio-iodine treatment of hyperthyroid-
ism recheck (n = 12), enteropathy e.g. enteritis, intestinal foreign body (n = 11), chronic
kidney disease (n = 8), allergic skin disease (n = 4), central nervous system disease
(n = 3), diabetesmellitus (n = 2), pancreatitis (n = 2), cholelithiasis (n = 1), chyloabdomen
(n = 1), anaemia (n = 1), dog bite wound (n = 1), portosystemic shunt (n = 1) and
idiopathic hypocalcaemia (n = 1).
Overall, there were 39 males (six M, 33 MN) and 45 females (six F, 39 FN) in
group 3; the median age was 8 years (range 0.7–19.5 years). The median age of group
3 (i) cats was 3 years (range 0.7–12 years) and the median age of group 3 (ii) cats
was 12 years (range 1–19.5 years). Breeds comprised domestic crossbred (n = 67),
Burmese (n = 3), Ragdoll (n = 3), Devon Rex (n = 2) and one each of Cornish Rex,
Table 1
Fungal species and serology results for group 1 cats with upper respiratory tract aspergillosis.
Cata Age (years) Sex Breed Form Fungal species b AGID ELISA (units/mL)
1 2 MN Ragdoll SNA A. thermomutatus (N. pseudoﬁscheri) − 35.7
2 2 FN DSH SOA A. felis + 273.1
3 5 FN Cornish Rex SOA A. felis − 797.9
4 13 MN DSH SNA A. felis − 5
5 14 FN Persian cross SNA A. lentulus − 38
6 3 MN DSH SOA A. felis − 26
7 8 FN Persian SOA A. felis + 215.5
8 2 MN British shorthair SOA A. felis + 110.7
9 7 MN Persian SNA A. fumigatus − 28.2
10 2 MN Himalayan SOA A. felis + 35.8
11 8 MN DLH SOA A. udagawae + 55.7
12 8 FN Scottish shorthair SNA A. fumigatus + 56.6
13 5 FN DSH SOA A. felis + 154.9
14 4 MN Ragdoll SOA A. felis + 49.7
15 3 FN Himalayan SOA A. felis + 78.3
16 2 FN DSH SOA A. felis − 295.1
17 14 FN Abyssinian SNA A. fumigatus − 16.1
18 3 MN Ragdoll SOA A. felis − 288.42
19 14 FN Persian SNA A. fumigatus − 24.6
20 4 MN DSH SNA A. ﬂavus − 6.3
21 7 MN DSH SNA A. fumigatus − 82.4
AGID, agar gel immunodiffusion; DSH, domestic shorthair; DLH, domestic longhair; FN, female neutered; MN, male neutered; SNA, sino-nasal aspergillosis; SOA, sino-orbital
aspergillosis.
a Country of origin was Australia except cats 17 (USA), 19 (UK) and 21 (Belgium).
b Signalment of cat and molecular identity of isolates for cats 1–15 has been reported elsewhere (Barrs et al., 2013, 2014; Barrs and Talbot, 2014).
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Abyssinian, Siamese, Birman, Bengal, Persian, Russian blue, British shorthair and
Singapura.
Agar gel double immunodiffusion
Detection of precipitating anti-Aspergillus antibodies by AGID (Ouchterlony
method) was performed using a commercially available test-kit (Fungal Immuno-
diffusion Kit, Meridian Bioscience) comprising agar immunodiffusion plates, an
aspergillin derived from the mycelial phase of cultures of A. fumigatus, A. niger and
A. ﬂavuswith a protein content of 1486 μg/mL (Aspergillus Immunodiffusion Antigen
reference number 100501, Meridian Bioscience) and goat anti-Aspergillus immuno-
diffusion control serum (reference number 100901, Meridian Bioscience). Testing was
performed in accordance with the manufacturer’s instructions using 20 μL each of
control sera, test serum and aspergillin. All samples were tested in duplicate. Gels
were examined for the presence of precipitin bands of identity or partial identity
after 24 h and again after an additional 48 h incubation (ﬁnal reading) in a humidi-
ﬁed chamber at room temperature. Visualisation of precipitin bands was facilitated
by directing a high-intensity light beam at a 45° angle below the plate, with the latter
held against a black background.
Aspergillus-speciﬁc IgG quantiﬁcation by indirect ELISA
An indirect ELISA for detection and quantiﬁcation of Aspergillus-speciﬁc IgG an-
tibodies in canine sera using the same aspergillin as for the AGID was modiﬁed for
use in cats (Billen et al., 2009). Binding activity using polyvinylchloride or polysty-
rene 96-well plates was assessed as similar. Two commercially available secondary
antibodies, rabbit anti-cat IgG (H&L), ALP conjugated, were evaluated (SAB 37008-1,
Sigma; AS10 1479, Agrisera).
The assay was optimised by performing checkerboard titrations to determine
the optimal dilutions of antigen, cat serum and secondary antibody. Inter- and intra-
plate coeﬃcients of variation were calculated by running 40 repeats of the positive
control sample (pooled positive control sera from seven cats with conﬁrmed as-
pergillosis and a positive AGID result) on four separate plates with 10 repeats on
each plate. Test samples were run in duplicate and each plate contained a dupli-
cate positive control, a negative control (pooled negative control sera from 15 healthy
controls with a negative AGID result), and a blank (phosphate buffered saline, PBS,
plus 0.05% Tween 20, Sigma; PBS-T). Sera were titrated in doubling dilutions from
1:800 to 1:102,400.
Ninety-six well enzyme immunoassay (EIA)/radioimmunoassay (RIA) polystyrene
plates (Costar 3590, Corning) were coated with 75 μL aspergillin (2.5 μg protein/mL)
and incubated at 4 °C overnight. Plates were blocked with 75 μL 1% w/v polyvinyl-
pyrrolidone (Sigma) in PBS for 1 h at room temperature. Fifty microlitres of patient
sera was diluted in 5% non-fat milk in PBS-T, titrated on plates in doubling dilu-
tions from 1:800 to 1:102,400 and incubated for 2 h at 37 °C. Fiftymicrolitres of 1:8000
rabbit anti-cat IgG (H&L), ALP conjugated, antibody solution (SAB 37008-1, Sigma)
diluted in PBS-T was added to each well and incubated for 1 h at 37 °C. Next, 200 μL
SigmaFAST p-nitrophenyl alkaline phosphate substrate (Sigma) was added to each
well, incubated in the dark for 45min then stopped with 50 μL of 3 M NaOH. Optical
density (OD) was determined using a plate reader with a 405 nm and 492 nmwave-
length ﬁlter (Benchmark Plus microplate spectrophotometer, Bio-Rad Laboratories).
All incubations were performed in a humidiﬁed chamber and wells were washed
three times between incubations with 150 μL PBS.
Statistical analysis
The mean age of cats was compared between groups using a general linear
model. Sex proportions were compared using a χ2 test. For the purpose of statisti-
cal analyses, breeds were grouped into brachycephalic (Persian/Persian-cross,
Himalayan, Ragdoll, Birman, Burmilla, British/Scottish shorthair) and non-
brachycephalic (Domestic short/longhair, Cornish/Devon Rex, Bengal, Russian blue,
Oriental, Siamese, Tonkinese, Singapura). Proportions of cats in brachycephalic
and non-brachycephalic groups, and proportions of positive test results for cats
infected with A. fumigatus versus cryptic species were compared using Fisher’s
exact test.
Values for median ELISA units (EU) in group 1 were compared between AGID
positive and AGID negative cats, and between cats with A. fumigatus infections and
those infected with cryptic species, using non-parametric Mann andWhitney U tests.
For analysis of ELISA data, the geometric mean optical OD for each set of duplicate
serum samples was calculated and log10 OD values were plotted against log10 serum
dilutions for positive control and test sera in Microsoft Excel. The curves generated
were compared for parallelism and IgG concentrations were expressed as EU/mL,
with the positive control serum standard having a concentration of 100 EU/mL
(Billen et al., 2009). Serum samples with fewer than three dilution points within
the linear range of the standard, and thus considered to have antibody concentra-
tions below the detectable limit of the ELISA (<2.5 EU/mL), were assigned a value
of 0 EU/mL. An association between age and IgG quantiﬁcation in EU/mL in con-
trols was investigated using simple linear regression.
Cut-off values were established by determination of the mean plus three SD of
the IgG concentration of the controls and by receiver operating characteristic (ROC)
analysis. ROC analysis was conducted by ﬁtting a logistic regression model of log
EU values on the binary outcome (1 or 0) created by specifying the URTA group as
1 and the control group as 0 (Dohoo et al., 2009). ROC analyses were conducted for
group 2, group 3 and both groups combined. The optimal cut-off value for each anal-
ysis was determined using Youden’s J index. Se and speciﬁcity (Sp) at the determined
cut-off values were reported as described by de Silva et al. (2013). Analyses were
conducted using SAS 2002–2003 (SAS Institute/IBM). A 5% level of signiﬁcance was
used for all statistical tests.
Results
Cats
In group 1, one cat (cat 5) was determined to be FIV-infected
on the basis of a positive FIV antibody response and no history of
FIV vaccination; the other 20 cats in group 1 tested negative for
FIV and FeLV (Table 1). The mean age of cats in group 1 (6.3 years)
was signiﬁcantly different from that of cats in group 2 (9.8 years;
P < 0.01) and group 3 (i) (4.0 years, P < 0.01), but not from the
combined group 3 (i and ii: 8.2 years, P = 0.1) or a combined
control group (groups 2 + 3: 8.7 years; P = 0.06). There were no
signiﬁcant differences in sex between groups (P = 0.9). The propor-
tions of brachycephalic breeds were signiﬁcantly different between
groups 1 and 2, and between groups 1 and 3, but not between
groups 2 and 3 (P = 0.2); 11/21 (52%) group 1 cats were brachyce-
phalic compared to 4/25 (16%) group 2 cats (P < 0.05) and 4/84
(5%) group 3 cats (P < 0.01).
Agar gel double immunodiffusion
Nine of 21 sera (43%) from cats with URTA (group 1) were
positive in the AGID (Table 1). Sera from all 25 cats in group 2 and
84 cats in group 3 tested negative. The Se, Sp, positive predictive
value (PPV) and negative predictive value (NPV) of AGID for the
diagnosis of URTA are given in Table 2. Of the nine cats with
positive AGID results, one was infected with A. fumigatus and
eight were infected with cryptic species, including A. felis (n = 7)
and A. udagawae (n = 1) (Table 1). There was no association between
test result (positive or negative) and infecting species (A. fumigatus
versus cryptic species; P = 0.3).
IgG ELISA
The intra- and inter-plate coeﬃcients of variation of the ELISA
were 7.4% and 9.3%, respectively. Sera from cats that did not generate
a dilution curve with a minimum of three dilution points within
the range of the standard serumwere assigned an Aspergillus-speciﬁc
IgG concentration of 0 EU/mL (20/25 group 2 cats and 74/84 group
3 cats). Cut-off values calculated using the mean plus three SD of
the IgG concentration and using ROC analysis were similar, yield-
ing results of 5.6 and 6.0 EU/mL, respectively, regardless of the control
group used. Se and Sp were optimal at a cut-off value of 6 EU/mL
Table 2
Diagnostic accuracy of agar-gel double immunodiffusion in 21 cats with sino-nasal
and sino-orbital aspergillosis.
Control group 2a
(n = 25)
Control group 3b
(n = 84)
Control groups
2 and 3 (n = 109)
% 95% CI % 95% CI % 95% CI
Se 42.9 21.9–66.0 42.9 21.9–66.0 42.9 21.9–66.0
Sp 100.0 86.2–100.0 100.0 95.7–100.0 100.0 96.6–100.0
PPV 100.0 66.2–100.0 100.0 66.2–100.0 100.0 66.2–100.0
NPV 87.5 50.2–100.0 97.7 79.2–93.4 90.1 83.3–94.8
CI, conﬁdence interval; Se, sensitivity; Sp, speciﬁcity; PPV, positive predictive value;
NPV, negative predictive value.
a Cats with other upper respiratory tract diseases (excluding aspergillosis).
b Healthy controls (n = 36) and sick cats (n = 48) with non-fungal, non-respiratory
illness.
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(Table 3); at this cut-off value, the Se was 95.2%, the Se was 92.0%,
the PPV was 90.9% (95% conﬁdence interval, CI, 70.8–98.6%) and the
NPV was 95.5% (95% CI 78.8–99.3%).
Using the calculated cut-off value of 6.0 EU/mL, a positive IgG
ELISA result was obtained for sera from 20/21 (95.2%) cats with URTA
(range 6.3–797.9 EU/mL) (Table 1), from 2/25 (8.0%) cats, both with
cryptococcal rhinitis, in group 2 (8.7 and 80.7 EU/mL) and 6/84 (7.1%)
cats in group 3 (7.3–8.9 EU/mL) (Fig. 1). The median Aspergillus-
speciﬁc IgG concentration in cats with URTA (group 1) was 55.7
EU/mL. Among cats with URTA, there was no signiﬁcant difference
in Aspergillus-speciﬁc IgG concentrations in cases with A. fumigatus
infection (median 67 EU/mL; n = 5) and cases with infection by
cryptic species (other members of the A. fumigatus complex; median
56.6 EU/mL; n = 15; P = 0.1). There was no association between test
result (positive or negative) and infecting species (A. fumigatus versus
cryptic species; P = 0.3). The median Aspergillus-speciﬁc IgG con-
centrations of cats with positive AGID results was 78.3 EU/mL,
compared to 31.95 EU/mL for cats with negative AGID results (P = 0.2).
There was no signiﬁcant effect of age on EU values of combined
groups 2 and 3 (P = 0.05) or group 3 alone (P = 0.2).
Discussion
In this study, we demonstrated that antibodies against four cryptic
species of Aspergillus (A. felis, A. udagawae, A. lentulus and A.
thermomutatus) can be detected in feline serumwith assays utilising
a commercial aspergillin derived from A. fumigatus, A. niger and A.
ﬂavus. Although this result was not unexpected given the close phy-
logenetic relationship of these cryptic species to A. fumigatus (Barrs
et al., 2013; Novakova et al., 2014), it is important to demonstrate
this cross reactivity, given the high frequency of infections with such
cryptic species in cats. A. felis and A. udagawae are the two most
commonly reported species of Aspergillus to cause SOA in cats (Kano
et al., 2008, 2013; Barrs et al., 2013, 2014; Barrs and Talbot, 2014).
There was a marked difference in the Se of the AGID and the IgG
ELISA for detection of Aspergillus-speciﬁc antibodies, while the Sp
for both assayswas high. In contrast to the IgG ELISA, which detects
one class of antibody, immunodiffusion assays detect precipitins
(Crowle, 1973). In AGID assays, optimal diffusion depends onmany
factors including suﬃciently large antigen (Ag) and antibody (Ab)
reservoirs tomaintain inﬁnite pools of reactants (Kunkel, 1988). Since
a commercial test kit was utilised in the present study, optimisation
of the assay was not performed. The same commercial AGID has
been evaluated for diagnosis of canine SNA, which is caused by A.
fumigatus in >95% of cases, with reported Se of 57–67% (Pomrantz
et al., 2007; Pomrantz and Johnson, 2010; Barrs and Talbot, 2014).
Another commercial AGID (Immuno-Mycologics) had a Se of 31%
for diagnosis of canine SNA (Peeters and Clercx, 2007). The highest
reportedSeof 76.5%usinganAGID fordiagnosis of canineSNAutilised
a customised Ouchterlony method (Billen et al., 2009).
The IgG ELISA had high Se and Sp overall, indicating that the pro-
duction of Aspergillus-speciﬁc IgG is a reliable indicator of URTA.
Depending on the cut-off value and control group used, the Se of
the assay was 91–100% and the Sp was 92–100%. Cases with URT
diseases other than aspergillosis (group 2) represent the most rel-
evant control group in a clinical situation. Of interest, both cats with
false positive IgG results in group 2 had cryptococcosis. The high
antibody titre detected in one cat with sino-orbital cryptococcosis
(80.7 EU/mL) was repeatable. The cat had a latex cryptococcal antigen
titre of 1024 (Meridian, CALAS 2010) and Cryptococcus gattii was
cultured from the nasal cavity. On CT there was a retrobulbar mass
arising from the nasal cavity, but yeasts were not seen on cytology
of ﬁne-needle aspirate biopsies. The cat was treatedwith itraconazole
for one year until the LCAT decreased to zero and clinical signs re-
solved. Possible explanations for the high antibody titre are a false
positive disease result or a true result due to co-infection with As-
pergillus spp., which is possible, but unlikely. Concurrent pulmonary
cryptococcosis and aspergillosis has been documented rarely in
humans (Lin et al., 2006; Enoki et al., 2012).
The high frequency of Aspergillus-speciﬁc IgG and the low fre-
quency of retroviral infection by serology in group 1 cats (0% for
FeLV; 4.7% for FIV) provide further evidence that cats with URTA
are not systemically immunocompromised (Whitney et al., 2013).
Other causes of immunosuppression documented in cats with DIA,
such as feline panleukopenia, feline infectious peritonitis or pro-
longed corticosteroid therapy (Ossent, 1987), were not evident
among cats with URTA tested in the present study. However, local
disease that may have predisposed to sino-nasal cavity fungal
colonisation was identiﬁed in two cats; one cat with A. fumigatus
infection had concurrent nasal adenocarcinoma (cat 17) and one
cat with A. ﬂavus infection had plantmaterial removed from the nasal
cavity during endoscopy (cat 20) (Table 1). To further our under-
standing of the immunopathogenesis of this disease, additional
studies of the humoral response to URTA, including quantiﬁcation
of IgM and IgA in affected cats, are warranted.
Table 3
Performance of IgG ELISA for detection of Aspergillus-speciﬁc antibodies at different cut-off values.
Controls AUC 95% CI for AUC Cut-off value (EU/mL)
5 6 9
Se Sp Se Sp Se Sp
Group 2 0.97 0.92–1.00 100.0% (21/21) 92.0% (23/25) 95.2% (20/21) 92.0% (23/25) 90.5% (19/21) 96.0% (24/25)
Group 3 0.97 0.98–1.00 100.0% (21/21) 91.7% (77/84) 95.2% (20/21) 92.9% (78/84) 90.5% (19/21) 100.0% (84/84)
Group 2 and 3 0.99 0.97–1.00 100.0% (21/21) 91.7% (100/109) 95.2% (20/21) 92.7% (101/109) 90.5% (19/21) 99.1% (108/109)
CI, conﬁdence interval; AUC, area under curve; EU, ELISA Units; SE, sensitivity; SP, speciﬁcity.
Fig. 1. ELISA units/mL for 21 group 1 sera (cats with aspergillosis; black circles),
25 group 2 sera (control cats with other upper respiratory tract disease; black stars)
and 84 group 3 sera (control cats, either healthy or sick with non-respiratory disease;
grey circles). Lines represent means ± standard deviations.
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Our ﬁnding that purebred cats of brachycephalic conformation
were signiﬁcantly more likely to develop URTA conﬁrms a
predisposition which, until now, has only been suspected (Tomsa
et al., 2003; Whitney et al., 2005; Barrs et al., 2012). Impaired sinus
aeration and drainage associated with brachycephalic skull confor-
mation that favours fungal colonisation have been proposed as a
mechanism for this breed association (Tomsa et al., 2003). A heritable
disorder of innate immunity has also been proposed (Barrs and
Talbot, 2014). Chronic invasive granulomatous fungal rhinosinusitis
of humans, similar to feline SOA, occurs in immunocompetent people
in the Indian subcontinent, especially those working in agricul-
ture and construction (Thompson and Patterson, 2012). In contrast
to feline SOA, the aetiological agent is usually A. ﬂavus. A. ﬂavus is
an uncommon cause of URTA in cats and only a single case has
been identiﬁed previously (Malik et al., 2004).
Using a cut-off value of 5 EU/mL to optimise the IgG ELISA for
Se makes this assay an ideal screening test for URTA in cats with
consistent clinical signs; positive results should be corroboratedwith
additional tests, such as CT/MRI ﬁndings, rhinosinuscopy, cytologi-
cal or histological detection of fungal elements in affected tissues
and fungal culture. Assay Sp was not 100% even at the cut-off value
optimised for Sp (9 EU/mL) in group 2 cats, the most clinically rel-
evant control group. Therefore, serology should not be relied upon
as the sole diagnostic test for URTA.
Conclusion
Detection of Aspergillus-speciﬁc IgG by AGID and ELISAwas highly
speciﬁc for the diagnosis of aspergillosis in cats. The Se of IgG de-
tection by ELISA was high, whereas the Se of detection using AGID
was low. Depending on the cut-off value used, the ELISA has good
discriminatory power to distinguish between presumed environ-
mental exposure, which increases with age, and that induced by
colonisation and infection. This study provides further evidence that
feline URTA affects systemically immunocompetent individuals.
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6.3 Conclusions 
The results of this study prove that feline antibodies against the four most commonly 
isolated cryptic species in Aspergillus section Fumigati (A. felis, A. udagawae, A. 
lentulus and A. thermomutatus/N. pseudofischeri) cross react with a commercial 
aspergillin containing A. fumigatus, A. niger and A. flavus. This result was not 
unexpected, given the close phylogenetic relationship of cryptic species to A. fumigatus 
(Barrs et al., 2013a; Novakova et al., 2013). However, it was important to demonstrate 
this for the development of a diagnostic serological assay that relies on the use of a 
commercially available aspergillin that includes A. fumigatus mycelial antigens.  
 
In chapter 3, a predilection for pure-bred cats with brachycephalic conformation was 
identified. In that study brachycephalic cats comprised 39% of the study population 
(Barrs et al., 2012a). Here for the first time, with the inclusion of two control groups 
comprising a group of cats with other upper respiratory tract disease, and a group of 
healthy cats and sick cats with non-fungal illnesses I was able to apply statistical 
analyses to demonstrate that cats with URTA were significantly more likely than all 
control groups to be pure-bred cats of brachycephalic conformation. 
 
The qualitative AGID had poor sensitivity and high specificity, while the quantitative IgG 
ELISA had both high sensitivity and high specificity for the diagnosis of URTA. Thus, the 
Ig-G ELISA is a valuable non-invasive diagnostic tool for URTA in cats, and could 
readily be commercialized and made available to veterinary practitioners. Furthermore, 
the high prevalence of Aspergillus-specific antibodies in cats with URTA adds to the 
growing body of evidence that affected cats are systemically immunocompetent. We 
also systematically tested the sera of all cats with URTA in this study for the two of the 
most common viral causes of immunosuppression in cats, FIV (antibody) and FeLV 
(antigen) and found no cats with FeLV infection and a low prevalence of FIV-infection 
(4.76%) compared to a prevalence of 8 to 10% reported in domestic cat populations in 
Australia (Chang-Fung-Martel et al., 2013; Norris et al., 2007).  There was also no 
evidence of other causes of systemic immunosuppression that have been documented 
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in cats with disseminated invasive aspergillosis, including feline panleukopenia virus 
infection, feline infectious peritonitis virus and prolonged corticosteroid therapy, in cats 
with URTA in this study.  
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Chapter 7. General Discussion 
 
7.1 Background 
The article included in this chapter was an invited review for Veterinary Clinics of North 
America. In it, I discuss my research findings in the wider context of other publications 
on upper respiratory tract aspergillosis around the time of submission of this thesis. 
7.2 Summary of Results 
This thesis presents the characterization of feline upper respiratory tract aspergillosis, 
including causative agents, aspects of pathogenesis, the spectrum of clinical disease, 
diagnosis, and treatment outcomes. The outcomes and results can be summarized as 
follows: 
1. Cases of FURTA were recruited, forming the foundations of a case-bank and fungal 
isolate bank for future study (Chapters 3, 4, 5 and 6).  
2. The clinical syndrome of FURTA was described. Two anatomic forms, SNA and SOA 
were recognised and fully characterised with regard to historical signs, clinical signs, 
and clinicopathological findings including haematological, serum biochemical, 
microbiological, histopathological, serological and computed tomographic findings. 
Haematological findings were non-specific. Hyperglobulinaemia was identified as the 
most common serum biochemical abnormality in cats with FURTA, and was only found 
in cats with SOA. Fungal culture of affected tissues in cats with URTA (sinonasal 
biopsies/fungal plaques/retrobulbar or pterygopalatine fossa biopsies) was found to be 
95%. Aspergillus spp. clinical isolates from cats were found to grow on readily available 
commercial agar preparations including Sabouraud’s dextrose agar and malt extract 
agar (Chapters 3, 5 and 6). 
3. Computed tomographic features of FURTA were identified and described. CT 
features found to be common to both anatomic forms included bilateral, symmetrical 
SNC involvement and unilateral paranasal sinus involvement. Orbital masses, abnormal 
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paranasal soft-tissue attenuation and a mass effect in the NC, FS, SS or NP, were 
features of cryptic species infections and SOA. Severe cavitated lysis of the SNC was 
most commonly seen in cats A. fumigatus infections and SNA. Orbital masses were 
found to show heterogeneous enhancement after the administration of iodinated 
contrast and had central coalescing hypoattenuating foci with peripheral rim 
enhancement (Chapter 5). 
4. The aetiological agents of FURTA were identified. A. fumigatus was found to be the 
most common cause of SNA in cats. Cryptic species within Aspergillus section 
Fumigati, and more specifically within the A. viridinutans complex, were found to be the 
most common cause of SOA in cats (Chapters 3, 4, 5, 6 and 7).  
5. A novel species of Aspergillus within section Fumigati was discovered and named A. 
felis. The novel species was assigned on the basis of demonstration of morphological, 
biological and phylogenetic species concepts. A. felis was identified as the most 
frequent isolate from cats with SOA. Species within Aspergillus section Nigri (A. niger) 
and Aspergillus section Flavi (A. flavus) were identified as other aetiological agents of 
SNA in cats. A pathogenic role was ascribed to A. wyomingensis for the first time 
(Chapters 3, 4, 5, 6 and 7). 
6. The novel species, A. felis, was identified as a pathogen in a dog with disseminated 
invasive aspergillosis and in a human with chronic invasive aspergillosis. Both infections 
were fatal. Antifungal susceptibility testing results of A. felis isolates from cats, dogs and 
humans identified resistance amongst some isolates to caspofungin, itraconazole, 
voriconazole or posaconazole. Amongst resistant isolates, cross-resistance to 
itraconazole and voriconazole, or to itraconazole, voriconazole and posaconazole was 
demonstrated. These results establish A. felis as another cryptic species with in vitro 
resistance to antifungal agents used routinely for prophylaxis and treatment of IA. 
(Chapter 4).  
7. Multi-modality treatment of SOA was investigated using a tri-azole antifungal drug 
(itraconazole, posaconazole or voriconazole) alone, in combination with amphotericin-B 
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and terbinafine. Posaconazole was found to be well tolerated overall, with infrequent 
mild transient hepatic enzyme elevations. Voriconazole was associated with significant 
side-effects. The addition of radical debridement surgery (exenteration) to the treatment 
regime did not improve treatment outcomes (Chapter 3).  
8. From post-mortem results, surgical exploration and computed tomographic findings, 
communications between the sinonasal cavity and orbit were identified in all cats with 
SOA. Furthermore, all cats with SOA were found to have sinonasal cavity involvement 
on computed tomographic examination. These findings are consistent with the nasal 
cavity as the portal of entry for Aspergillus spp. conidia in feline URTA and support that 
the route of extension to involve the orbit is via direct naso-orbital communication from 
bone lysis (Chapters 3 and 5). 
9. Brachycephalic pure-bred cats of Persian lineage were identified to be predisposed to 
both anatomic forms of FURTA (Chapters 3, 5 and 6). Systemic immunosuppression 
was not identified in the vast majority of cats with FURTA. Common viral causes of 
immunosuppression including FIV, FeLV, FIP and feline panleukopenia virus infection 
were absent except in one case that was found to be infected with FIV. There was no 
history of previous corticosteroid usage or other immunosuppressive therapy prior to the 
onset of clinical signs in affected cats. The majority of cats with URTA had a robust IgG 
response to Aspergillus spp. infection (Chapter 3 and Chapter 6). 
These results have improved our knowledge and understanding of the pathogenic role 
of cryptic species within Aspergillus section Fumigati in animals and humans.  
7.3 Main article 
Barrs VR, Talbot JJ. Feline Aspergillosis. Veterinary Clinics of North America 2014: 44 
(1):51-73; http://dx.doi.org/10.1016/j.cvsm.2013.08.001  
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KEY POINTS
 There are two forms of upper respiratory tract aspergillosis (URTA): sinonasal aspergillosis
(SNA) and sino-orbital aspergillosis (SOA). Both infections start in the nasal cavity, and
SOA is the most common form (65% of cases).
 Brachycephalic breeds of cats, especially Persian and Himalayan, are predisposed to
URTA.
 Feline SNA can be invasive or noninvasive. Noninvasive disease resembles SNA in dogs.
The most common causes of SNA are Aspergillus fumigatus and Aspergillus niger.
 The most common cause of SOA is a recently described novel species, A felis, which is an
A fumigatus-like fungus. Molecular identification is required to differentiate A felis from
A fumigatus.
 The prognosis for SNA is favorable with topical antifungal therapy alone, or combined with
systemic antifungals.
 Disseminated and non-URT focal forms of invasive aspergillosis are uncommon in cats,
with little known about the etiologic agents. Young to middle-aged cats are affected.
Concurrent immunosuppressive diseases have been identified in some cats.INTRODUCTION
Aspergillosis is a mycosis of a diverse range of human and animal hosts including
mammals and birds. Among the most common molds on earth, Aspergillus spp. are
filamentous ascomycetes distributed primarily in soil and decaying vegetation that
have an important role in recycling environmental carbon and nitrogen.1 The genus
is named after “aspergillum,” a brush or implement with a perforated head used by
Roman Catholic priests for sprinkling holy water, which resembles the fungi’s
spore-bearing conidial heads.2Faculty of Veterinary Science, University Veterinary Teaching Hospital Sydney, The University of
Sydney, Evelyn Williams Building, B10, Sydney, New South Wales 2006, Australia
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Barrs & Talbot52 Chapter 7Feline upper respiratory tract aspergillosis (URTA) was first described in the early
1980s.3 Of the more than 55 cases now reported, over two-thirds were described in
the last 5 years.3–16 Other forms of aspergillosis in cats including disseminated5,17–21
and focal (non-URT) invasive infections17,19,20,22–32 are reported less commonly and
little is known about the etiologic agents.
CLASSIFICATION SCHEMES
Aspergillosis can be classified by body system involvement, duration of infection, pa-
thology, and pathogenesis. Disease is defined as invasive if there is hyphal invasion
into tissues.33 The respiratory tract is the most common site of disease in humans
and animals reflecting the primary inhalational route of infection.
Invasive aspergillosis (IA) in humans occurs predominantly in the sinopulmonary
tract of immunocompromised individuals associated with inhalation of Aspergillus
spp conidia, and invasive pulmonary aspergillosis accounts for more than 90% of IA
cases.34 URTA occurs less commonly and is classified as invasive or noninvasive
fungal rhinosinusitis. The classification of sinopulmonary forms of aspergillosis in
humans is summarized in Table 1.35–38
By contrast, URTA is the most common form of aspergillosis reported in mostly
immunocompetent cats and dogs.11,39 URTA can be further subdivided into sinonasal
aspergillosis (SNA) and sino-orbital aspergillosis (SOA). In dogs SNA accounts for
more than 99% of cases and is noninvasive, whereas in cats SOA is the most common
form and is invasive (65% of cases).3–5,7,8,11,14,16,40–45
Disseminated IA typically occurs in immunocompromised hosts and is defined as
active infection in two or more noncontiguous sites or the hematogenous spread of
disease.35 There are few reports of disseminated IA in cats and most cases had pul-
monary involvement.17–21 Focal (non-URT) invasive infections have also been reported
in cats involving lung,17,19,20,22–25,28 gastrointestinal tract,20,30–32,46 or urinary
bladder.26,27
ETIOLOGY
Several hundred species have been ascribed to the genus Aspergillus, which includes
four major subgenera; Circumdati, Nidulantes, Fumigati, and Aspergillus. Each subge-
nus comprises from two to six sections.47 The most common isolates to cause URTA
in cats and dogs are from the subgenus Fumigati section Fumigati, also known as the
A fumigatus complex.11,48–52 In contrast to dogs, in which A fumigatus is the single
most common agent of SNA,53 a more diverse range of Aspergillus species has
been identified from cases of feline URTA (Table 2).11,12,15,42
Based on current evidence, A fumigatus (section Fumigati) and A niger (section
Nigri) are the most common agents of SNA,9,11,42 whereas a recently discovered spe-
cies, A felis (section Fumigati), is the most common cause of SOA followed by A uda-
gawae (section Fumigati) (see Table 2).12,15,16 Section Nigri isolates, known as the
black aspergilli, are phenotypically distinct from section Fumigati (Fig. 1).54
Recent Advances in Identification of Fungal Pathogens in URTA
The ability to accurately identify fungal species that cause aspergillosis has increased
with the widespread availability of molecular techniques including polymerase
chain reaction (PCR) and sequencing.55 Members of the A fumigatus complex cannot
be reliably identified on the basis of phenotypic features alone. A fumigatus–like or
“cryptic” species have similar morphology and other phenotypic features to
A fumigatus.51 Misidentification of cryptic species causing feline URTA including104
Feline Aspergillosis 53Chapter 7A felis, A udagawae, and A lentulus is likely when only morphologic typing methods are
used.11,12,51
In four cases of SOAwhere A fumigatuswas reported as the etiologic agent, isolates
were identified by phenotypic features alone.10,43–45 For three of the isolates where
antifungal susceptibility to amphotericin B (AMB) was tested, minimum inhibitory con-
centrations of AMB were high, increasing the likelihood that these isolates were
cryptic species.10,43,44 Compared with A fumigatus, the minimum inhibitory concen-
trations of AMB for cryptic species, such as A lentulus and A udagawae, are
high.51,56 To date, of 35 cases of feline URTA in which the species identity of isolates
was confirmed using PCR and sequencing of the internal transcribed spacer (ITS) and
partial b-tubulin genes, A fumigatus has only been identified in cases of SNA (see
Table 2) (Barrs and Talbot, unpublished data, 2013).11,12,15,16
Disseminated and Focal IA
The Aspergillus spp that cause disseminated IA and focal IA in cats remain largely
unknown because most cases were diagnosed at postmortem only from histologic
findings.17–21 A fumigatus was identified from fungal culture morphology only in two
cats with mycotic pneumonia,25,28 one cat with mycotic cystitis,26 and one cat with
disseminated IA.18 A nidulans was identified from fungal culture morphology only in
one cat with mycotic cystitis.27 Molecular confirmation of isolate identity was not
performed in any case.
Current Fungal Taxonomy: What’s in a Name?
The A fumigatus complex contains asexual members (anamorphs), many of which also
have sexual forms (teleomorphs). The anamorph is typically mold-like and bears
mitotic spores (conidia). The teleomorph is characterized by the production of meiotic
spores (ascospores) that develop within sacs (asci) inside enclosed fruiting bodies
(cleistothecia).55
Controversy has surrounded the fungal taxonomy of the A fumigatus complex
because of the system of dual nomenclature used to describe anamorphic and tele-
omorphic phases of the same fungus. Traditionally the anamorphic phase was
assigned to the genus Aspergillus, whereas the teleomorph of the same organism
was assigned to the genus Neosartorya. The teleomorphic name received taxonomic
precedence, such that species with known sexual stages were referred to by their tele-
omorph names.57 Although this system of dual nomenclature provided a practical so-
lution for distinguishing organisms that produce ascospores, confusion arose for such
organisms as A fumigatus, where the teleomorph (Neosartorya fumigata) was only
recently discovered and the taxon continued to be referred to by its anamorph
name.58
In reforms to the International Code of Nomenclature for Algae, Fungi and Plants a
“one-fungus, one-name” principle was adopted in July 2011.59 In accordance with the
Amsterdam declaration on fungal nomenclature, Neosartorya is now included in genus
Aspergillus and teleomorphs are referred to by an informal cross-reference name (eg,
A fumigatus [neosartorya-morph]).60
EPIDEMIOLOGY
Feline URTA occurs worldwide, with cases reported in Australia,3,11–13,40 the United
States,7–10,41,42,45 Europe,4,8,14,43 and Japan.15,16 No age or gender predilection
is apparent. The median age at diagnosis is 6.5 years (range, 16 mo to
13 years).3–5,7,8,11,14,16,40–45105
Table 1
Classification of respiratory aspergillosis in humans
Anatomic Location Invasive/Noninvasive Immune Status Pathology
Lower respiratory
tract
IPA (angioinvasive) Immunocompromised
 Prolonged severe neutropenia
Vascular invasion by fungal elements
IPA (nonangioinvasive) Immunocompromised nonneutropenic:
 HIV/AIDS
 Corticosteroids
 Hematopoietic stem cell transplant recipients
 Heritable immunologic defect
(chronic granulomatous disease)
No evidence of vascular invasion
Pyogranulomatous inflammatory infiltrate
Chronic IPA
(nonangioinvasive):
 Chronic necrotizing PA
 Chronic cavitary PA
 Chronic fibrosing PA
Immunocompromised:
 Structural lung disease (eg, neoplasia, asthma,
emphysema, infection)
 Corticosteroids
 HIV/AIDS
 Diabetes
 Alcohol abuse
Hyphae mostly contained within cavity with only
occasional direct tissue invasion (chronic
necrotizing PA)
Invasive bronchial
aspergillosis
Immunocompromised Hyphal invasion of large airways
Aspergilloma
 Noninvasive
Immunocompetent Single cavity with fungal ball
No hyphal invasion of parenchyma
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Upper respiratory
tract
Acute invasive FRS
(angioinvasive)
Immunocompromised:
 Neutropenia
 Allogenic stem cell transplant recipients
Hyphal invasion of sinuses and contiguous
structures (eg, orbit); coagulative necrosis, sparse
inflammatory infiltrate, angioinvasion
Chronic invasive FRS
(angioinvasive)
Immunocompromised:
 Diabetes
 Corticosteroids
 HIV/AIDS
Hyphal invasion of sinuses and contiguous
structures (eg, orbit); infiltrative mass, mixed
inflammatory response, angioinvasion
Granulomatous FRS
 Invasive
Immunocompetent:
 Location-dependent disease
(Sudan, Middle-East, Indian subcontinent)
Hyphal invasion of sinuses and contiguous
structures (eg, orbit); highly cellular
granulomatous inflammatory response, no
angioinvasion; similar to feline sino-orbital
aspergillosis
Sinus aspergilloma
(fungal ball)
 Noninvasive
Immunocompetent:
 Structural sinus disease
(eg, dental root filling material)
Fungal mass within sinus; chronic
nongranulomatous inflammatory response to
fungal mass
Allergic FRS
 Noninvasive
Immunocompetent An allergic/hypersensitivity response to the
presence of extramucosal fungi within the sinus
Chronic erosive
noninvasive FRS
Immunocompetent Similar to canine sinonasal aspergillosis; marked
inflammatory response and sinonasal bony lysis
Abbreviations: FRS, fungal rhinosinusitis; IPA, invasive pulmonary aspergillosis; PA, pulmonary aspergillosis.
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Table 2
Etiologic agents in genus Aspergillus of SNA and SOA in cats
Number of
Cases Identification (PhenotypicP/MolecularM)
SNA SOA Subgenus Section Species
7 0 Fumigati Fumigati A fumigatusM
1 0 Fumigati Fumigati A lentulusM
1 1 Fumigati Fumigati N pseudofischeri (A thermomutatus)M
1 18 Fumigati Fumigati A felisM
0 4 Fumigati Fumigati A udagawaeM
0 1 Fumigati Fumigati A virdinutansM
3 0 Circumdati Nigri A nigerP (n52), M (n51)
Molecular identification is based on polymerase chain reaction and sequencing of the internal
transcribed spacer and b-tubulin regions.
Abbreviations: SNA, sinonasal aspergillosis; SOA, sino-orbital aspergillosis.
Data from Refs.9,11,12,15,16,42; and Barrs & Talbot unpublished data, 2013.
Barrs & Talbot56 Chapter 7Of cases where serologic testing for feline immunodeficiency virus and feline leuke-
mia virus was performed, only one cat tested positive for feline leukemia virus.4 Dia-
betes mellitus, a recognized risk factor for aspergillosis in humans (see Table 1),
was present in two cats diagnosed with URTA.40,42 As has been reported in canine
SNA,39,61,62 feline URTA occurs occasionally in association with facial trauma, nasal
neoplasia, and nasal foreign bodies (Barrs, unpublished data, 2013).
In contrast to canine SNA where dolicocephalic and mesaticephalic breeds
are overrepresented,39 pure-bred brachycephalic cats, predominantly of Persian
or Himalayan breed, account for more than a third of all feline URTA
cases.3–5,7,8,11,14,16,40–45
No gender or breed predisposition has been recorded for disseminated and focal IA
in cats. Affected cats are usually young to middle-aged. Evidence of systemic immu-
nocompromise in some cases included feline panleukopenia virus infection, feline leu-
kemia virus infection, feline infectious peritonitis, or prolonged corticosteroid
therapy.17–21,30–32,46Fig. 1. Isolates of Aspergillus fumigatus (A), Aspergillus felis (B), and Aspergillus niger (C) on
malt extract agar, from cats with URTaspergillosis. The black aspergilli (Section Nigri; [C]) are
phenotypically distinct from Section Fumigati (A, B). Species within Section Fumigati cannot
be reliably identified from phenotypic features. Some, like A felis (B), are generally slow to
sporulate.
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The ability of fungi to cause disease depends on a complex interplay between the
pathogen (virulence factors) and the host (innate and adaptive immune responses).
In humans, host factors that predispose individuals to IA include disorders of innate
immunity, such as reduced mucociliary clearance (eg, cystic fibrosis); decreased
numbers of phagocytic cells (ie, neutropenia); and phagocytic cell dysfunction (eg,
chronic granulomatous disease, in which there is impaired production of oxidative
intermediates).63
After inhalation, Aspergillus conidia that escape mucociliary clearance are mostly
phagocytosed by macrophages and dendritic cells.34 Phagocytic host cells express
pattern recognition receptors (PRRs) that recognize specific fungal epitopes known
as pathogen-associated molecular patterns (PAMPs) and damaged host cell compo-
nents known as damage-associated molecular patterns (DAMPs). The major PAMPs
of filamentous fungi are cell-wall components including b-glucans, chitin, and man-
nans, whereas DAMPs include nucleic acids and alarmins. The major PRRs of host
cells, as characterized in humans, include C-type lectin receptors; toll-like receptors
(TLRs); nucleotide oligomerization domain-like receptors (NOD-like receptors or
NLRs); and galectin family proteins.63,64
Is URTA Associated with a Disorder of Innate Immunity?
To date no studies have been performed to investigate innate or immune responses
in cats with URTA. Several single nucleotide polymorphisms in PRRs that increase
susceptibility to IA have been described in humans including single nucleotide poly-
morphisms in TLRs 1, 3, 4, and 6, and in the C-type lectin receptors Dectin-1 and
DC-SIGN.64,65 Whether similar genetic mutations could be associated with increased
susceptibility to URTA in Persian/Himalayan cats has not been investigated. By
contrast, several studies have evaluated the immune response to SNA in dogs.66–69
It is characterized by a dominant T-helper cell 1 (Th1) response with upregulation of
interleukin-10. A dominant Th1 response correlates with protective antifungal immu-
nity and is thought to be important in preventing invasive disease.39 Upregulation of
interleukin-10 is important in limiting the extent of local tissue destruction70 but para-
doxically could also be the reason why affected dogs are unable to clear infection
spontaneously. The inflammatory process in fungal infection is beneficial in containing
the infection but an uncontrolled inflammatory response is detrimental and might
inhibit disease eradication.64
To explore the hypothesis that a dysfunction in innate immunity could be an
etiologic factor in the development of canine SNA, the expression of messenger
RNA (mRNA) encoding TLRs 1 to 10 and NLRs 1 and 2 was quantified in nasal mucosal
biopsies from dogs with SNA and control dogs using quantitative real-time PCR.68 In
dogs with SNA there was significantly higher expression of all PRRs except for TLR3,
TLR5, and NLR1 compared with normal dogs. The significance of these findings is un-
known because little is known about the function of PRRs in canine nasal immunity in
health and disease.
Is URTA Associated with Impaired Mucociliary Clearance?
The increased risk of URTA observed in brachycephalic cats could reflect reduced
mucociliary clearance from abnormal sinonasal cavity conformation. Decreased sinus
aeration and drainage of respiratory secretions secondary to infection, polyps, and
allergic rhinosinusitis is a risk factor for invasive fungal rhinosinusitis in humans.71
Mucosal edema and impaired drainage of URT secretions caused by turbulent airflow109
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nization in brachycephalic cats.8 However, because brachycephalic dogs are under-
represented for SNA, additional risk factors, such as previous viral URT infection or
recurrent antimicrobial therapy, could also be involved.4,8,11
Fungal Virulence Factors
An important virulence factor of Aspergillus spp is their thermotolerant nature that en-
ables survival in mammals.72 Toxic secondary metabolites are associated with host
immunosuppression or evasion of the immune system.73 Gliotoxin, a mycelial-
derived product, prevents phagocytosis by macrophages, reduces T-cell prolifera-
tion and activation, and induces macrophage apoptosis.73–75 Other putative fungal
virulence factors include the ability to adhere to host tissue by conidia and
laminin-binding components, factors interfering with fungal cell opsonization, and
the production of proteases capable of macromolecule degradation to provide fungal
nutrients.73 Species-specific fungal virulence factors could be involved in the devel-
opment of invasive URTA because different fungal species are implicated in SNA and
SOA in cats.12
Progression from SNA to SOA
SOA results from extension of a primary sinonasal infection to involve paranasal struc-
tures including, but not limited to the orbit. The evidence for this includes:
 Documented progression of disease from SNA to SOA.7
 History of nasal signs preceding development of an orbital fungal
granuloma.3,7,11,16,45
 Detection of concurrent sinonasal cavity involvement on imaging, at surgery, or
at necropsy.3,6,10,11
 Detection of a direct communication between the orbit and nasal cavity on
computed tomography, surgery, or necropsy in the orbital lamina and less
commonly the frontal bone.11,43,76
 Isolation of A felis, the most common cause of SOA, from a cat with SNA.12 A
large defect in the orbital lamina was present on computed tomography. Infec-
tion was arrested with aggressive antifungal therapy and SOA did not develop.11
CLINICAL PRESENTATION
Clinical findings in feline SNA (outlined in Box 1) are similar to those reported for
chronic rhinosinusitis (discussed elsewhere in this issue). Most cats with SOA are pre-
sented for clinical signs associated with an invasive retrobulbar fungal granuloma
(Box 2, Fig. 2).3,7,10,11,14–16,43–45 In most cats exophthalmos is unilateral, but in severe,
chronic infections, bilateral exophthalmos can occur.3,11,43 Nasal signs are absent in
40% of SOA cases at presentation; however, the medical history usually reveals
sneezing or nasal discharge in the preceding 6 months. Pain on opening the mouth
and neurologic signs are uncommon at initial presentation. However, cats with
advanced disease are often euthanized because of the development of neurologic
signs, which can include seizures, nystagmus, circling, facial muscle fasciculation,
hyperesthesia, and blindness.11,44,45
DIFFERENTIAL DIAGNOSES
Differential diagnoses for cats presenting with chronic nasal signs are listed in Box 3
and for cats presenting with exophthalmos are listed in Box 4. Brachycephalic110
Box 1
Clinical signs in sinonasal aspergillosis
Common signs
 Sneezing
 Stertor
 Unilateral or bilateral serous to mucopurulent nasal discharge
 Ipsilateral mild mandibular lymphadenopathy
Less common signs
 Epistaxis (30% of cases)
 Fever
 Discharging sinus or soft tissue mass involving the nasal bone or frontal sinus
Feline Aspergillosis 59Chapter 7conformation should increase suspicion for aspergillosis, although these cats are also
overrepresented for viral URT infections. Where epistaxis is present neoplasia,
mycotic rhinitis, or severe chronic rhinosinusitis are more likely, along with systemic
hypertension. Inability to retropulse the globe and measurement of intraocular pres-
sure enables differentiation of exophthalmos from buphthalmos (abnormal enlarge-
ment of the globe).45 Other infectious or neoplastic processes extending from the
nasal cavity to the orbit can have a similar presentation to SOA, including cryptococ-
cosis, nasal lymphoma, and nasal carcinoma.Box 2
Clinical signs in sino-orbital aspergillosis
Common signs
 Nasal signs (clinical or historical finding within the previous 6 months)
 Unilateral exophthalmos with dorsolateral deviation of the globe
 Ipsilateral conjunctival hyperemia
 Ipsilateral prolapse of the nictitating membrane
 Ipsilateral exposure keratitis
 Oral mass or ulcer in the ipsilateral pterygopalatine fossa
 Paranasal soft tissue swelling
 Nasal signs
 Mild mandibular lymphadenopathy
Less common signs
 Fever
 Bilateral exophthalmos
 Ulceration of the hard palate
 Neurologic signs
 Discharging sinus (facial)
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Fig. 2. British Shorthair cat with sino-orbital aspergillosis. Infection was caused by Asper-
gillus felis. Note the left-sided third eyelid prolapse, hyperemia, and edema, and the
paranasal soft tissue swelling (A), and the pterygopalatine fossa mass (B), caused by an inva-
sive retrobulbar fungal granuloma.
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Diagnosis of feline URTA requires various combinations of serology, advanced imag-
ing, rhinosinuscopy, cytology, histology, fungal culture, and molecular identification.
Definitive diagnosis is based on identification of fungal hyphae on cytologic or histo-
logic examination of tissue biopsies or sinonasal fungal plaques. Similar to canine
SNA, diagnosis can also be made by visualization of sinonasal fungal plaques on
endoscopy.4,42 However, given the more diverse range of fungal pathogens that
can cause feline URTA, definitive identification of fungal pathogens should always
be attempted.
Hematology and Biochemistry
Hematology is unremarkable or there is evidence of a stress or inflammatory leuko-
gram. Peripheral eosinophilia is uncommon (10% of cases).7,8,10,11,16,42–45 Mild to se-
vere hyperglobulinemia is the most common abnormality on serum biochemistry. This
was reported in 9 of 16 cats with SOA and one cat with SNA caused by A felis infec-
tion.7,10,11,45 This finding suggests that in cats with confirmed URTA the presence of
hyperglobulinemia is a marker for invasive disease. However, prospective studies
are required to investigate this.Box 3
Differential diagnoses of nasal signs
Neoplasia (lymphoma, carcinoma, other)
Inflammatory (chronic rhinosinusitis, nasal/nasopharyngeal polyp, nasopharyngeal stenosis)
Infectious
Viral (Feline Herpesvirus-1, Feline Calicivirus)
Mycotic rhinitis (cryptococcosis, aspergillosis, sporotrichosis, phaeohyphomycoses, other)
Bacterial (Bordetella, Mycoplasma, Chlamydophila felis, Actinomycetes)
Foreign body
Congenital (choanal atresia, palatine defects)
Dental disease (oronasal fistula)
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Box 4
Differential diagnoses of orbital mass lesions
Neoplasia
Lymphoma
Adenocarcinoma/undifferentiated carcinoma
Squamous cell carcinoma
Fibrosarcoma
Osteoma/osteosarcoma
Other
Infectious
Bacterial abscess/granuloma (odontogenic, penetrating bite wound, hematogenous)
Mycotic granuloma
Aspergillosis
Cryptococcosis
Penicilliosis
Phaeohyphomycosis
Hyalohyphomycosis
Pythiosis
Inflammatory
Orbital myofascitis
Orbital pseudotumor (idiopathic sclerosing inflammation)
Zygomatic or lacrimal adenitis
Foreign body (eg, grass awn)
Orbital fat prolapse
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Aspergillus antigen detection in URTA
Galactomannan (GM) is a polysaccharide component of the cell wall of Aspergillus and
other filamentous fungal species that is released into the circulation during hyphal in-
vasion into tissue.77 A recent study evaluated serum GM measurement for diagnosis
of feline URTA.78 A one-stage, immunoenzymatic sandwich enzyme-linked immuno-
sorbent assay (ELISA) (Platelia, Bio-Rad, Marnes-la-Coquette, France) was used to
detect serum GM in four groups of cats: Group 1 cats had confirmed URTA
(N 5 13; six SNA, seven SOA); Group 2 cats had other URT diseases (N 5 15); Group
3 cats were treated with b-lactam antibiotics for non–respiratory tract disease
(N5 14); and Group 4 were healthy cats (Group 4a cats1 year of age, N5 28; Group
4b cats >1 year of age, N5 16). Using a cut-off optical density index of 1.5, 3 of 13 cats
with URTA (two SOA, one SNA) tested positive for serum GM. The overall sensitivity
and specificity of the assay was 23% and 78%, respectively. False-positive results
occurred in 29% of cats in Group 3 and 32% of cats in Group 4a. Specificity increased
to 90% when Groups 3 and 4a were excluded from the analysis.
The low sensitivity of detection of serum GM in feline URTA is likely to be associ-
ated with systemic immunocompetence of the host. In humans, the sensitivity of the113
Barrs & Talbot62 Chapter 7GM ELISA for detection of IA is more than 90% in neutropenic patients,79 whereas in
nonneutropenic patients the sensitivity is less than 30%.80,81 In the former, antigen is
cleared by neutrophils, which possess mannose-binding receptors, or by complexing
with circulating anti-Aspergillus antibodies.82,83 Also, low sensitivity of GM detection
in feline SNA could reflect absence of tissue invasion, as is the case in canine SNA
where fungal hyphae colonize superficially but do not penetrate the sinonasal
epithelium.84
The poor specificity of the Platelia GM assay for diagnosis of feline URTAmimics the
situation in humans where false-positive results have been identified in pediatric pa-
tients, and in patients treated with b-lactam antibiotics that contain small amounts
of GM introduced during themanufacturing process.85,86 Except in the setting of ruling
out URTA in cats with respiratory disease, serum GM is not useful as a routine diag-
nostic test for feline URTA.
Antibody tests
Serum anti-Aspergillus antibodies can be detected by numerous methods including
counter-immunoelectrophoresis, agar gel immunodiffusion, or ELISA. Results of
serologic tests performed in commercial laboratories have been published in
case-reports totaling 10 cats with URTA (nine SNA, one SOA), of which five were
seropositive.4,8,9,11,42
Preliminary results of a prospective study to evaluate the diagnostic sensitivity and
specificity of anti-Aspergillus antibody detection in feline URTA indicate that anti-
bodies to A felis cross-react with the same aspergillin preparation evaluated for diag-
nosis of canine SNA (Aspergillus Immunodiffusion Antigen, Meridian Bioscience,
Cincinnati, Ohio, USA) (Barrs, unpublished data, 2013).Diagnostic Imaging: Computed Tomography and Magnetic Resonance Imaging
Advanced imaging (computed tomography [CT] or magnetic resonance imaging [MRI])
is recommended for all cases of suspected feline URTA. As for canine SNA, cribriform
plate integrity should be assessed before treatment with topical antifungal prepara-
tions. Evidence of invasive disease, including paranasal soft tissue infiltration and
orbital involvement, may not be apparent on physical examination. Determination of
orbital involvement will affect subsequent case management.11 CT is generally supe-
rior to MRI for evaluation of destructive lesions in bony structures contiguous with the
sinonasal cavity. In cats with suspected intracranial extension of infection, MRI after
intravenous contrast administration is superior to CT for evaluation of intracranial
soft tissues.
CT findings in SNA
CT findings in cats with SNA have been reported in a small number of cases and seem
to be more variable than in canine SNA.9,41,42,76 Common findings are listed in Box 5.
In one study of five cats with SNA, findings that are relatively specific for SNA in dogs,
including cavitated-like turbinate lysis, mucosal rim thickening adjacent to the bones
of the sinonasal cavity, soft tissue accumulation, and reactive bony-changes, were
absent.41 However, these changes have been observed recently in cats with SNA
caused by A fumigatus (Barrs, unpublished data, 2013).
A calcified nasal cavity concretion was reported in one case of feline SNA.8 Calcifi-
cation of fungal plaques occurs in sinonasal Aspergillus spp infections in humans, in
approximately 50% of non-IA sinus fungal balls with maxillary sinus involvement.87
It is caused by deposition of calcium oxalate or phosphate crystals that are thought
to be fungal metabolites.114
Box 5
CT findings in SNA
 Nasal cavity involvement is usually bilateral
 Turbinate lysis
 Increased soft tissue attenuation within the nasal cavities
 Fluid or soft tissue accumulation within frontal and sphenoid sinuses
Additional CT findings in SOA
 Ventromedial orbital mass
 Dorsolateral displacement of the globe, which may be indented
 Heterogeneous and peripheral rim post contrast enhancement of orbital mass
 Paranasal soft tissue mass effect: pterygopalatine fossa, adjacent maxilla
 Lytic lesions in paranasal bones
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CT Features of SOA (see Box 5) overlap those seen in malignant nasal neoplasia (eg,
nasal lymphoma, nasal carcinomas) and other invasive mycoses, such as cryptococ-
cosis (Fig. 3).41 Overlapping features include osteolysis of paranasal bones, moderate
to severe turbinate destruction, mass-effect, and extension of disease into the orbit or
paranasal soft tissues.43–45,76,88,89Biopsy Procedures
Endoscopic visualization of the sinonasal cavity can be performed using nasophar-
yngoscopy, rhinoscopy, and sinuscopy. Biopsy specimens are obtained for cytology
and/or histology, and culture. Biopsy specimens can be stored frozen for PCR if URTA
is suspected but fungal culture is negative. Nasal cavity lavage may yield larger biopsy
specimens than can be acquired endoscopically and assists in debridement of
mucosal plaques (Fig. 4).
Sinuscopy is indicated when CT findings indicate sinus involvement and fungal
plaques are not visualized on rhinoscopy. Anatomic landmarks have been defined
for sinus trephination in cats.90 Trephine openings are made slightly to the side of
the mid-line on a line that joins the anterior borders of the supraorbital processes.
For cats with SOA, biopsies of retrobulbar masses can be obtained by the oral cav-
ity where there is pterygopalatine invasion.11 CT-guided biopsies of orbital or other
paranasal mass lesions can be performed.45
Fungal culture
Fungal pathogens that cause feline URTA can be readily cultured from tissue biopsies
or fungal plaques using commercial culture media. In one study 22 of 23 cases of feline
URTA were culture positive.11 Culture of nasal swabs for diagnosis of feline URTA has
not been evaluated.
Molecular identification of fungi
In the clinical setting comparative DNA sequence analysis used in conjunction with
traditional phenotype-based methods is a practical approach to identification of spe-
cies within the genus Aspergillus.52 Fungal DNA can be extracted for sequencing
directly from fresh or frozen clinical specimens, or from fungal culture material. One115
Fig. 3. CT features of sino-orbital aspergillosis (A), including nasal cavity soft tissue attenuation, lysis of paranasal bones, and mass-effect (ventromedial
orbital mass), overlap those of other mycoses (eg, cryptococcosis) (B), and neoplasia (eg, lymphoma) (C).
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Fig. 4. Plaques of Aspergillus fumigatus retrieved from the nasopharynx of a cat after nasal
lavage under general anesthesia, with sterile saline.
Feline Aspergillosis 65Chapter 7of the limitations of using formalin-fixed paraffin embedded tissues is that they often
only yield short DNA fragments, thus limiting the gene targets for amplification.
The genome of all fungi contains multiple copies of the ribosomal DNA (rDNA) gene
complex, consisting of highly variable regions, the ITS regions, which are flanked by
highly conserved gene sequences that are suitable targets for primers. Sequence het-
erogeneity within the ITS regions is useful for the separation of genera and species,
and appropriately exploited as a “panfungal” PCR for identification of fungi in clinical
specimens.91,92 The rDNA gene complex includes three genes: (1) the 18s rDNA gene,
also known as the small-subunit rDNA gene, which is 1800 base pairs (bp) long; (2) the
5.8S gene (159 bp); and (3) the 28S rDNA, also known as the large-subunit rDNA gene
(3396 bp) (Fig. 5).93 Comparative sequence analysis of ITS1-5.8S-ITS2 is an appro-
priate locus to first identify Aspergillus isolates to the level of subgenus/complex.52
However, because some closely related species show little or no variation in ITS
sequences, accurate identification of the fungal species requires additional analyses
of one or more partial gene regions.94
Histopathology
SNA
Histologic changes in canine SNA are characterized by ulcerated and severely
inflamed mucosa, often covered by a plaque of necrotic tissue containing hyphae,
and/or luminal exudates containing hyphae.9,42,84 Fungal hyphae do not penetrate
the mucosal epithelium, and the underlying lamina propria is typically heavily infiltrated
by a dense sheet of mixed mononuclear inflammatory cells. Histologic changes in
noninvasive feline SNA have not been reported systematically but seem similar to
canine SNA. Changes include severe inflammatory rhinitis with lymphoplasmacyticFig. 5. Representation of the ribosomal DNA (rDNA) gene complex in fungi denoting gene
order of small subunit (SSU) and large subunit (LSU) and position of internal transcribed
spacer (ITS) regions.
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of fungal hyphae.8,9,11,42 Histopathologic detection of tissue invasion by fungal hyphae
is important because progression to SOA can occur in invasive infections, and
evidence of invasion affects treatment decisions (discussed later).8
SOA
Cats with SOA have granulomatous invasive mycotic rhinitis and sinusitis with variable
submucosal invasion and bony lysis.3,11,43 Granulomas are comprised of central
necrotic cellular debris within which parallel-walled dichotomously branching, septate
fungal hyphae are confined that can be readily identified using special stains (eg,
periodic acid–Schiff, Grocott methenamine silver, or Gridley stain).3,7,10,11,43,45 Sur-
rounding the central area of coagulative necrosis are zones of inflammatory cells
and peripheral fibrosis that wall off the hyphae. In some lesions eosinophilic inflamma-
tion is prolific, whereas in others neutrophilic inflammation is predominant. Adjacent to
these are activated and epithelioid macrophages with vacuolated cytoplasm that form
sheets in some places. Peripherally there is a zone of fibroblasts and a cuff of lympho-
cytes and plasma cells. Inflammatory lesions can efface adjacent skeletal muscle and
bone.11 The globe is resistant to infiltration by fungal hyphae; however, invasion of
adjacent structures including the nictitating membrane and eyelid has been observed
(Barrs and Day MJ, unpublished data, 2011).10,44 Mycotic invasion of the optic nerve
and optic chiasm in cats that developed blindness has been reported.11 Development
of central nervous system signs in some cases implies fungal invasion of central ner-
vous system tissue; however, brain histology was not performed in the two cats in
which seizures were described.44,45
TREATMENT AND PROGNOSIS
SNA
The prognosis for feline SNA is favorable, although only small numbers of cases have
been treated. Signs resolved in 11 of 14 treated cases in which follow-up information
was available.4,8,9,11,42 Successful treatment regimes included systemic antifungal
therapy alone in five cases (itraconazole or posaconazole monotherapy or combined
with AMB); systemic triazole therapy (itraconazole or posaconazole) and topical intra-
nasal clotrimazole infusion in two cases; and topical intranasal clotrimazole infusion
alone in two cases. As for canine SNA,95 debridement of fungal lesions in the nasal
cavity was an important part of therapy for most cases.4,8,11,42
Evidence-based treatment protocols are not available. A suggested therapeutic strat-
egy for treatment of feline SNA, based on previous reports, treatment of canine SNA,
and considering whether infection is invasive or noninvasive, is outlined in Box 6.
Because of the propensity for feline SNA to progress to SOA, where there is any doubt
about the presence of invasion, or where A felis, a species highly correlated with inva-
sive disease, is identified, concurrent topical and systemic therapy is recommended.
Techniques for intranasal clotrimazole infusion are adapted from procedures used
to treat canine SNA and are described in detail elsewhere.8,39,42 Polyethylene glycol
should be used as the vehicle for 1% intranasal clotrimazole infusions, not polypro-
pylene glycol, because the latter can cause severe mucosal edema and ulceration.96
Response to therapy can be assessed from repeat CT and endoscopy. As for canine
SNA, multiple clotrimazole infusions may be required to resolve infection.11
SOA
SOA carries a poor prognosis. Optimal treatment protocols for treatment of SOA have
not been identified. Based on treatment responses in individual cases7,10,11,16,45 the118
Box 6
Therapeutic approach for treatment of feline SNA
 Record the identity of the fungal isolate and its antifungal susceptibility.
 Assess whether infection is invasive or noninvasive based on histopathology and CT findings.
 Determine the integrity of the cribriform plate on CT.
 Debride fungal plaques/lesions from the nasal cavity and frontal sinuses using endoscopic
techniques and saline irrigation.
 For noninvasive infections instill an intranasal infusion of 1% clotrimazole in polyethylene
glycol (1 hour soak under general anesthesia). Ensure drainage of the infusion from the
nasal cavities at the end of the procedure by tilting the head.
 For invasive infections or where Aspergillus felis is identified, give additional systemic
antifungal therapy (see SOA treatment).
Feline Aspergillosis 67Chapter 7recommended therapeutic approach is posaconazole or itraconazole given as mono-
therapy or combined with AMB (Table 3). Administration of systemic antifungals for
6 months or longer can be necessary in some cases and reinfection or relapse of infec-
tion can occur.11,16 A felis, the most common cause of SOA, usually shows in vitro
susceptibility to AMB.12 AMB was used in the successful treatment of one case of
SNA and one case of SOA caused by A felis, in combination with itraconazole or
posaconazole.11
Surgical debridement of large granulomas is logical but a clear advantage over
medical therapy has not been demonstrated in SOA. Three of six cases that
responded to therapy had surgery including orbital exenteration in two cases and
debridement of the orbital granuloma in the other.7,10,45 One of these also had lavage
of orbital tissues at surgery with 1% voriconazole.45 In only one of these cases was
resolution of infection confirmed by follow-up CT10 and one cat was euthanized
4 months after exenteration, with likely progressive disease.7 In the largest case series
of 12 cats with SOA for which treatment outcomes could be assessed, there were 11
treatment failures including five cases treated with combined surgery and antifungal
therapy and six with medical therapy alone. One case treated successfully with med-
ical therapy alone relapsed 19 months after treatment was stopped, responded to
further medical therapy, and is disease free 5 years later.11
Fluconazole is not recommended for treatment of aspergillosis because most
Aspergillus species are resistant to this drug. Antifungal susceptibility testing should
be performed before treatment, because resistance to AMB and some triazole drugs
has been identified in isolates from cases of SOA.10,12,43,44
Establishing pretreatment renal function and base-line liver enzymes is also impor-
tant because nephrotoxicity and hepatotoxicity is common with some antifungal drugs
(see Table 3).
Voriconazole (structurally similar to fluconazole) and posaconazole (structurally
similar to itraconazole) are fungicidal triazoles that were developed as more effica-
cious agents for treatment and prophylaxis of IA in humans and to improve on the ab-
sorption, tolerability, and drug interaction profile of itraconazole. Although their
pharmacologic characteristics have not been determined in cats, posaconazole is
well tolerated after oral administration and liver enzyme elevations are infre-
quent.10,11,44 Serious adverse neurologic effects (hindlimb paraplegia and blindness)
were reported after voriconazole administration in cats,11,45,97 and it is not recommen-
ded for treatment of feline URTA unless other therapies have failed.119
Table 3
Dosages of antifungals used in the treatment of feline upper respiratory tract aspergillosis
Drug/Formulation
Dosage/Route of
Administration Adverse Effects
Itraconazole
100-mg capsules
10 mg/mL oral suspension
(Sporanox)
Capsules: 5 mg/kg q 12 h or
10 mg/kg q 24 h PO
Administer with food
Oral suspension:
1–1.5 mg/kg q
24 h PO
Gastrointestinal: anorexia,
vomiting
Hepatotoxicity: elevated liver
enzyme levels, jaundice.
Monitor ALP/ALT monthly. If
hepatotoxicity occurs,
reduce dosage to 5 mg/kg q
24 h or 10 mg/kg q 48 h PO
(capsules)
Posaconazole
40 mg/mL liquid (Noxafil)
5–7.5 mg/kg divided twice
daily PO
Administer with food
Hepatotoxicity: unlikely to
occur at 5 mg/kg divided
twice daily PO
Voriconazole
50-mg tablets
40 mg/mL powder for oral
suspension (Vfend)
5 mg/kg q 24 h PO Gastrointestinal: anorexia
Neurologic: blindness, ataxia,
stupor, hind-limb paraplegia.
Consider use only when other
therapies have failed
Terbinafine
250-mg tablets (Lamisil)
30 mg/kg q 24 h PO Gastrointestinal: anorexia,
vomiting, diarrhea
Amphotericin B
deoxycholate
50-mg vial (Fungizone)
0.5 mg/kg of 5 mg/mL stock
solution in 350 mL per
cat of 0.45% NaCl 1 2.5%
dextrose SC two or three
times weekly to a
cumulative dose of
10–15 mg/kg
Nephrotoxicity: monitor
urea/creatinine every 2 wk.
Discontinue for 2–3 wk if
azotemic
Liposomal amphotericin
(AmBisome)
1–1.5 mg/kg IV q 48 h to a
cumulative dose of
12–15 mg/kg
Give as a 1–2 mg/mL solution
in 5% dextrose by IV
infusion over 1–2 h
Nephrotoxicity: less nephrotoxic
than amphotericin B, but
azotemia can occur. Monitor
urea/creatinine 1–2  weekly
Barrs & Talbot68 Chapter 7Echinocandins, a novel class of semisynthetic amphiphilic lipopetides, inhibit syn-
thesis of the fungal cell wall component 1,3-b-glucan. They are used for treatment
of refractory IA in humans.98 Caspofungin was well tolerated and efficacious in one
cat with SOA that failed treatment with AMB and posaconazole.11 In another case
treatment with micafungin was unsuccessful.15 As with other polypeptides, echino-
candins can cause histamine release.
SUMMARY
Feline URTA, the most commonly reported form of aspergillosis in cats, com-
mences as an infection in the nasal cavity. In SNA, infections remain confined to
the sinonasal cavity. In SOA, which is an invasive mycosis, infection extends from
the nasal cavity to involve paranasal structures, including the orbit. In contrast to
canine SNA, feline URTA is caused by a diverse range of Aspergillus species,
mostly from the A fumigatus complex. Phenotypic methods of identification are un-
reliable, but fungi can be readily identified using PCR and sequencing of the ITS and120
Feline Aspergillosis 69Chapter 7b-tubulin gene regions. SNA carries a favorable prognosis with treatment, whereas
the prognosis for SOA is poor. Optimal treatment regimes for feline URTA have not
been identified.REFERENCES
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7.4 Further discussion 
Further characterisation of the Aspergillus viridinutans complex 
Before I commenced my research, the A. viridinutans complex was known to consist of 
three species: A. viridinutans, A. aureolus and A. udagawae. A. viridinutans was first 
isolated from sand and rabbit dung in Frankston, near the Mornington Peninsula in 
Victoria in 1954 (McLennan et al., 1954). Interestingly, although A. viridinutans sensu 
stricto was the first to be discovered in the A. viridinutans complex, it is also the least 
common isolate in the A. viridinutans complex. In fact, astonishingly, no other isolate 
identical to the type-strain described by McLennan and others (1954), based on 
molecular methods, has been published. A. viridinutans can grow at 42 oC but not at 45 
oC (Barrs et al., 2013a). 
A. aureolus was first characterised in 1955 by Fennell and Raper. The two type strains 
were identified from soil isolated during the spring of 1950s from samples of soil 
submitted by C.F. Charter, West African Cacao Research Institute, Tafo, Gold Coast, 
Africa and by Prof. J.T. Baldwin, Monrovia, Liberia, respectively. It has also been 
isolated from soil in other tropical countries including Brazil, Ghana and Suriname, and 
from passion-fruit juice in Fiji (Novakova et al., 2013). A. aureolus is the only 
homothallic species within the complex, and ascomata are visible within one week of 
incubation on malt extract agar (MEA) at 25 oC (Novakova et al., 2013). A pathogenic 
role for A. aureolus is yet to be ascribed. A. aureolus can grow at 42 oC but not at 45 oC. 
A. udagawae was first characterised in 1995 from an isolate from Brazilian soil (Horie et 
al., 1995). Since then it has also been isolated from soil in other parts of South America, 
from Korea and the USA (Novakova et al., 2013). It was the first heterothallic species 
with a fully functioning reproductive cycle to be described in the A. viridinutans complex. 
Ascomata are visible after 3 weeks incubation on MEA at 25 oC. 
 
With the advent of molecular methods of identification, A. udagawae has been identified 
as an emerging agent of aspergillosis in humans, as previously discussed.  It has been 
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isolated from human lung, upper respiratory tract, brain, cornea and nail from the Czech 
Republic, Italy, Japan and the USA (Balajee et al., 2006; Gyotoku et al., 2012; 
Posteraro et al., 2011; Sugui et al., 2010; Vinh et al., 2009b; Yaguchi et al., 2007). My 
research and that of others has established A. udagawae as the second most common 
cause of SOA in cats (Barrs et al., 2014; Barrs et al., 2013a; Kano et al., 2008; Kano et 
al., 2013). 
 
In 2013 I discovered a fourth member of the A. viridinutans complex, namely A. felis, 
and demonstrated that it is a heterothallic species with a fully functional reproductive 
cycle (Barrs et al., 2013a). Slightly later in 2013, Novakova and others discovered a fifth 
member of the A. viridinutans complex, A. wyomingensis, from a soil reclamation site in 
Wyoming, USA. In naming A. wyomingensis, the research team adhered to the “one 
fungus one name principle” that we adopted as per the revisions of the International 
Code of Botanical Nomenclature discussed in Chapter 2. Support for these 
nomenclature revisions seems to be building amongst mycologists. 
 A. wyomingensis is also heterothallic and has a functional sexual cycle. Maximum 
growth temperature studies were performed for all A. viridinutans complex members. I 
have since discovered an isolate of A. wyomingensis in a cat with SOA and am the first 
to ascribe a pathogenic role to this species. 
Another finding in the study by Novokova and others (2013) was that all isolated 
species had maximum growth temperature of between 42 and 45 oC. All isolates grew 
at 42 oC and none grew at 47 oC. Similar to the findings of my study, A. viridinutans had 
a maximum growth temperature of 42 oC and did not grow at 45 oC. In contrast to my 
study where all isolates of A. felis grew restrictedly at 45 oC, Novakova found growth at 
45 oC was isolate-dependent for A. felis and also for A. wyomingensis and A. 
udagawae. The morphology of ascospores alone was found to clearly differentiate all 
heterothallic species within the A. viridinutans complex (see panels D and E in Figure 4 
of Barrs and others 2013, Chapter 4). This is in marked contrast to anamorph 
morphology, which is notoriously unreliable in Aspergillus section Fumigati taxonomy. 
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Interestingly, however, when A. viridinutans was first discovered, the feature of “nodding 
heads” was described, where the arrangement of the vesicle and phialides is at such 
angle as to present a “nodding appearance” (McLennan et al., 1954). Although upright 
heads were often seen, the nodding type was more frequent. Put more simply, some 
vesicles are borne at an angle to the stipe. I found that A. felis had this similar feature. 
This can be seen in panels D and E from the monograph of A. felis that I published in 
2013 (Figure 7.4.2). Similarly, Novokova found that nodding heads nodding heads 
occurred in all species within the A. viridinutans complex. However, the feature is not 
reliable for morphological identification because it is also present in some non-related 
species from Aspergillus section Fumigati including A. brevipes, A. duricaulis, .A 
marvanovae, A. unilateralis, N. pseudofischeri (A. thermomutatus), A. brevistipitatus 
and A. conversis (McLennan et al., 1954; Novakova et al., 2013; Smith, 1952; Varga et 
al., 2000) 
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Figure 7.1.4 Comparison of ascospore morphology of homothallic A. aureolus 
and three heterothallic species in A. viridinutans complex as observed by 
scanning electron microscopy a) A. aureolus, b) A. felis, c) A. udagawae, d) A. 
wyomingensis. Scale bars 2 μm. Images courtesy of Dr. Vit Hubka 
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7.5 Future directions 
• Cats are an excellent model of a spontaneously occurring invasive form of 
aspergillosis in an immunocompetent host, and a translational approach could be 
taken to study similar aspergillosis syndromes in immunocompetent humans, 
including chronic granulomatous rhinosinusitis. In order to apply this translational 
approach it is important to understand the unique pharmacologic disposition of 
cats in the metabolism of antifungal drugs. Drugs that require hepatic 
glucuronidation, in which drugs are conjugated with glucuronic acid, catalysed by 
the uridine diphosphate glucuronosyltransferase (UGTs), are metabolized 
uniquely in cats compared to humans because of deficiency of certain UGT 
isoforms (Court, 2013). Posaconazole is one such drug, whose metabolism is 
mediated by UGT enzyme pathways. Its metabolism has been studied widely in a 
number of mammalian species, including humans, mice, rats, rabbits, dogs and 
cynomolgus monkeys, but not in cats (Nomeir et al., 2000). Although some 
treatment success has been documented in my studies on URTA using 
posaconazole, the pharmacokinetics and pharmacodynamics of this drug in cats, 
need to be determined. There is a need for the pharmacological disposition of 
many other antifungal drugs to be studied in cats, including the newer triazole 
drugs voriconazole, ravuconazole, pramiconazole, and isavuconazole, and the 
echinocandins, e.g. caspofungin. As a first step, my group has initiated a study to 
determine the pharmacological disposition of posaconazole in domestic cats.   
• The predilection for pure-bred brachycephalic cats of Persian lineage, including 
Persians, Himalayans, Exotic shorthairs, British Shorthairs, Scottish shorthairs 
and Ragdoll cats is intriguing. Future studies are need to determine whether the 
predilection is a heritable defect in immunity or whether it is related to the 
abnormal bony conformation of the nasal cavity and paranasal sinuses in these 
breeds of cats. An approach similar to that taken by Professor Dominique 
Peeter’s group at the University of Liege to study the immunopathogenesis of 
canine SNA could be taken. A first basic step would be to perform an 
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immunohistochemical study using archived formalin-fixed tissues to characterize 
the phenotype and distribution of leukocytes and immunoglobulins in the 
sinonasal mucosa and other affected tissues of cats with URTA (Peeters et al., 
2005). Prospective studies would then be required to study both the innate and 
adaptive immune-response. Comparison of cytokine and chemokine mRNA 
expression, and of PRR mRNA expression from cats with URTA, from cats with 
other upper respiratory diseases, and from brachycephalic and non-
brachycephalic healthy cats could be compared. Also, given the finding of SNPs 
in several PRRs in humans that increase susceptibility to aspergillosis, a 
mutational analysis of PRR genes could be performed in brachycephalic cats of 
Persian lineage, in cats with aspergillosis, and in healthy non-brachycephalic 
cats.  
• A. viridinutans sensu stricto was first isolated from rabbit dung in Australia 
(McLennan et al., 1954) . All other members of the A. viridinutans complex have 
been isolated from Australia. A. felis is the only member of the A. viridinutans 
complex to be isolated from host animals but not from the environment. The 
environmental distribution of A. felis and other members of the A. viridinutans 
complex has not been studied in Australia. Therefore the risk of exposure in 
susceptible hosts is unknown. An environmental isolation study could be 
performed, starting with soil sample collection from the homes of cats diagnosed 
with aspergillosis in Australia. 
• Given the discovery of a high proportion of Aspergillus section Fumigati isolates 
being cryptic species, and the innate antifungal resistance properties of these 
isolates, prospective molecular identification studies of fungal isolates from 
human patients with aspergillosis is warranted in Australia. 
• I have investigated the computed tomographic features of aspergillosis in cats. 
Interestingly, the CT features of cryptococcosis, a more common mycosis than 
that of aspergillosis, have not been systematically reported. It is my clinical 
impression that sino-orbital cryptococcosis is quite common, but given the 
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excellent sensitivity and specificity of antigen tests for diagnosis of 
cryptococcosis, CT is usually not performed in affected cats. Finally, whether 
post-contrast features will aid in differentiating SOA from neoplasia in cats 
requires characterisation of the latter. 
The incidence of aspergillosis and other invasive mycoses in companion animals and 
humans predicted to increase with global warming. This thesis provides an important 
step in increasing our understanding of aspergillosis by the characterisation, diagnosis 
and treatment of one form of aspergillosis in the domestic cat. 
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FELINE SINO-ORBITAL ASPERGILLOSIS: AN EMERGING CLINICAL SYNDROME 
Vanessa R. Barrs, BVSc(hons), MVetClinStud, FACVSc (Feline Medicine) GradCertEd (Higher Ed) 
Sydney, NSW, Australia 
INTRODUCTION 
Until recently, little information has been available regarding aspergillosis affecting the upper 
respiratory tract (URT) of cats. URT aspergillosis in cats is a more aggressive disease than canine 
sinonasal aspergillosis (SNA). Whilst some cats present with SNA characterised by sneezing and nasal 
discharge, there is a propensity for extension of infection beyond the sinonasal cavity to involve adjacent 
structures including the orbit, palate, nasopharynx and cribriform plate. Thus, the first presenting signs of 
URT aspergillosis in cats may be referable to orbital invasion resulting in sino-orbital aspergillosis (SOA), 
which can be considered a progression from SNA. The fungal pathogens identified in many feline cases, 
Neosartorya spp, are related to but distinct from the major canine pathogen, Aspergillus fumigatus.  
 
ETIOLOGY 
Classification of fungal pathogens 
Both Aspergillus spp and Neosartorya spp are implicated as fungal pathogens in feline URT 
aspergillosis.1,2 These two closely related genera are classified within Aspergillus section Fumigati. Both 
are ubiquitous, filamentous, saprophytic, ascomycetes distributed primarily in soil and decaying 
vegetation. Confusion may arise over nomenclature because fungi can exist in different physical states 
corresponding to different stages of the life cycle; the anamorphic, asexual stage is typically mould-like 
and bears conidia (spores) whereas the teleomorphic, sexual stage, produces fruiting bodies 
(cleistothecia) containing ascospores. The total organism is referred to as the holomorph. Some 
Aspergillus species are strictly anamorphic, and therefore reproduce by asexual means only. 
Teleomorphic species within Aspergillus section Fumigati have been assigned to the genus Neosartorya.  
Aspergillus section Fumigati currently includes 9 strictly anamorphic Aspergillus spp and 24 Neosartorya 
spp.3,4 Aspergillus fumigatus, previously thought to be strictly anamorphic, was recently shown to have a 
fully functional sexual reproductive cycle that leads to the production of cleistothecia and ascospores. Its 
teleomorph is Neosartorya fumigata.4   
 
Identification of fungal pathogens in cats 
Prior to 2007, complete reports of feline URT aspergillosis have been limited to case reports 
describing infections in 13 cats.5-13  Affected cats presented with signs referable to sinonasal cavity 
infection (SNA) or sino-orbital infection (SOA). The fungal pathogen was often not identified either 
because fungal culture was negative or was not performed. In 5 cases where fungal culture was positive, 
isolates were proposed to be Aspergillus spp in 4 cases and Penicillium spp in another.5,6,11,13 
Identification to species level based on fungal culture morphology was performed in only 2 cases where A 
fumigatus and A niger were documented.11,13  
In 2006, 3 cases of feline URT aspergillosis were diagnosed at the author’s institution. This 
prompted a medical record search, which identified only 3 cases in the preceding 19 year period (January 
1986 to December 2005). Following publication of a description of the syndrome of SOA and a call for 
cases, a further 15 cases were recruited for study between 2006 and 2008.  Clinicopathological data from 
the resulting cohort of 21 cats from Eastern Australia provides new information on this disease in cats.1,2  
Fungal pathogens were readily isolated; culture on Sabouraud’s dextrose agar was attempted in all 21 
cases and was positive in 20. On the basis of fungal colony morphology, A fumigatus was the most 
common isolate identified in this cohort. However, it is not possibly to correctly identify some species 
belonging to Aspergillus section Fumigati using morphological and cultural characteristics alone.  Thus, 
molecular diagnostics were performed on the fungal cultures and/or on formalin-fixed paraffin embedded 
(PE) or fresh tissues from affected cats to confirm the identity of the isolates. A panfungal PCR that 
amplifies the internal transcribed spacer 1 (ITS1) region of the ribosomal DNA gene cluster between the 
18S and 5.8S rRNA genes was used for PE or fresh tissues. A second panfungal PCR that targets a 
larger region of the rDNA gene cluster including the ITS1, 5.8S gene and ITS2 regions was performed on 
fungal cultures. The ITS1 regions was targeted because it is multicopy (≥ 100 copies in the fungal 
genome), universal fungal primers are available and it contains highly variable regions for species 
identification.14 PCR products were sequenced and compared with those in the GenBank database.   
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Results of these molecular analyses indicated that the majority of feline isolates that had been identified 
as A fumigatus based on culture morphology were actually Neosartorya spp.1,2 In several cats, A 
fumigatus was identified using both fungal colony morphology and PCR of culture material or tissue. PCR 
of fungal culture material and/or tissue obtained from canine SNA cases was also carried out at the same 
time and identified A fumigatus in all cases.1 For Neosartorya spp isolates, in most cases it was not 
possible to distinguish between several possible species of Neosartorya using the panfungal PCR 
because of limited sequence variation in the ITS1 region. In one case, N pseudofischeri was identified 
from PCR of both culture material and fresh tissue with 100 percent identity to sequences in the GenBank 
database.  
Because of limitations for species identification using morphological criteria alone, a polyphasic 
taxonomic approach is recommended for definitive identification of species within Aspergillus section 
Fumigati. This involves a combination of macro- and micromorphology, extrolite (fungal metabolite) 
profiles and PCR determination of targeted genes including β-tubulin, calmodulin, ITS and actin.3  
 
EPIDEMOLOGY 
No age or sex predilection for feline URT aspergillosis is apparent. Disease has been reported in 
15 females and 18 males; most were desexed.1,2,5-13 The median and mean age at diagnosis was 6 years 
with a range from 1 and ½ to 13 years. An intriguing finding is the preponderance of brachycephalic cats 
affected; 16 of 34 cases were brachycephalic, including 8 Persians and 6 Himalayans. This contrasts 
starkly with canine SNA where dolicocephalic or mesocephalic breeds are typically affected. The basis for 
this potential brachycephalic breed association in cats is not clear. Impaired drainage of URT secretions 
due to brachycephalic conformation may be important. In humans, decreased sinus aeration and 
drainage of respiratory secretions secondary to infection, polyps and allergic rhinosinusitis have been 
identified as risk factors for invasive SNA aspergillosis. It is likely that additional risk factors are present in 
brachycephalic cats, since brachycephalic dogs are under-represented for SNA. These may include 
heritable defects in mucosal immunity or common environmental factors such as antecedent viral URT 
infection.11 Chronic FHV infection markedly alters sinonasal cavity architecture because of turbinate lysis 
secondary to intense inflammation, resulting in altered local mucosal defense mechanisms. One third of 
the Australian cohort of cats had a history of chronic recurrent rhinosinusitis before aspergillosis was 
diagnosed.1,2 So far there is no evidence of a retroviral association with feline URT aspergillosis; of 19 
affected cats tested for feline leukaemia virus antigen, only 1 was positive and all 19 cats tested for feline 
immunodeficiency virus were seronegative. Therefore, it appears that URT aspergillosis in cats occurs in 
apparently systemically immunocompetent individuals, some of which have identifiable breaches in local 
defence mechanisms. The apparent increased prevalence at our institution is likely a consequence of 
increased recognition of cases. Cases have been reported mostly in Eastern Australia and the USA with 
individual cases from Switzerland and the United Kingdom.1,2,5-13 
 
PATHOGENESIS 
Neosartorya spp have only rarely been associated with disease; isolated cases of invasive 
pulmonary infection, osteomyelitis, endocarditis, peritonitis and mycotic keratitis have been described in 
immunocompromised humans.15 Mistaken identification of Neosartorya spp as A fumigatus is considered 
likely to have resulted in underestimation of disease caused by Neosartorya spp in humans.15 Compared 
to SNA in dogs where fungal infection is usually confined to the sinonasal cavity, infections in cats have a 
tendency to become locally invasive with extension to involve the orbit.1,2,5,6,8-10,13 In canine SNA fungal 
hyphae do not invade the nasal mucosa and are typically present within overlying superficial necrotic 
plaques. Like SNA in dogs, infection in cats starts in the sinonasal cavity. It is likely that SNA and SOA in 
cats represent a spectrum of disease, with SOA being a manifestation of more chronic, invasive infection. 
Progression from SNA to SOA has been documented in individual cases.10 Furthermore, all cases of 
feline SOA to date have shown evidence of sinonasal cavity involvement on diagnostic imaging or at 
necropsy. 1,2,5,6,8-10,13 The orbital lamina, situated between the orbit and frontal sinus, is the most common 
anatomic region where extension of infection from the sinonasal cavity to the orbit has been identified.2  
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However, only some cases of SNA progress to SOA. The factors that determine whether infections will 
progress from SNA to SOA in individual cats have not yet been identified.  
 
CLINICAL SIGNS 
In dogs the triad of muzzle pain, profuse mucoid to haemorrhagic chronic nasal discharge and 
depigmentation, crusting or ulceration of one or both nares is highly suggestive of SNA. In cats, 
presenting signs of SNA are less specific. Most cats will have a history of sneezing and a unilateral or 
bilateral serous to mucopurulent nasal discharge.1,2,7,11,12  Intermittent epistaxis occurs in 40%. In contrast 
to dogs, neither nasal depigmentation nor ulceration has been documented in cats with SNA. A 
discharging sinus or soft-tissue mass may be identified overlying the frontal sinus or the nasal bone as a 
result of bony lysis and fungal proliferation. Stertor is variably present due to excessive nasal secretions 
and/or a mass lesion in the caudal nasal cavity and/or nasopharynx.   
Combining data from previously reported cases and the Australian cohort, 21 of 39 cats had 
SOA.1,2,5-13,16 Although most cats with SOA have a history of sneezing or nasal discharge in the 6 months 
prior to presentation, at the time of presentation, nasal signs may be subtle or absent. Rather, cats with 
SOA typically present with a constellation of clinical signs referable to invasive expansion of a fungal 
granuloma in the ventromedial orbit. These include unilateral exophthalmos with third eyelid prolapse, 
exposure keratitis and conjunctival hyperemia and a mass or ulcer in the ipsilateral pterygopalatine fossa 
behind the last molar tooth.1,2,13 Invasion through the palatine bone causes ulceration of the hard palate. 
Stertor is also common. In severe, chronic infections, exophthalmos can be bilateral.1,2,5,6 Pain on opening 
the mouth is not usually present. Extension of infection outside the sinonasal cavity can also result in 
facial distortion, including swelling of the nasal bridge, periorbital tissues and soft tissues adjacent the 
maxilla. Neurological signs are uncommon but develop subsequent to CNS invasion through the 
cribriform plate or sphenoid sinus. Submandibular lymph node enlargement and pyrexia are also 
common. In contrast, cats with SNA are not usually pyrexic.   
 
DIAGNOSIS 
 Definitive diagnosis of URT aspergillosis in cats is achieved by cytological or histological 
identification of fungal hyphae in affected tissue together with identification of the fungal pathogen. 
Obtaining a definitive diagnosis may require various combinations of diagnostic tests including 
radiography, CT, endoscopy, cytology, serology, fungal culture and molecular techniques. Serum 
anti-Aspergillus antibodies can be detected by counter-immunoelectrophoresis (CIE), agar gel 
immunodiffusion (AGID) or ELISA. The diagnostic utility of serum anti-Aspergillus antibody detection in 
cats with URT aspergillosis has not been evaluated. Two of 3 cats with SNA tested positive for serum 
antibodies against A fumigatus using CIE and another cat with SNA tested positive using  
 
 
AGID.7,11 Galactomannan (GM), a water-soluble polysaccharide cell wall component of Aspergillus and 
some other fungal species, is released in variable quantities during hyphal growth in tissues. This antigen 
can be detected in the serum of human patients with invasive Aspergillus infections using a commercially 
available sandwich ELISA (PlateliaTMAspergillus). GM antigen levels correlate with the tissue fungal 
burden and can be used to monitor clinical outcomes and response to therapy.17 Rising GM levels are 
associated with treatment failures in humans. The use of GM assays for diagnosis and monitoring of 
feline URT aspergillosis is currently under investigation in our laboratory. 
 For investigation of suspected sinonasal cavity or sino-orbital disease, CT is the imaging modality 
of choice. Reported changes in mycotic rhinosinusitis in cats include lysis of turbinates, palatine bone, 
nasal septum, frontal bone and/or cribriform plate.16 Nasal cavity involvement is usually bilateral. CT 
findings on cats with SOA within the Australian cohort included punctate lysis of the orbital lamina, 
ventromedial soft tissue orbital mass, opacification of the sphenoid and frontal sinuses due to fluid or soft-
tissue, and a soft-tissue mass in the choanae or nasopharynx.2 Sinonasal cavity involvement in SOA is 
usually bilateral. In cats with URT aspergillosis differentiation of invasive mycotic disease from malignant 
neoplasia may not be possible from imaging findings alone.16  
152 
 
Appendix 1 
 
TREATMENT AND PROGNOSIS 
  The typical antifungal susceptibility profile of Neosartorya spp isolated from cats with aspergillosis 
includes susceptibility to amphotericin B (AMB) and posaconazole (PCZ), intermediate or dose-
dependent susceptibility to itraconazole (ICZ) and voriconazole (VCZ), and resistance to 5-flucytosine, 
ketoconazole and fluconazole. Elevated minimum inhibitory concentrations of VCZ to Neosartorya spp 
have been documented elsewhere.15 In contrast, both VCZ and PCZ typically have greater activity than 
ICZ in vitro against A fumigatus.18 However, the correlation between in vitro antifungal susceptibility test 
results and in vivo response to therapy is only modest at best. For treatment of invasive aspergillosis in 
humans, VCZ has replaced AMB as the drug of choice for first-line therapy. PCZ is used for antifungal 
prophylaxis in high-risk patients and for salvage therapy. The echinocandins, including caspofungin, are 
reserved for salvage therapy or combination antifungal therapy for refractory invasive aspergillosis.19 
Combination antifungal therapy may provide enhanced efficacy compared to single drug therapy for 
treatment of invasive aspergillosis.20,21  
 URT aspergillosis in cats is more difficult to treat than SNA in dogs. Treatment of SNA carries a 
better prognosis than for SOA.2 The prognosis for resolution of SOA is generally poor. Antifungal triazole 
drugs are the mainstay of therapy for SNA, given alone or in combination with terbinafine or AMB. 1,2,11,12 
AMB can be administered as amphotericin deoxycholate (AMB-D) or as liposomal AMB (AMB-L).2 ICZ or 
PCZ are the triazoles of choice, although the pharmacokinetics and pharmacodynamics of the latter are 
yet to be studied in cats. Single topical sinonasal clotrimazole (CLT) infusions have been reported in 3 
cats.10,11,13 In one cat where infection was confined to the sinonasal cavity treatment with oral ICZ and a 1 
per cent CLT infusion was successful.11 In 2 other cats with SOA, a CLT infusion was part of a multimodal 
therapeutic approach. One cat was euthanased because of suspected progression of infection despite 
treatment with ICZ and radical surgical debridement of the orbit, including extenteration of the globe.10 In 
another cat treatment with ICZ, topical CLT and AMB-D did not resolve infection. However, the cat was 
cured after treatment with oral PCZ administered for 16 weeks.13 The use of topical CLT infusions should 
be restricted to treatment of cats with SNA where there is an intact cribriform plate, no evidence of orbital 
involvement on CT, and no histological evidence of submucosal fungal invasion.2 Concomitant systemic 
antifungal therapy with ICZ or PCZ is also recommended. 
  The optimal treatment regimen for SOA in cats has not been identified. Of 14 cases where 
treatment was attempted, infection resolved in only 4.2,13  Three of those were treated with medical 
therapy alone, including 1 which resolved after PCZ administration for 16 weeks.13  In another cat, 
infection resolved after 7 months of combination therapy using ICZ and AMB-D (cumulative dose 11 
mg/kg) and terbinafine. A third cat responded well to 8 months of therapy with ICZ and AMB-D 
(cumulative dose 14 mg/kg). However, clinical and CT evidence of infection recurred 3 weeks after ICZ 
was stopped. Treatment was reinstituted with terbinafine and PCZ for 4 months, followed by PCZ alone 
for a further 3 months. Signs resolved and the cat remained asymptomatic 1 year later. The fourth case 
was treated with surgical debridement of the frontal sinuses during diagnostic investigation followed by 
AMB-D (cumulative dose 10 mg/kg) and ICZ for 7 months. Clinical signs of infection resolved and the cat 
was asymptomatic 2 years later. Treatment failures occurred in 4 cats which were treated with medical 
therapy alone and in 6 cases treated with medical therapy and radical surgical debridement of orbital 
granulomas, including exenteration in 5 cases.2 Ongoing studies of the pathogenesis of URT aspergillosis 
in cats, combined with pharmacokinetic/pharmacodynamic data for newer antifungals in this species will 
assist in identifying the optimal therapeutic approach to treatment of this disease. 
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FELINE UPPER RESPIRATORY ASPERGILLOSIS: HOW DIFFERENT IS IT FROM CANINE 
SINONASAL ASPERGILLOSIS? 
Vanessa R. Barrs, University of Sydney, NSW 2006, Australia; vanessa.barrs@sydney.edu.au 
 
Introduction 
Canine sinonasal aspergillosis (SNA) was first reported in 1897 while reports of a similar 
disease in cats did not appear until the 1980s (1-2). Upper respiratory tract aspergillosis (URTA) 
is an emerging feline infection with over two-thirds of the approximately 50 reported cases being 
published in the last 5 years. In dogs the major form of disease (>99% of cases) is SNA, while 
in cats sino-orbital aspergillosis (SOA), is the more common form (63% of cases).  
 
Aetiology - Controversies in fungal nomenclature and identification (ID) 
More than 250 species have been ascribed to the Genus Aspergillus. Isolates from canine and 
feline URTA are usually from the subgenus Fumigati section Fumigati (the Aspergillus fumigatus 
complex) (3-4).This complex contains asexual members (anamorphs), many of which also have 
sexual forms (teleomorphs). Teleomorphs have been assigned to a different genus – 
Neosartorya. Classical nomenclature requires that an organism with alternate names be labeled 
with that of its sexual phase. This created confusion for organisms such as A. fumigatus where 
the teleomorph (Neosartorya fumigata) was only recently discovered (5). In sweeping reforms to 
the nomenclature code a “one-fungus, one-name” principle was adopted in 2011 (6). In the 
revised code (to be published in 2013) it is likely that the oldest generic name (eg. A. 
fumigatus), irrespective of whether it is typified by a species name with a teleomorphic or an 
anamorphic type, will be used. Members of the A. fumigatus complex cannot be reliably 
identified using phenotypic features alone. A. fumigatus-mimetic species have very similar 
anamorph colony morphology to A. fumigatus. Of 86 isolates from human patients with invasive 
aspergillosis previously identified as A. fumigatus, 12 were subsequently identified on 
comparative partial sequence analyses of genes encoding beta-tubulin and rodlet A as A. 
udagawae (Neosartorya udagawae) (7).  In this subset of patients the median duration of illness 
was 7 times longer and disease was refractory to standard therapy. A. fumigatus-mimetic 
species have higher in vitro minimum inhibitory concentrations for amphotericin-B (AMB) and 
triazole antifungal drugs than A. fumigatus. 
 
Aetiology - Advances in ID of fungal pathogens in feline and canine URTA 
Isolates from 23 Australian cats with URTA were identified using PCR and sequencing of the 
Internal Transcribed Spacer (ITS) region (3). A. fumigatus was identified in 4 of 6 cats with SNA 
while all 17 isolates from cats with SOA were identified as A. fumigatus-mimetic species. 
Individual species determination was not possible using ITS sequence analysis alone. In a 
subsequent study of these and other isolates at the CBS KNAW Fungal Biodiversity Centre in 
Utrecht, using sequence comparisons of the beta-tubulin, calmodulin and rodlet A regions, a 
single novel species of Aspergillus was identified from the majority of cats with SOA and from 1 
cat with SNA (unpublished). A. udagawae was identified as a cause of feline SOA in a single 
case report from Japan (8). Current evidence suggests that A. fumigatus is the most common 
cause of feline SNA and that SOA is only caused by A. fumigatus-mimetic species. Phenotypic 
ID of a large number of isolates from dogs with SNA has implicated A. fumigatus as the most 
common aetiologic agent (4). Molecular ID has been performed on a small number of isolates 
only (3,9). In 14 dogs with SNA, DNA of Penicillium or Aspergillus spp. was detected in nasal 
mucosal biopsies using a genus-specific real-time PCR assay (9). Species specific PCRs to  
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detect DNA of A. fumigatus, A.niger, A. terreus or A. flavus were positive for A. fumigatus in 7 
dogs and negative in the other 7 dogs. These isolates could have been Penicillium spp. or 
another Aspergillus spp. or there may have been insufficient A. fumigatus DNA present to be 
positive with the specific PCR. In another study, ITS sequencing of archival tissues from 7 dogs 
with SNA identified A. fumigatus in all 7 cases (3).  
 
Pathogenesis 
URTA in cats and dogs starts in the sinonasal cavity. Extension of infection into adjacent 
structures including the orbit and paranasal tissues occurs in SOA, as evidenced by progression 
of SNA to SOA (10), sinonasal cavity involvement on imaging or at necropsy in cases of SOA 
(3) and by isolation of the same novel species of Aspergillus that causes SOA in a case of SNA 
. Infecting fungal species may be a major determinant of progression. Canine SNA is a non 
invasive mycosis - fungal hyphae do not invade the nasal mucosa and are located in adjacent 
superficial necrotic plaques (9). In feline SOA fungal hyphae invade the respiratory epithelium 
and form granulomas within the orbit and paranasal tissues.  
 
Epidemiology 
In both cats and dogs URTA typically occurs in young to middle-aged animals. Of 49 reported 
feline cases the mean age at diagnosis was 6.5 years (range 1.5 -13 years). In case-series of 
canine SNA, mean age at diagnosis was 5 to 6 years. No sex-predisposition has been identified 
for feline URTA whereas males are over-represented in canine SNA. In feline URTA 
brachycephalic breeds (mostly Persian or Himalayan) account for 40% of cases. By contrast 
dolicocephalic and mesaticephalic breeds of dogs are predisposed to SNA. Overall (61%) cats 
with SNA were brachycephalic while (33%) cases of SOA were brachycephalic. Most cats and 
dogs with URTA are systemically healthy. Risk factors for URTA in humans include decreased 
sinus aeration and drainage secondary to infection, polyps and allergic rhinosinusitis. Reduced 
drainage of URT secretions due to brachycephalic conformation could be a risk factor in cats. 
However, since brachycephalic dogs are under-represented for SNA, it is likely that additional 
risk factors are present in cats, eg. heritable defects in mucosal immunity, previous viral URT 
infection and previous antibiotic treatment favouring fungal colonisation (11).  
 
Clinical Presentation 
In dogs the triad of muzzle pain, profuse mucopurulent to haemorrhagic nasal discharge and 
depigmentation, crusting or ulceration of one or both nares is highly suggestive of SNA. Clinical 
signs (CS) in feline SNA are more subtle and include sneezing, mucopurulent nasal discharge 
and intermittent epistaxis (40% of cases). Occasionally there is a cutaneous sinonasal 
discharging sinus or soft-tissue mass. Cats with SOA are presented for unilateral exophthalmos 
and other CS referable to invasive expansion of a retrobulbar fungal granuloma:  dorsolateral 
deviation of the globe, conjunctival hyperaemia, third eyelid prolapse, exposure keratitis and an 
oral mass or ulcer in the ipsilateral pterygopalatine fossa behind the last molar tooth. Extension 
of infection into paranasal tissues may cause facial distortion. Nasal signs are absent in 40% of 
cases but the medical history usually reveals sneezing or nasal discharge in the previous 6 
months. Neurological signs (15% of cases) include blindness, circling, facial muscle 
fasciculation and hyperesthesia. 
 
Diagnosis 
Diagnosis of feline and canine URTA may require various combinations of serology, computed 
tomography, endoscopy, cytology, histology and fungal culture. The sensitivity and specificity of  
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anti-Aspergillus antibody detection for the diagnosis of feline URTA is not known. Five of 10 
reported cases (9 SNA, 1 SOA) tested seropositive (2-3, 11-13). By contrast, two recent studies 
evaluated serology for diagnosis of canine SNA (4, 14). In one study agar gel immunodiffusion 
(AGID) was compared with fungal culture of nasal biopsies (4) and in the other antibody 
detection by AGID and ELISA were compared (14). Both methods used a purified aspergillin 
preparation composed of A. fumigatus, A. niger and A. flavus extracts (14).  Fungal culture was 
more sensitive (81%) than serology (67%) while specificity was high for both fungal culture 
(100%) and serology (98%) (4). In the second study ELISA had higher sensitivity (88%) than 
AGID (76%) and specificity was high for both methods (ELISA 97%, AGID 100%) (14). 
Seropositivity for Aspergillus spp. is highly suggestive of SNA in dogs but negative test results 
do not rule out aspergillosis. Serum galactomannan (GM) measurement for diagnosis of feline 
URTA was recently evaluated using the PlateliaTM ELISA (15). GM was measured in cats with 
URTA (n=13; 6 SNA, 7 SOA), other URT disease (n=15), β-lactam antibiotic treated cats (n=14) 
and healthy cats (n=44). Overall sensitivity was 24% and specificity was 78% for a cut-off 
optical density index (ODI) of 1.5.  High numbers of false positive results were identified in 
young cats and antibiotic-treated cats. Using the same ELISA, GM was measured in dogs with 
SNA (14). Using a cut-off ODI of 0.5, 24% of dogs with SNA tested positive, as did 11% of dogs 
with nasal tumours, 9% of dogs with non-fungal rhinitis and 24% of healthy dogs. Overall 
sensitivity was 24% and specificity was 82%. Currently available antigen tests cannot be 
recommended in the evaluation of feline or canine patients with URTA. 
 
Treatment 
Overall the prognosis for treatment of feline and canine SNA is good. Topical therapy is 
preferred for canine SNA because of direct contact with fungal plaques, although multiple 
applications are often required. In a multicentre, retrospective study of 81 dogs treated with 
topical clotrimazole or enilconazole using catheters placed intranasally and/or via sinus 
trephination, a single treatment was successful in 47% (16). Techniques reported to improve 
efficacy of topical antifungals include endoscopic/sinuscopic debridement of fungal plaques, 
endoscopic guidance of infusion catheters into the caudal frontal sinus and use of depot 
preparations (eg 1% clotrimazole or bifonazole cream).  Of 14 feline SNA cases with available 
follow-up, signs resolved in 11 (78%) (2-3, 11-13). The most common successful treatment 
regimes were systemic antifungal therapy alone (triazole +/- AMB) (n=5), systemic triazole 
therapy and topical intranasal clotrimazole (n=2) or topical therapy alone (single 1% intranasal 
clotrimazole infusions) (n=2).  Few cases of feline SOA have been treated successfully despite 
aggressive therapy including orbital exenteration and systemic fungicidal antifungals (3, 17-18). 
Posaconazole or itraconazole are recommended for first-line therapy. Use of triazole antifungals 
in combination with AMB may improve outcomes. Voriconazole should not be used initially due 
to a high frequency of adverse neurological events (19). Molecular ID of pathogens causing 
feline URTA will facilitate development of optimal treatment protocols.  
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Although most small animal practitioners will be familiar 
with the clinical syndrome of canine sinonasal aspergil-
losis (SNA), little information has been available regard-
ing aspergillosis affecting the upper respiratory tract 
(URT) of cats. Informative recent studies have highlighted 
major species differences that have implications for the 
recognition and treatment of this disease in this species. 
In cats, URT aspergillosis often is much more aggressive 
than its canine counterpart.
Although some cats present with SNA characterized by 
sneezing and nasal discharge, there is a propensity for the 
infection to extend beyond the sinonasal cavity to involve 
adjacent structures including the orbit, palate, nasophar-
ynx, and cribriform plate. Therefore the first presenting 
signs of URT aspergillosis in cats may be referable to 
orbital invasion resulting in sino-orbital aspergillosis 
(SOA), which can be considered a progression from SNA.
Clinical signs in SOA are the result of an invasive ret-
robulbar fungal granuloma and include exophthalmos, 
prolapse of the nictitating membrane, exposure keratitis, 
a lesion (mass or ulcer) in the pterygopalatine fossa, and 
stertor.
The fungal pathogens identified in the majority of 
feline cases, Neosartorya spp., are related to, but distinct 
from, the major canine pathogen, Aspergillus fumigatus. 
Until more information is available on the most effective 
treatment for feline aspergillosis, the prognosis remains 
guarded, especially for SOA. Topical antifungal triazole 
therapy using clotrimazole infusions in combination 
with an oral antifungal triazole is recommended for early 
SNA. In all other cases, systemic antifungal therapy using 
combinations of triazoles, amphotericin B, and terbin-
afine is indicated.
ETIOLOGY
Until recently, reports of feline URT aspergillosis have 
been limited, describing infections in a total of 13 cats.1-9 
The affected cats presented with signs referable to sino-
nasal cavity infection (eight cases) or sino-orbital infec-
tion (five cases). The fungal pathogen often was not 
identified in these reports, either because fungal culture 
was negative or was not performed. In five cases in which 
fungal culture was positive, isolates were proposed to be 
Aspergillus spp. in four cases and Penicillium spp. in 
another.1,2,6,8,9 Identification to species level based on 
morphological and cultural characteristics was performed 
in only two cases, in which A. fumigatus and A. niger were 
documented.8,9
In 2006 three cases of feline URT aspergillosis were 
diagnosed at the authors’ institution. This prompted a 
search of our medical records, which identified only three 
cases in the preceding 19-year period (January 1986 to 
December 2005). Following publication of a description 
of the syndrome of SOA and a call for cases, we actively 
recruited 15 additional cases for prospective study 
between 2007 and 2008.10 Clinicopathological data from 
the resulting cohort of 20 cats from Eastern Australia 
provide exciting new information on this disease in 
cats.11 Fungal pathogens were cultured readily. Culture 
was attempted in all 21 cases and was positive in 19. 
36
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Sabouraud’s dextrose agar was used with addition of gen-
tamicin and chloramphenicol when bacterial contamina-
tion of diagnostic samples was suspected. Cultures were 
incubated at 37° C and 28° C. On the basis of colony 
morphology, A. fumigatus was the most common isolate 
identified in this cohort. However, it is important to 
understand that the correct identification of some species 
of fungi belonging to Aspergillus section Fumigati can not 
be achieved using morphological and cultural character-
istics alone.12,13 Therefore molecular diagnostics were per-
formed on the fungal cultures and/or on formalin-fixed 
paraffin embedded (PE) or fresh tissues from affected cats 
to confirm the identity of the isolates. A panfungal poly-
merase chain reaction (PCR) that amplifies the internal 
transcribed spacer 1 (ITS1) region of the ribosomal DNA 
gene cluster between the 18S and 5.8S rRNA genes was 
used for PE or fresh tissues. A second panfungal PCR that 
targets a larger region of the rDNA gene cluster including 
the ITS1, 5.8S gene, and ITS2 regions was carried out on 
material obtained from fungal culture. These regions of 
the fungal genome were chosen because they are multi-
copy (= 100 copies in the fungal genome) and because 
they contain highly variable regions facilitating species 
identification in some cases. Polymerase chain reaction 
products were sequenced and compared with those in the 
GenBank database.14,15
Significantly, results of these molecular analyses indi-
cated that the majority of feline isolates that had been 
identified as A. fumigatus based on culture morphology 
were actually Neosartorya spp. (Table 5-1). In most cases, 
it was not possible to classify the fungal pathogen further 
using the panfungal PCR because of limited sequence 
variation in the ITS1 region; for example, it was not pos-
sible to distinguish between N. udagawae, N. fischeri, and 
N. aureola. In one case, N. pseudofischeri was identified 
from PCR of both culture material and fresh tissue with 
100 per cent identity to sequences in the GenBank data-
base. In four cats, A. fumigatus was identified using both 
fungal colony morphology and PCR of culture material 
or tissue. In three of these cats, disease was confined to 
the sinonasal cavity. Polymerase chain reaction of fungal 
culture material and/or tissue obtained from seven canine 
SNA cases also was carried out and identified A. fumigatus 
in all cases.14 These findings suggest that A. fumigatus 
possibly may be associated with less invasive disease. Our 
experience has demonstrated that, unlike SNA in dogs, 
the most common isolates in URT aspergillosis in cats are 
Neosartorya spp. and that molecular diagnostic tests are 
required for the correct identification of these fungal 
pathogens.
CLASSIFICATION OF FUNGAL PATHOGENS
Both Aspergillus spp. and Neosartorya spp. are implicated 
as fungal pathogens in feline URT aspergillosis. These two 
genera are very closely related, and a brief review of their 
taxonomy is pertinent. Both are classified within Aspergil­
lus section Fumigati. These ubiquitous, filamentous, sap-
rophytic ascomycetes are distributed primarily in soil and 
decaying vegetation.16 Confusion may arise over nomen-
clature because fungi can exist in different physical states 
corresponding to different stages of the life cycle; the 
anamorphic, asexual stage typically is moldlike and bears 
conidia (spores), whereas the teleomorphic, sexual stage 
is characterized by the production of fruiting bodies (cle-
istotheica) containing ascospores. The total organism is 
referred to as the holomorph. Some Aspergillus species are 
strictly anamorphic and therefore reproduce by asexual 
means only. Teleomorphic species within Aspergillus 
section Fumigati have been assigned to the genus Neosar­
torya. Aspergillus section Fumigati currently includes 9 
strictly anamorphic Aspergillus spp. and 24 Neosartorya 
spp.16,17 Aspergillus fumigatus, previously thought to be 
strictly anamorphic, was shown recently to have a fully 
functional sexual reproductive cycle that leads to the 
production of cleistothecia and ascospores. Its teleo-
morph is Neosartorya fumigata.17a
Species implicated in feline URT aspergillosis are listed 
in Table 5-2. Neosartorya spp. can exist in both anamor-
phic and teleomorphic states. The anamorphic states of 
some Neosartorya spp. can be mistaken for A. fumigatus, 
if identification is based on phenotypic characteristics 
such as thermotolerance and conidiophore morphol-
ogy.13,14 Phenotypic identification of Neosartorya spp. can 
be achieved partially from its teleomorph, including mor-
Table 5-1 Comparison of Fungal Culture Morphology versus PCR of Fungal Culture and/or Formalin-Fixed 
Paraffin-Embedded Tissues (PE) or Fresh Tissue for Fungus Identification (ID) in 18 Cases
Number of Cases SOA or SNA
Fungal Culture 
Morphology ID PCR of Fungal Culture ID PCR of PE or Fresh Tissue ID
1 SNA A. fumigatus ND A. fumigatus
3 SNA (2)
SOA (1)
A. fumigatus A. fumigatus ND
1 SNA A. fumigatus N. fischeri/ N. aureola / 
N. udagawae
ND
1 SOA Negative ND A. lentulus/Neosartorya spp.
1 SOA A. fumigatus N. pseudofischeri N. pseudofischeri
12 SOA A. fumigatus N. fischeri/ N. aureola / 
N. udagawae
ND (n = 7)
Negative (n = 2)
A. lentulus/N. fischeri (n = 2) C
August_Chapter 5_main.indd   37 5/12/2009   8:35:39 PM
Appendix 2
160
Section I Infectious Diseases38
phology of ascospores. However, induction of the teleo-
morphic state of Neosartorya spp. to produce these fruiting 
bodies can be achieved only under specific growth condi-
tions with specialized media. Even under optimal condi-
tions, some species may not produce fruiting bodies in 
the laboratory.14 Because of these limitations for species 
identification using morphological criteria alone, a poly-
phasic taxonomic approach is recommended for identifi-
cation of species within Aspergillus section Fumigati. This 
involves a combination of macromorphology and micro-
morphology, extrolite (fungal metabolite) profiles, and 
PCR determination of gene sequences including ß-tubu-
lin, calmodulin, ITS, and actin.16,18 The phylogenetic 
relatedness of species belonging to Aspergillus section 
Fumigati, including pathogens implicated in feline URT 
aspergillosis based on ß-tubulin sequence data, is depicted 
in Figure 5-1.
EPIDEMIOLOGY AND RISK FACTORS
No age or sex predilection for feline URT aspergillosis is 
apparent. Disease has been reported in 15 females and 18 
males; most were neutered. The median and mean age at 
diagnosis was 6 years, with a range from 18 months to 
13 years.1-9,11 An intriguing finding is the preponderance 
of brachycephalic cats affected; sixteen of 34 cases were 
brachycephalic, including eight Persians and six Himala-
yans. This contrasts starkly with canine SNA, in which 
dolichocephalic or mesocephalic breeds are typically 
affected.19 The basis for this potential brachycephalic 
breed association in cats is not clear. Impaired drainage 
of URT secretions due to brachycephalic conformation 
may be important. Certainly, decreased sinus aeration 
and drainage of respiratory secretions secondary to infec-
tion, polyps, and allergic rhinosinusitis have been identi-
fied as risk factors for invasive SNA aspergillosis in human 
beings.20 It is likely that additional risk factors are present 
in brachycephalic cats because brachycephalic dogs are 
Table 5-2 Species Belonging to Aspergillus Section 
Fumigati that Have Been Implicated in 
Feline Sinonasal and Sinorbital 
Aspergillosis16
Strict Anamorphic Species Teleomorph
Aspergillus lentulus
Aspergillus viridinutans
None
Anamorph Teleomorphic Species
Aspergillus aureoluteus
Aspergillus fischeranus
Aspergillus thermomutatus
Aspergillus udagawae
Aspergillus fumigatus
Neosartorya aureola
Neosartorya fischeri
Neosartorya pseudofischeri
Neosartorya udagawae
Neosartorya fumigatu
Figure 5-1 Based on ß-tubulin 
sequence data, the phylogenetic 
relatedness of species belonging to 
Aspergillus section Fumigati, including 
pathogens implicated in feline upper 
respiratory aspergillosis is depicted.
N. spinosa CBS 483.65
N. warcupii NRRL 35723
A. unilateralis CBS 126.56
N. papuensis CBS 841.96
N. assulata KACC 41691
N. aurata CBS 466.65100
N. stramenia CBS 498.65 
N. galapagensis CBS 117522
N. multiplicata CBS 646.95
N. australensis CBS 112.55
N. fennelliae CBS 598.74
N. denticulata CBS 652.73a
N. ferenczii NRRL 4179
N. glabra CBS 111.55
N. nishimurae IFM 54133
A. turcosus KACC 42091
N. tatenoi CBS 407.93
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100
97
95
76 98
86
85
99
N. aureola CBS 105.55
N. udagawae CBS 114217
A. viridinutans CBS 127.56
N. laciniosa KACC 41657
A. fumigatiaffinis IBT 12703
A. novofumigatus IBT 16806
N. coreana KACC 41659
N. fischeri CBS 544.65
A. fumigatus CBS 133.61
A. lentulus FH5
A. fumisynnematus IFM 42277
N. hiratsukae CBS 294.93
N. spathulata CBS 408.89
N. pseudofischeri CBS 208.92
N. quadricinta CBS 135.52
A. brevipes CBS 118.53
A. duricaulis CBS 481.65
A. clavatus CBS 513.65100
0.02C
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underrepresented for SNA. These factors may include 
heritable defects in mucosal immunity or common envi-
ronmental factors such as antecedent URT infection. Pre-
vious viral URT infection by feline calicivirus (FCV) or 
feline herpesvirus-1 (FHV) has been suggested as a pos-
sible risk factor for aspergillosis in cats.7 In particular, 
chronic FHV infection can alter sinonasal cavity architec-
ture severely because of turbinate lysis secondary to 
intense inflammation, resulting in altered local mucosal 
defense mechanisms. Six of 20 cats in one study had a 
history of chronic recurrent rhinosinusitis before asper-
gillosis was diagnosed, and FHV infection was confirmed 
by PCR in one cat.11 Other possible risk factors identified 
were craniofacial trauma, diabetes mellitus, and a grass 
seed foreign body. There is no evidence currently of a 
retroviral association with feline URT aspergillosis; of 19 
cats with aspergillosis tested for feline leukemia virus 
(FeLV) antigen, only one was positive, and all 19 cats 
tested for feline immunodeficiency virus (FIV) were sero-
negative.3,5-9,11 Therefore it appears that URT aspergillosis 
in cats occurs in apparently systemically immunocompe-
tent individuals, some of whom have identifiable breaches 
in local defense mechanisms.
Information on the prevalence and geographic distri-
bution of feline URT aspergillosis is incomplete but is 
likely to be forthcoming now that the syndrome of SOA 
has been described.10 The apparent increased prevalence 
at our institution is likely a consequence of increased 
recognition of cases. Cases have been reported most com-
monly in Eastern Australia (including 12 cats domiciled 
in New South Wales, two in Victoria, and seven in 
Queensland) and the United States, with individual cases 
from Switzerland and the United Kingdom.1-3,5-9,11
PATHOGENESIS
Aspergillus spp. and Neosartorya spp. are ubiquitous and 
their spores are inhaled readily. Aspergillus spp. can cause 
localized sinusitis in immunocompetent human beings 
or severe systemic disease as an opportunistic pathogen 
in immunocompromised human patients. Neosartorya 
spp. have been associated only rarely with disease; iso-
lated cases of invasive pulmonary infection, osteomyeli-
tis, endocarditis, peritonitis, and mycotic keratitis have 
been described in immunocompromised human beings.13 
The difficulty in distinguishing A. fumigatus from Neosar­
torya spp. using morphological criteria is likely to have 
resulted in underestimation of the frequency of disease 
caused by Neosartorya spp.13
Compared to SNA in dogs in whom fungal infection 
generally is confined to the sinonasal cavity, infection in 
cats appears to have a greater tendency to local invasion, 
with extension to involve the orbit. Of the 34 reported 
cases, 14 cats had SNA and 20 had SOA.1,2,5,6,9,11 A brief 
consideration of mycotic rhinosinusitis syndromes in 
human beings has comparative significance because these 
syndromes can be either invasive or noninvasive. Inva-
sive mycoses include acute (necrotizing) invasive fungal 
sinusitis, chronic invasive fungal sinusitis, and chronic 
granulomatous fungal rhinosinusitis. Noninvasive infec-
tions include fungal ball or sinus aspergilloma, allergic 
fungal sinusitis, and chronic erosive noninvasive fungal 
sinusitis.21-24 Canine SNA bears many similarities to 
chronic erosive noninvasive fungal sinusitis in human 
patients and recently has been proposed as a model for 
studying the immunopathogenesis of disease in people.24 
A. fumigatus is the most common pathogen in dogs, 
although A. niger, A. nidulans, and A. flavus are implicated 
occasionally. A. fumigatus or A. flavus are isolated most 
commonly from human patients.19,22,,24 Neither dogs nor 
human beings with this type of SNA are immunocompro-
mised systemically. Fungal hyphae do not invade the 
nasal mucosa and typically are present within overlying 
superficial necrotic plaques. There is a mixed mononu-
clear inflammatory response within the often ulcerated 
nasal mucosa that contains lymphocytes and plasma cells 
predominantly, with some macrophages.19,21,22
Like SNA in dogs, infection in cats starts almost cer-
tainly in the sinonasal cavity. It is likely that SNA and 
SOA in cats represent a spectrum of disease, with SOA 
being a manifestation of more chronic, invasive infection 
and progression from SNA. Progression from SNA to SOA 
has been documented in individual cases.6 However, not 
all cases of SNA progress to SOA. Virulence factors of the 
fungal pathogen, including toxic secondary metabolites, 
are likely to be involved. Gliotoxin is considered an 
important virulence factor in invasive aspergillosis in 
human patients. All 20 cases of SOA in cats showed evi-
dence of sinonasal cavity involvement on diagnostic 
imaging or at necropsy.* The orbital lamina, situated 
between the orbit and frontal sinus, is the most likely 
region where extension of infection from the sinonasal 
cavity to the orbit occurs. Computed tomographic (CT) 
examination of the skull in cases of SOA frequently iden-
tifies punctate areas of lysis in the orbital lamina (Figure 
5-2). In one case of SOA, a fistula was identified at surgery 
in the dorsomedial aspect of the orbit, communicating 
with the ipsilateral frontal sinus.11 Systemic dissemina-
tion of disease is rare. A single case of feline SOA with 
Figure 5-2 Transverse CT of skull of a cat with SOA. There is a 
right retrobulbar mass and diffuse opacification of the left nasal 
cavity. Punctate areas of lysis are visible in the right orbital 
lamina.
*References 1, 2, 5, 6, 9, 11. C
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concurrent pulmonary involvement has been reported. 
The retroviral status of that cat was unknown.1
SOA in cats bears a striking clinical and histological 
resemblance to chronic granulomatous sinusitis in people. 
The latter is an invasive mycosis caused by A. flavus or A. 
fumigatus that occurs in immunocompetent human 
beings subjected to hot, dry environmental conditions 
and poor hygiene. Most cases have been reported in Asia 
and Africa, predominantly in agricultural workers. The 
nasal cavity or sinuses invariably have been implicated as 
the primary site of infection following inhalation of 
fungal spores. A fungal granuloma forms within the 
sinuses. These granulomas are relatively avascular, con-
sisting of a highly cellular inflammatory infiltrate of epi-
thelioid macrophages (“giant cells”), histiocytes, plasma 
cells, and fungal hyphae. They may be necrotic or fibrotic 
and tend to invade contiguous structures such as the 
orbit or brain. Unilateral exophthalmos is common at 
presentation.20,23 The histological features of URT asper-
gillosis in cats are not fully characterized. Both lympho-
plasmacytic and suppurative noninvasive rhinitis have 
been described for infections confined to the sinonasal 
cavity.7,8 SOA is clearly invasive, and we have found evi-
dence of submucosal infection in the sinonasal cavity of 
affected cats.11 In feline SOA, the granulomas are charac-
terized by a necrotic center containing fungal hyphae. 
This is surrounded by granulation tissue that may be 
fibrous, infiltrated with neutrophils, lymphocytes, plasma 
cells, and eosinophils.1,2,9 Commonly, we have seen ret-
robulbar granulomas surrounding the optic nerve. They 
typically feature a necrotic center containing branching 
septate PAS-positive fungal filaments and an inflamma-
tory infiltrate of sheeting epithelioid macrophages with 
variable numbers of lymphocytes, plasma cells, and neu-
trophils extending into a zone of peripheral fibrosis 
(Figure 5-3). These fungal granulomas are well vascular-
ized and in some cases are accompanied by heavy infil-
trates of eosinophils.
HISTORY AND CLINICAL SIGNS
SINONASAL ASPERGILLOSIS
In dogs, the triad of muzzle pain, profuse mucoid to 
hemorrhagic chronic nasal discharge and depigmenta-
tion, and crusting or ulceration of one or both nares is 
highly suggestive of SNA. In cats, presenting signs of SNA 
are less specific. Most affected cats will have a history of 
sneezing and a unilateral or bilateral serous to mucopu-
rulent nasal discharge that usually can be detected on 
physical examination (Figure 5-4). Intermittent epistaxis 
occurs in 40 per cent of cats with SNA. Interestingly, and 
in contrast to dogs, neither nasal depigmentation nor 
ulceration has been documented to date in cats with SNA. 
A discharging sinus or soft tissue mass may be identified 
overlying the frontal sinus or the nasal bone as a result 
of bony lysis and fungal proliferation (Figure 5-5). Facial 
distortion may be a feature.
Owners should be questioned specifically regarding 
any URT noise because this may be subtle, and the pattern 
of respiration should be evaluated carefully on physical 
examination. If it can be established that the cat has a 
stertor, at least part of the disease process can be localized 
to the caudal nasal cavity and/or nasopharynx. The 
stertor in SNA may result from excessive nasal secretions 
and/or a mass lesion in the caudal nasal cavity and/or 
nasopharynx (Table 5-3).
SINO-ORBITAL ASPERGILLOSIS
Although most cats with SOA have a history of sneezing 
or nasal discharge in the 6 months prior to presentation, 
it is important to note that, at the time of presentation, 
nasal signs may be subtle or absent. Rather, cats with SOA 
present typically with a constellation of clinical signs 
Figure 5-3 Histological examination of a retrobulbar fungal granuloma from a cat with SOA. A, Low magnification. 
B, High magnification. Within the necrotic center are branching, septate PAS-positive fungal filaments, surrounded 
by an inflammatory infiltrate of sheeting epithelioid macrophages with variable numbers of lymphocytes, plasma 
cells, and neutrophils, extending into a zone of peripheral fibrosis.
A
500 µm
B
20.0 µm
C
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referable to invasive expansion of a fungal granuloma in 
the ventromedial orbit. These include unilateral exoph-
thalmos with third eyelid prolapse, exposure keratitis and 
conjunctival hyperemia (Figure 5-6), and a mass or ulcer 
in the ipsilateral pterygopalatine fossa behind the last 
molar tooth (Figure 5-7). Stertor also is common. In the 
majority of affected cats, exophthalmos is unilateral, but 
in severe, chronic infections, bilateral exophthalmos can 
occur. Pain on opening the mouth typically is not present. 
In one cat with confirmed fungal sinusitis, marked uni-
lateral exophthalmos resulted from retrobulbar myo-
fascitis rather than from a fungal granuloma.5 Invasion 
Figure 5-4 The presenting complaint in this Persian cat with SNA 
was sneezing and unilateral right nasal discharge.
Figure 5-5 In addition to nasal discharge and sneezing, this cat 
with SNA had a discharging sinus over the left frontal sinus.
Table 5-3 Spectrum of Clinical Signs in Cats with 
SNA and SOA
Clinical Presentation Clinical Signs
Sinonasal aspergillosis Nasal discharge
Discharging sinus/mass over 
frontal sinus or nasal bone
Stertor
Epistaxis
Sino-orbital aspergillosis Exophthalmos
Corneal ulceration
Conjunctival hyperemia
Mass or ulcer, pterygopalatine 
fossa
Ulceration of hard palate
Discharging sinus over frontal 
sinus
Mandibular lymph node enlarged
Stertor
Pyrexia (temp > 39.3° C)
Figure 5-6 Unilateral exophthalmos with A, prolapse of the third 
eyelid, and B, deep corneal ulceration, in two cats with SOA.
A
B
C
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through the palatine bone can cause ulceration of the 
hard palate (Figure 5-8).
In addition to exophthalmos, extension of infection 
outside the sinonasal cavity can result in facial distortion, 
including swelling of the nasal bridge, periorbital tissues, 
and soft tissues adjacent the maxilla (Figure 5-9). Neuro-
logical signs can develop subsequent to invasion of the 
central nervous system (CNS) through the cribriform 
plate or sphenoid sinus. One cat with intracranial exten-
sion of disease from the sphenoid sinus had hyperesthe-
sia and blindness due to involvement of the optic 
chiasm.11 Submandibular lymph node enlargement and 
pyrexia also are common at presentation (see Table 5-3). 
In contrast, cats with SNA usually are not pyrexic.
DIFFERENTIAL DIAGNOSIS
The differential diagnoses for URT aspergillosis depend 
on whether cats present with signs referable to sinonasal 
cavity infection or to orbital infection, or both. For cats 
presenting with chronic nasal discharge and sneezing, 
many infectious, inflammatory, neoplastic, and other 
causes are possible (Box 5-1). Consideration should be 
Figure 5-7 Three cats with SOA with a mass (A and B) or ulcer (C) in the 
pterygopalatine fossa.
A
B
C
Figure 5-8 Invasion of a retrobulbar fungal granuloma through 
the palatine bone has resulted in ulceration of the hard palate and 
a mass in the left pterygopalatine fossa.C
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given to the age and breed of the cat to help rank dif-
ferential diagnoses. Brachycephalic conformation should 
increase suspicion for SNA, although these cats also are 
overrepresented for viral URT infections. When epistaxis 
is reported, ulcerative rhinitis, neoplasia, or mycotic rhi-
nitis are more likely. Because secondary bacterial rhinitis 
is common, a transient response to antimicrobial therapy 
does not exclude mycotic rhinitis or neoplasia. Although 
our experience suggests that feline URT aspergillosis is 
more common than thought previously, cryptococcosis 
remains the most commonly described cause of mycotic 
rhinitis. For cats with stertor and suspected nasopharyn-
geal mass lesions, nasophar yngeal polyps and cryptococ-
cosis are common inflammatory causes, while lymphoma 
is the most common neoplastic cause.25
The syndrome of clinical signs present in cats with 
SOA could occur with other expansive infectious or neo-
plastic processes occurring within the orbit. Inability to 
retropulse the exophthalmic globe enables differentiation 
from buphthalmos or abnormal enlargement of the 
globe. The differential diagnoses for retrobulbar mass 
lesions are listed in Box 5-2. Direct extension of any of 
these processes to involve the sinonasal cavity could 
result in concurrent nasal discharge, sneezing, and/or 
epistaxis. For example, orbital lymphoma may be indis-
tinguishable clinically from SOA (Figure 5-10).
DIAGNOSIS
Definitive diagnosis of URT aspergillosis in cats is achieved 
by cytological or histological identification of fungal 
hyphae in affected tissue, together with identification of 
the fungal pathogen using culture and a polyphasic taxo-
nomic approach, as described previously (see section on 
classification of fungal pathogens). Obtaining a definitive 
Figure 5-9 Right exophthalmos, third eyelid prolapse, and facial 
distortion including swelling of the nasal bridge and maxillary soft 
tissues in a cat with SOA.
Box 5-1 Differential Diagnoses of Sinonasal Cavity 
and Nasopharyngeal Disease in Cats
Neoplasia
Lymphoma
Carcinoma
Other
Inflammatory
Nasal/nasopharyngeal polyp
Nasopharyngeal stenosis
Infectious
Viral
Feline herpesvirus-1
Feline calicivirus
Mycotic nasopharyngeal diseases
Cryptococcosis
Aspergillosis
Phaeohyphomycosis
Blastomycosis
Histoplasmosis
Trichosporonosis
Sporotrichosis
Bacterial infections (primary)
Mycoplasma spp.
Bordetella bronchiseptica
Chlamydophila felis
Mycobacteria spp.
Actinomyces spp.
Foreign body
Congenital
Choanal atresia
Palatine defects
Dental disease
Oronasal fistula
Advanced periodontal disease
Tooth root abscess
Accumulation of excessive nasal secretions
Box 5-2 Differential Diagnoses of Feline Retrobulbar 
Mass Lesions
Foreign body (e.g., grass awns)
Abscess (odontogenic, penetrating bite wound, 
hematogenous)
Orbital myofascitis (medial pterygoid muscle)
Zygomatic salivary gland and lacrimal gland disease
Mycotic granuloma
Phaeohyphomycosis
Cryptococcosis
Aspergillosis
Pythiosis
Orbital pseudotumor
Orbital fat prolapse
Neoplasia
Squamous cell carcinoma
Lymphoma
Adenocarcinoma/undifferentiated carcinoma
Fibrosarcoma
Melanoma
Osteoma/osteosarcoma C
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diagnosis may require various combinations of diagnostic 
tests including radiography, CT, endoscopy, cytology, 
serology, fungal culture, and advanced mycological tech-
niques. A stepwise diagnostic approach is recommended 
because there are many other differential diagnoses.
In cats with signs of sinonasal cavity disease, physical 
examination should include otoscopic examination to 
identify chronic otitis media and/or inflammatory polyps 
(see Chapter 30). Neurological examination is recom-
mended because neurological sequelae such as otitis 
media/interna may occur with nasopharyngeal diseases 
and because infection can extend intracranially in cats 
with aspergillosis. Noninvasive investigations should be 
performed next, including hematology, serum biochem-
istries, urinalysis, serology, and thoracic radiography, to 
determine lower respiratory tract involvement. Retroviral 
serology should be performed routinely. Serological tests 
for aspergillosis are discussed in the next section.
A latex cryptococcal antigen agglutination test (LCAT) 
should be performed to exclude cryptococcal rhinitis. 
This test is sensitive and specific for the diagnosis of 
cryptococcosis. Fungal culture of superficial swabs from 
the rostral nasal cavity or nasal discharge is not recom-
mended as a stand-alone test for the diagnosis of aspergil-
losis or cryptococcosis because these fungi may be 
contaminants or asymptomatic colonizers in this loca-
tion.26,27 However, isolation of Cryptococcus spp. in a 
patient with a positive LCAT or with cytological or 
histopathological evidence of infection is highly 
significant.
Bacterial culture of superficial nasal swabs rarely is 
rewarding due to the presence of normal flora and because 
bacterial rhinitis usually occurs secondary to an underly-
ing disease. For cats with suspected viral URT infection, 
confirmatory tests including virus isolation, immuno-
fluorescence, enzyme-linked immunosorbent assay 
(ELISA), or PCR can be performed using oropharyngeal or 
conjunctival swabs. When enlarged local lymph nodes or 
facial soft tissue masses are identified, they should be 
aspirated for cytological examination and culture. For 
cats presenting with exophthalmos, diagnostic investiga-
tion should include fluorescein staining of the cornea, 
retinal fundic examination, and evaluation of the orbit, 
in addition to investigation of the sinonasal cavity. 
Transocular ultrasonography is an expedient tool for con-
firmation of a retrobulbar mass. The next step of the 
investigation, incorporating diagnostic imaging, endo-
scopic examination of the sinonasal cavity, and biopsy 
collection is performed with the patient anesthetized.
RESULTS OF DIAGNOSTIC INVESTIGATIONS 
FOR CATS WITH URT ASPERGILLOSIS
Hematology and Serum Biochemistries
Results of complete blood counts and serum biochemis-
try profiles usually are unremarkable or they may reflect 
inflammation: for example, an inflammatory leukogram 
and hyperglobulinemia.6,9,11 Establishing pretreatment 
renal function and baseline liver enzyme values is impor-
tant, because nephrotoxicity and hepatotoxicity are 
common with some antifungal drugs (see treatment).
Serology
Serological tests for aspergillosis include detection of 
serum anti-Aspergillus antibodies or detection of Asper­
gillus antigen. Use of the former test has been described 
as an adjunct to the diagnosis of SNA in dogs. Antibodies 
can be detected by three methods; counterimmunoelec-
trophoresis (CIE), agar gel immunodiffusion (AGID), or 
ELISA. The AGID test, based on the principle of double 
diffusion, is used most commonly. In recent studies 
using a commercially available standardized purified 
aspergillin composed of A. fumigatus, A. niger, and A. 
flavus, the sensitivity of AGID was found to be good (67 
to 77 per cent) and the specificity was excellent in dogs 
(97 to 100 per cent).27,28 The ELISA has the advantage of 
quantification of serum immunoglobulins and, using the 
same antigen preparation as the AGID, has good sensitiv-
ity and excellent specificity.28 There is little information 
on the diagnostic utility of serum anti-Aspergillus anti-
body detection in URT aspergillosis in cats and specificity 
has not been evaluated. Two of three cats with SNA tested 
positive for serum antibodies against A. fumigatus using 
CIE, and another cat with SNA tested positive using 
AGID.3,7
Galactomannan (GM) is a water-soluble polysaccha-
ride cell wall component of Aspergillus and some other 
fungal species that is released in variable quantities during 
hyphal growth in tissues. This antigen can be detected in 
the serum of human patients with invasive Aspergillus 
infections using a commercially available sandwich ELISA 
(Platelia Aspergillus). GM antigen levels correlate with the 
tissue fungal burden and can be used to monitor clinical 
outcome and response to therapy. Rising GM levels are 
often associated with treatment failures in human 
Figure 5-10 Differential diagnoses for SOA include neoplastic 
and infectious expansive orbital masses. This cat with right 
exophthalmos, purulent left nasal discharge, and an ulcerative 
plaque on the hard palate had orbital lymphoma.
C
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patients.29 There are limitations to the use of the GM 
ELISA in patients with invasive aspergillosis. For example, 
false-positive results can occur following treatment with 
ß-lactam antibiotics due to contamination with cell wall 
components of Penicillium spp. during drug production. 
The sensitivity of the GM ELISA varies considerably with 
immune status. In profoundly immunocompromised 
patients, sensitivity is greater than 90 per cent, while in 
less immunocompromised patients, sensitivity may be as 
low as 30 per cent. This is partly due to a lower fungal 
burden in the latter group. Further, concurrent antifungal 
therapy may delay detection of GM and result in lower 
GM levels due to decreased fungal load.29 This same com-
mercially available ELISA has been evaluated in dogs and 
was found to be unreliable for the diagnosis of SNA.28 A 
GM optical density (OD) index of greater than 0.5 was 
considered to be positive. This is the accepted standard 
for diagnosis of invasive aspergillosis in human beings 
and the standard recommended by the manufacturer. 
Test results were positive in 24 per cent of dogs with SNA, 
11 per cent of dogs with nasal tumors, 9 per cent of dogs 
with lymphoplasmacytic rhinitis, and 24 per cent of 
control dogs.28 Given that SNA in dogs is noninvasive, 
the low sensitivity is hardly surprising. Reasons for poor 
specificity were not identified; concomitant use of ß-lac-
tam antimicrobials was found to have a negligible influ-
ence on results in dogs.
The use of GM assays for diagnosis and monitoring of 
feline aspergillosis has not been evaluated. GM was mea-
sured in six of our culture-positive cases using the Platelia 
Aspergillus assay. Using a cut-off value of 0.5, three cats 
with SOA were negative (GM OD index 0.11 to 0.34), one 
cat with SNA was positive at 20.98, and two cats with 
SOA were positive at 18.22 and 3.82. In the latter case, 
in which combination antifungal treatment using ampho-
tericin B, posaconazole, and terbinafine failed, the GM 
OD index increased subsequently to 14.83. Further studies 
are underway to investigate the use of GM assay in diag-
nosis and monitoring of therapy in cats with URT 
aspergillosis.
Diagnostic Imaging—Radiography, CT, 
and Ultrasonography
Imaging studies should be performed prior to more inva-
sive diagnostic procedures including rhinoscopy and 
biopsy because any resultant inflammation or hemor-
rhage may obscure subtle lesions and induce imaging 
abnormalities. For cats presenting with exophthalmos, 
transocular ultrasonography is recommended to identify 
retrobulbar mass lesions (Figure 5-11). For further inves-
tigation of suspected sinonasal cavity or sino-orbital 
disease, CT is the diagnostic imaging modality of choice. 
Both CT and magnetic resonance imaging (MRI) have the 
advantage over conventional radiography of cross-sec-
tional imaging. Other advantages of CT over conven-
tional radiography demonstrated in dogs with SNA 
include increased diagnostic sensitivity, ability to adjust 
the contrast scale to optimize optical density and dis-
criminate fine turbinate structures, and better evaluation 
of the cribriform plate using multiplanar reconstruc-
tions.30,31 Computed tomography generally is superior to 
MRI for the evaluation of destructive lesions in bony 
structures contiguous with the sinonasal cavity. In cats 
with suspected intracranial extension of infection, MRI 
after intravenous contrast administration is superior to 
CT for evaluation of intracranial soft-tissues.
Regardless of which imaging modality is used, the 
nasal cavity, nasopharynx, frontal sinuses, and tympanic 
bullae should be evaluated routinely. In patients with 
nasopharyngeal mass lesions, occlusion of the auditory 
tubes can result in secondary bullous effusion, which 
may be asymptomatic.32 If radiography is used, views 
should include lateral skull, ventrodorsal skull, dorso-
ventral occlusal view or open-mouth ventrodorsal view, 
and rostrocaudal open-mouth or rostral 10° ventrocau-
dodorsal oblique views. Findings on radiography in cats 
with SNA and SOA include destructive rhinitis, lysis 
of paranasal bones, and focal increased soft tissue 
opacities.3,7
We have performed CT on 10 cats with URT aspergil-
losis, including three with SNA and seven with SOA. Our 
findings are summarized in Table 5-4. The most common 
findings were punctate lysis of the orbital lamina (see 
Figure 5-2), opacification of the sphenoid and frontal 
sinuses due to fluid or soft tissue (Figure 5-12), and a soft 
tissue mass in the choanae or nasopharynx. Eight of the 
10 cases had punctate lysis of the orbital lamina, includ-
ing two of three cases of SNA. Of the seven cases of SOA, 
six had an orbital mass, and in one case the CT was per-
formed after exenteration of the orbit. There was irregular 
enhancement of the orbital mass in all cases after intra-
venous contrast administration (Figure 5-13). Orbital 
masses were present in the ventromedial aspect of the 
orbit, causing lateral and dorsal displacement of the 
globe. In five cats with SOA, there was a mass effect 
involving the soft tissues adjacent the maxilla, and four 
cats had soft tissue palatine masses. Punctate lysis of the 
cribriform plate was seen in two cases, one cat with SNA 
and one with SOA (Figure 5-14). Thickening of the 
mucosa adjacent to the inner surface of the bones of the 
frontal sinus, a typical finding in canine SNA, was seen 
in three cats, one with SNA and two with SOA (Figure 
Figure 5-11 Transocular ultrasound of a cat with a retrobulbar 
fungal granuloma, 10 MHz linear probe.
C
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5-15).30,31 There was evidence of unilateral sinonasal 
cavity involvement in three cases and of bilateral disease 
in seven affected cats. The tympanic bullae were normal 
in all cases. Computed tomographic findings in previ-
ously reported cases (six cats with SNA and three cats 
with SOA) were similar, except for one case of SNA in 
whom a free, irregular calcified mass was present in the 
cranial part of the right nasal cavity.5-9 On histological 
examination, the mass was identified as calcified necrotic 
tissue containing fungal hyphae. Concretions formed 
from deposition of calcium oxalate or phosphate crystals 
within tissues occur in human patients with sinus 
aspergilloma.33
Computed tomographic findings in cats with SOA are 
similar to those in human beings with chronic invasive 
fungal sinusitis and chronic granulomatous invasive 
Table 5-4 Computed Tomographic Findings in 10 Cases of Feline URT Aspergillosis
Structure Lysis Sclerosis
Soft Tissue or 
Fluid Density Thickened Mucosa Soft Tissue Mass
Turbinates 5 3 4
Maxilla 4 5
Palate 3 4
Cribriform plate 2
Orbital lamina 8
Frontal sinus and frontal bone 2 7 3
Sphenoid sinus 7
Septum 2
Cribriform plate 2
Nasopharynx/choanae 7
Orbit 1 6
Data from three cats with SNA and seven with SOA. In one case, CT was performed after exenteration of the globe.11 Sinonasal abnormalities were 
unilateral in three cases and bilateral in seven cases.
Figure 5-12 Transverse CT of skull. Opacification of the sphenoid 
and left frontal sinuses and nasopharyngeal mass in a cat with an 
expansive left orbital fungal granuloma.
Figure 5-13 Postcontrast CT of cat in figure 5-12 showing 
irregular enhancement of the left orbital mass.
Figure 5-14 Sagittal CT skull. Punctate lysis of the cribriform plate 
and lysis of the nasal bone dorsally, in a cat with severe SNA.C
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Figure 5-15 Transverse CT skull. Thickening of the mucosa 
adjacent to the inner surface of the bone of the left frontal sinus 
in a cat with SNA.
fungal sinusitis.34 On noncontrast CT in human patients, 
a hyperattenuating soft tissue collection, sometimes 
masslike, within one or more paranasal sinuses is typical. 
There may be destruction of sinus walls and extension 
into adjacent tissues. In both human beings and cats with 
URT aspergillosis, differentiation of invasive mycotic 
disease from malignant neoplasia may not be possible 
from imaging findings alone. On CT, destruction of max-
illary turbinates is seen commonly in cats with inflam-
matory or neoplastic sinonasal disease.35 Severe destruction 
of both maxillary turbinates and ethmoturbinates, par-
ticularly when unilateral, and/or lysis of paranasal bones 
have been considered more predictive of sinonasal neo-
plasia than of inflammatory disease.35 However, there 
were no cases of mycotic rhinitis in the inflammatory 
disease group in that study. Many findings that were 
significantly associated with neoplasia are common in 
cats with URT aspergillosis, including unilateral lysis of 
ethmoturbinates, unilateral lysis of the maxilla, lysis of 
the vomer bone, lysis of the orbital lamina, and unilateral 
soft tissue or fluid within the sphenoid sinus, frontal 
sinus, and/or retrobulbar space.35
Collection of Diagnostic Biopsies
Nasopharyngoscopy and rhinoscopy are performed next 
to visualize the nasopharynx and nasal cavity and to 
obtain biopsy specimens for cytological and histological 
examination and culture. We freeze additional biopsy 
specimens routinely at this time. These samples can be 
retrieved for PCR if fungal hyphae are seen in tissues but 
fungal culture is negative. Because many cats with both 
SNA and SOA have granulomatous mass lesions contain-
ing fungal hyphae within the choanae or nasopharynx, 
retroflexed endoscopy using a pediatric bronchoscope 
often is rewarding (Figure 5-16). Masses in this location 
can be biopsied using endoscopic biopsy forceps. During 
nasopharyngeal endoscopy, each ventral nasal meatus is 
catheterized via the naris with a urinary catheter (size 5 
or 6 French gauge) to check patency and to help dislodge 
foreign material or masses. Regional anesthesia of the 
pharynx with 2 per cent topical lidocaine gel and maxil-
lary nerve blocks using 0.5 per cent bupivacaine facili-
tates a decreased plane of general anesthesia in some cats 
during nasopharyngeal endoscopy.
The rostral nasal cavity can be evaluated using rigid 
rhinoscopy to visualize turbinate destruction and fungal 
plaques. Rhinoscopes with constant irrigation systems 
that enable biopsies to be taken during direct examina-
tion are preferred because fungal plaques could be missed 
during blind collection.
Nasal cavity lavage may yield larger biopsy specimens 
than can be acquired endoscopically. Vigorous saline 
flushing from the nasal cavities into the nasopharynx is 
useful to dislodge foreign bodies and diagnostic frag-
ments of friable tumors such as lymphoma or granulo-
mas. A cuffed endotracheal tube should be used. The 
pharynx is packed with sterile swabs to trap flushed mate-
rial. A 10-mL aliquot of sterile saline is flushed briskly 
through one naris into the ventral nasal meatus while 
occluding the other naris. The procedure is repeated 
several times on each side. Culture of lavage fluid usually 
returns nonspecific results.
For cats with SOA, fine-needle biopsies of retrobulbar 
masses can be obtained under ultrasound guidance or via 
the oral cavity. Computed tomography–guided biopsies 
and aspirates also have been described.9 Computed 
tomography is useful to identify involvement of parana-
sal subcutaneous soft tissues and sinuses. The former can 
be biopsied surgically, and the latter can be accessed via 
sinus trephination. When sinus involvement is identified 
and diagnostic biopsies can not be collected during rhi-
noscopy or nasopharyngeal endoscopy, sinus trephina-
tion using a Jacob chuck and intramedullary pin (3.2 to 
4 mm diameter) enables endoscopic examination of the 
lateral compartment of the frontal sinuses and ready 
access to material for culture, histology, and PCR. This 
procedure should be performed with caution in brachy-
cephalic cats because they have shallow sinuses in close 
proximity to the cranial vault.
Figure 5-16 Choanal mass in a cat with SOA visualized using a 
retroflexed pediatric endoscope, before biopsy.
C
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TREATMENT AND PROGNOSIS
ANTIFUNGAL SUSCEPTIBILITY TESTING
The typical antifungal susceptibility profile of Neosartorya 
spp. isolated from cats with aspergillosis includes suscep-
tibility to amphotericin B and posaconazole, intermedi-
ate or dose-dependent susceptibility to itraconazole and 
voriconazole, and resistance to 5-flucytosine, ketocon-
azole, and fluconazole.11 In contrast, both voriconazole 
and posaconazole typically have greater activity than itra-
conazole in vitro against both A. fumigatus and other 
Aspergillus spp.36 Interestingly, elevated minimum inhibi-
tory concentrations (MICs) of voriconazole to Neosartorya 
spp. have been documented elsewhere.13 However, the 
correlation between in vitro antifungal susceptibility test 
results and in vivo response to therapy is only modest at 
best. Other factors that influence antifungal activity in 
vivo include drug pharmacokinetics (e.g., stability, 
metabolism, drug interactions, protein binding, metabo-
lites, tissue penetration), host factors (e.g., immune 
status, underlying disease), site of infection (e.g., presence 
of foreign body, source of infection), and virulence factors 
of the fungal pathogen.37 Further, in vitro results are 
influenced by technical factors including the concentra-
tion of the fungal inoculum, the composition and pH of 
the medium, incubation temperature, and duration of 
incubation.
SYSTEMIC ANTIFUNGAL THERAPY
For treatment of invasive aspergillosis in human beings, 
voriconazole has replaced amphotericin B as the drug of 
choice for first-line therapy. Posaconazole is used for anti-
fungal prophylaxis in high-risk patients and for salvage 
therapy. The echinocandins are reserved for salvage 
therapy or combination antifungal therapy for refractory 
invasive aspergillosis.38 Combination antifungal therapy 
may provide enhanced efficacy compared to single-drug 
therapy for treatment of invasive aspergillosis. This 
concept has been controversial because in previous 
studies, when mice with invasive aspergillosis were 
treated with ketoconazole prior to amphotericin B, there 
was a marked decrease in the efficacy of the latter drug. 
It was proposed that the azole blocked the synthesis of 
the ergosterol target necessary for the binding of ampho-
tericin B. Antagonism between itraconazole and ampho-
tericin B also has been demonstrated in vitro against 
isolates of A. fumigatus.39 However, more recently treat-
ment of murine models of invasive aspergillosis with a 
triazole antifungal (voriconazole or posaconazole) and 
amphotericin B was not antagonistic, and treatment with 
liposomal amphotericin B and voriconazole in combina-
tion was significantly superior to monotherapy with 
either drug.40,41
Triazole Antifungals
Triazole antifungals, which have three nitrogen mole-
cules in the azole ring, include fluconazole, itraconazole, 
voriconazole, and posaconazole. By binding to lanos-
terol-14a-demethylase, triazoles inhibit the synthesis of 
ergosterol, an essential lipid component of fungal cell 
walls. Fluconazole has low activity against filamentous 
fungi and is not recommended for treatment of aspergil-
losis.42 Itraconazole has fungistatic activity against Asper­
gillus, and its pharmacological disposition has been 
studied in cats.43 It is metabolized by the liver and dis-
tributed widely in body tissues other than the CNS. Oral 
bioavailability can be variable and is highest for capsules 
when administered with food and for oral solution when 
administered on an empty stomach. The oral solution is 
absorbed more effectively than capsules in cats, such that 
dose reduction may be necessary. Adverse effects includ-
ing gastrointestinal signs and hepatotoxicity are not 
uncommon, are usually dose related, and resolve on ces-
sation of therapy (Table 5-5). Voriconazole (structurally 
similar to fluconazole) and posaconazole (structurally 
similar to itraconazole) were developed as more effica-
cious agents for treating filamentous fungal infections 
and to improve on the absorption, tolerability, and drug 
interaction profile of itraconazole. Both voriconazole and 
posaconazole are fungicidal against Aspergillus. Their 
pharmacokinetics have been studied in human beings 
and dogs but not in cats at the time of writing.44,45 
Posaconazole is available only as a suspension for oral 
use. Its absorption is increased with food, especially high-
fat meals, and is optimal in human patients when given 
as four daily divided doses. Posaconazole is metabolized 
in the liver by glucuronidation and is excreted primarily 
in bile and urine. Common adverse effects include head-
aches and gastrointestinal signs such as nausea, diarrhea, 
and vomiting. Hepatoxicity is uncommon.42
Posaconazole was used in the treatment of 10 cats with 
URT aspergillosis (see Table 5-5).11 Inappetence and a 
twofold elevation in alkaline phosphatase (ALP) were 
seen in one cat, both of which resolved when the drug 
dosage was decreased. Posaconazole was well tolerated in 
the other nine cats and no adverse effects were recorded. 
Liver enzymes were within reference ranges during 
routine serum biochemical monitoring, which was per-
formed at least twice in all cats. There are two other case 
reports describing the clinical use of posaconazole in cats 
for treatment of SOA and infection of the subcutis of the 
nose by Mucor species respectively. Posaconazole was well 
tolerated in both cases.9,46 Voriconazole, in contrast, has 
95 per cent bioavailability after oral administration in the 
absence of food. It is metabolized in the liver by several 
cytochrome P450 enzymes. In human beings, adverse 
effects are more common with voriconazole than with 
posaconazole and include visual disturbances and hepa-
totoxicity. Blurred vision, photophobia, and other visual 
changes occur in up to one third of patients treated with 
either IV or oral formulations. These changes often 
resolve in a few weeks even if therapy is continued.42 
There are no published reports of the use of oral voricon-
azole in cats. The authors have treated three cats with 
URT aspergillosis using voriconazole, two of whom 
showed adverse effects that resolved after drug discon-
tinuation. One cat who had received 12 mg/kg (50 mg) 
daily for four doses developed anorexia and neurological 
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signs including altered mental status, dilated pupils, and 
hind limb ataxia. Another cat treated with 5 mg/kg daily 
developed behavioral changes and apparent visual impair-
ment. A third cat was treated with 6 mg/kg daily (25 mg) 
for 10 days with no adverse effects.
Polyenes
Amphotericin B is a polyene macrolide antibiotic derived 
from the actinomycete Streptomyces nodosus with fungi-
cidal activity against Aspergillus. Preferential binding to 
ergosterol in the fungal cell membrane results in altered 
permeability, leakage of cell components, and cell death. 
Amphotericin B deoxycholate must be administered par-
enterally, either intravenously or as a subcutaneous infu-
sion (see Table 5-5). The major toxicity in all species is 
nephrotoxicity. The development of lipid formulations of 
amphotericin B, which are less toxic than amphotericin 
B deoxycholate (AMB-D), has resulted in enhanced anti-
fungal activity because increased doses of amphotericin 
B can be administered with improved delivery of active 
drug to sites of infection. Lipid formulations of ampho-
tericin B are concentrated in the reticuloendothelial 
system, and liposomal amphotericin B attains high con-
centrations in brain tissue. The authors have used liposo-
mal amphotericin B (AMB-L) in cats with aspergillosis at 
a dosage of 1 to 1.5 mg/kg IV q48h (see Table 5-5). 
Although AMB-L is much less nephrotoxic than AMB-D, 
nephrotoxicity still can occur, and renal function should 
be monitored during the treatment period. AMB-D has 
been administered directly into the retrobulbar space in 
isolated cases of invasive SOA in human beings as an 
adjunct to surgical debridement when maximal drug 
doses have been given systemically.47 In vitro and in vivo 
resistance to amphotericin B has been reported in one 
case of feline SOA.9 In vitro resistance to amphotericin B 
(MIC > 2 mg/L) is rare and arises because of a mutation 
in the ergosterol biosynthesis pathway resulting in pro-
duction of ergosterol-like compounds that have reduced 
binding affinity for amphotericin B.48
Terbinafine
Terbinafine is an allylamine antifungal. It inhibits fungal 
ergosterol synthesis via inhibition of the enzyme squa-
lene mono-oxygenase, which converts squalene to ergos-
terol. Synergy between antifungal triazoles and terbinafine 
has been demonstrated against filamentous fungi in 
vitro.49 To date, the main indication for terbinafine in cats 
has been in the treatment of dermatophytosis.50
Echinocandins
The echinocandins, including caspofungin, micafungin, 
and anidulafungin, inhibit 1,3-ß-D-glucan synthesis, an 
essential polysaccharide cell wall component of many 
fungal species. The echinocandins are the most recently 
developed class of antifungal drug and are characterized 
by low toxicity and rapid fungicidal activity. They have 
additive or synergistic activity with amphotericin B and 
triazoles against filamentous fungi, including Aspergil­
lus.51 Because the oral bioavailability of echinocandins is 
very low, they must be administered parenterally. In 
human beings, they are eliminated primarily as metabo-
lites in the urine and in the feces following degradation 
Table 5-5 Drugs Used for Treatment of Aspergillosis in Cats
Drug and Formulation Dosage and Route of Administration Adverse Effects
Itraconazole
100 mg capsules
10 mg/mL oral suspension
(Sporanox; Janssen)
5 mg/kg PO q12h or
10 mg/kg PO q24h
Gastrointestinal—anorexia, vomiting
Hepatotoxicity—increased liver enzyme activity, 
jaundice. Monitor ALP/ALT monthly. If 
hepatoxicity occurs, reduce dose to 5 mg/kg PO 
q24h or 10 mg/kg PO q48h
Posaconazole
40 mg/mL liquid
(Noxafil, Schering-Plough)
2.5-3.75 mg/kg PO q12h Hepatotoxicity
Voriconazole
50 mg tablets
40 mg/mL powder for oral suspension
(Vfend, Pfizer)
5 mg/kg PO q24h Neurotoxicity—blindness, ataxia, dazed.
Terbinafine 250 mg tablets
(Lamisil, Novartis)
30 mg/kg PO q24h Gastrointestinal—anorexia, vomiting, diarrhea
Amphotericin B deoxycholate
50 mg vial (Fungizone, Bristol-Myers)
0.5 mg/kg of 5 mg/mL stock solution 
in 350 mL/cat of 0.45% NaCl + 
2.5% dextrose SQ 2-3 × weekly to 
a cumulative dose of 10-15 mg/kg.
Nephrotoxicity—pretreatment of stock solution by 
heating to 60° C for 5 minutes reduces 
nephrotoxicity. Monitor urea/creatinine every 2 
weeks. Discontinue for 2-3 weeks if azotemia.
Liposomal Amphotericin (AmBisome, 
Gilead)
1-1.5 mg/kg IV q48h to a cumulative 
dose of 12-15 mg/kg.
Given as a 1-2 mg/mL solution in 5% 
dextrose by IV infusion over 1-2 h
Azotemia.
C
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in the liver via nonoxidative pathways. Metabolism is 
thought to be independent of the cytochrome system 
and does not inhibit cytochrome P450 isoenzymes. The 
pharmacology and pharmacokinetics of echinocandins 
have not been studied in cats, and there are no reports 
of their use in this species.
THERAPEUTIC APPROACH TO SNA AND 
SOA IN CATS
Because of its more invasive nature, URT aspergillosis in 
cats is more difficult to treat than SNA in dogs. In general, 
treatment carries a better prognosis for SNA than SOA. 
The prognosis for resolution of SOA is poor.
SNA—Topical Clotrimazole Infusions
The technique of single topical sinonasal clotrimazole 
infusions, which has good efficacy for treatment of SNA 
in dogs, has been reported in three cats.6-8 In one cat, 
infection was confined to the sinonasal cavity and treat-
ment with oral itraconazole and a 1 per cent clotrimazole 
infusion was successful.7 In two other cats with SOA, a 
clotrimazole infusion was part of a multimodal therapeu-
tic approach. One cat was euthanized because of sus-
pected progression of infection despite treatment with 
itraconazole and radical surgical debridement of the 
orbit, including exenteration of the globe.6 In another 
cat with SOA, treatment with itraconazole, topical 
clotrimazole, and AMB-D did not resolve infection. 
However, the cat was cured after treatment with oral 
posaconazole administered for 16 weeks.9 Our current 
recommendation is to restrict the use of topical 1 per 
cent clotrimazole infusions to the treatment of cats with 
SNA in whom there is an intact cribriform plate, no evi-
dence of orbital involvement on CT, and no histological 
evidence of submucosal fungal invasion. Commercial 
preparations of 1 per cent clotrimazole in a polyethylene 
glycol base are available. Formulations that contain pro-
pylene glycol or isopropyl alcohol should be avoided 
because of greater potential for pharyngeal edema, as 
reported in dogs.52 Concomitant systemic antifungal 
therapy with itraconazole or posaconazole also is 
recommended.
SNA—Systemic Antifungal Therapy
Antifungal triazole drugs are the mainstay of therapy and 
can be given alone or in combination with terbinafine or 
amphotericin B (see Table 5-5). Itraconazole or posacon-
azole are the triazoles of choice. When concurrent topical 
azole therapy is administered (i.e., topical clotrimazole 
infusion) and disease is mild, amphotericin B administra-
tion may not be necessary. Also, it should be noted that 
treatment with itraconazole alone has been successful 
occasionally in resolving SNA.8 For cases of severe SNA 
where there is evidence of lysis of the orbital lamina or 
cribriform plate and risk of extension of infection beyond 
the sinonasal cavity, we recommend concurrent admin-
istration of amphotericin B (see Table 5-5). When the 
course of amphotericin B is completed, therapy can be 
continued with the oral triazole and terbinafine. The 
duration of treatment necessary to resolve SNA varies 
depending on the severity of infection, but usually is 4 
to 6 months.7
SOA—Systemic Antifungal Therapy
The optimal treatment regimen for SOA in cats has not 
been identified. Of 20 reported cases, treatment was 
attempted in 14 and infection resolved in only four 
patients.9,11 Of the cases treated successfully, three were 
treated with medical therapy alone, including one that 
resolved after posaconazole administration for 16 weeks.9 
Infection resolved in one cat treated for 7 months with 
combination therapy using itraconazole, AMB-D (cumu-
lative dose 11 mg/kg), and terbinafine. A third cat 
responded well to 8 months of therapy with ICZ and 
AMB-D (cumulative dose 14 mg/kg). Exophthalmos 
improved dramatically in this patient after 7 days of treat-
ment with itraconazole and AMB-D (cumulative dose 
14 mg/kg). However, clinical and CT evidence of infec-
tion recurred 3 weeks after itraconazole was stopped and 
after 8 months of treatment. Treatment was reinstituted 
with combination therapy using terbinafine and posacon-
azole for 4 months, followed by posaconazole alone for 
a further 3 months. Signs resolved and the cat remained 
asymptomatic 1 year later. The third case was treated with 
surgical debridement of the frontal sinuses during diag-
nostic investigation followed by AMB-D (cumulative dose 
10 mg/kg) and itraconazole for 7 months. Clinical signs 
of infection resolved and the cat was asymptomatic 2 
years later. Treatment failures occurred in four cats who 
were treated with medical therapy alone, and in six 
patients treated with combination antifungal medical 
therapy and radical surgical debridement of orbital gran-
ulomas, including exenteration in five cases.11
It is clear that the factors that determine whether a cat 
with SOA will respond to treatment have yet to be identi-
fied. Consideration should be given to surgical debride-
ment of large fungal granulomas within the retrobulbar 
space, although evidence for efficacy of this approach in 
cats currently is lacking. Treatment of immunocompetent 
humans with chronic granulomatous sinusitis involves 
aggressive surgical debridement and chronic antifungal 
therapy.52 Current recommendations for medical therapy 
in cats with SOA are the same as for cats with severe SNA 
(see Table 5-5).
SUMMARY
URT aspergillosis can cause a spectrum of disease in cats 
ranging from noninvasive sinonasal cavity infection to 
severe invasive sino-orbital disease. Aspergillus fumigatus 
is the cause of some infections, but a closely related 
species, Neosartorya is implicated more commonly. Iden-
tification of Neosartorya infection requires a polyphasic 
taxonomic approach, including fungal colony cultural 
characteristics and PCR. Aspergillosis should be included 
in the differential diagnosis of retrobulbar disease, and 
diagnostic investigations should include imaging of the 
sinonasal cavity. More work needs to be done to identify 
the optimal therapeutic approach to treatment of upper 
respiratory aspergillosis in cats.C
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